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Cardiovascular disease (CVD) such as hypertension and stroke are serious illnesses 
that impact on the lives of millions all over the world, with 972 million (26% of the 
world’s population) suffering from hypertension in year 2000, and an estimated 1.56 
billion to be affected by 2025. Hypertension, being one of the most common CVD is 
associated with the development of stroke, peripheral vascular diseases, myocardial 
infarction, renal failure as well as cardiac failure. 
Several studies have shown a seasonal correlation for both the systolic and diastolic 
blood pressure in mankind. A hypertension trial done by the Medical Research 
Council in the 1980s showed the average blood pressure being lower in summer than 
winter, and this difference was more significant in the elderly than the younger 
population. Other than seasonal variation, blood pressure (including hypertension 
prevalence) is also noted to correlate with latitude, being higher at places further 
away from the equator. Other cardiovascular related diseases such as stroke and 
acute coronary syndrome are also shown occur more frequently in winter. The 
morbidity and mortality of CVD could be due to various factors including diet, 
culture, race and social status, but within the United Kingdom, all cause mortality 
(with cerebral-vascular disease being the major one) correlates with latitude even 
after accounting for all known risk factors, with CVD risks highest in the north. 
We propose that this difference in cardiovascular mortality is caused by variations in 
ultraviolet exposure other than temperature. Known mechanisms of sunlight 
exposure that affect cardiovascular health include temperature and the ultraviolet B 
(UVB) mediated photolysis of 7-dehydrocholesterol in the skin to produce 1,25 
dihydroxycholecalciferol (Vitamin D). UVB is however a potent skin carcinogen, 
and calculating risk-benefit ratios for exposure will be important. 
We believe that independently of vitamin D, nitric oxide plays an important role in 
blood pressure regulation and cardiovascular health, accounting for seasonal and 
latitude variation. In 1961, Furchgott demonstrated relaxation of rabbit aorta by 
irradiating them with ultraviolet light, and in later research he noted this effect is 




rich store of various nitro-species within human skin and Oplander showed a 
reduction of blood pressure in human after giving whole body UVA irradiation. We 
therefore hypothesize that independently of vitamin D, NO mediates the UVA 
induced beneficial effects on cardiovascular health. 
To support our hypothesis, in vivo as well as in vitro studies were conducted. We 
recruited a total of 63 healthy 
volunteers and monitored 
blood pressure, forearm 
blood flow as well as other 
cardiovascular parameters 
before and after UVA 
irradiation. Blood samples 
were also taken for the 
measurement of circulatory nitro-species. We have noted a significant reduction of 
blood pressure (from 84.5±1.76 to 81.33±1.37 mmHg) and increased forearm blood 
flow (1.95±0.28 to 2.94±0.47 mL/100mL of tissue/min) after UVA irradiation of 
human skin; simultaneously, we also noted a rise in circulatory nitrite (0.5±0.04 µM 
before irradiation to 0.72±0.04 µM) and a drop in circulatory nitrate (11.79±0.64 µM 
before irradiation and 8.99±0.4 µM). 
For us to further clarify the role of nitric oxide in different latitude, a monochromator 
machine that generates specific wavelength of light was been used to irradiate 
aqueous nitrite solution, and the total amount of nitric oxide release at different 
latitude was then calculated according to the irradiance of various wavelength across 
the globe. 
The results of our studies provide evidence suggesting that nitric oxide release 
induced by UVA irradiation of the skin can account for the difference in 
cardiovascular mortality and morbidity by latitude. The current public health advice 





LIST OF ABBREVIATIONS 
5MTHF  5-methyltetrahydrofolate 
7-DHC  7-dehydrocholesterol 
ANOVA  Analysis of variance 
BC   Before Christ 
BP   Blood pressure 
bpm   Beats per minute 
CI   Confidence interval 
cm2   Centimeter square 
CO   Cardiac output 
CFR   Coronary flow reserve 
CSV   Comma-separated values 
CVD   Cardiovascular disease 
CVP   Central venous pressure 
DBP   Diastolic blood pressure 
DNA   Deoxyribonucleic acid 
EDRF   Endothelial derived relaxing factor 
EDTA   Ethylenediaminetetraacetic acid 
eNOS   Endothelial nitric oxide synthase 
EU   European Union 
FBF   Forearm blood flow 
FDA   Food and Drug Administration 
HR   Heart rate 
HTN   Hypertension 
IHD   Ischaemic heart disease 
iNOS   Inducible nitric oxide synthase 
irrad.   Irradiation 
ISO   International organization for standardization 
J   Joules 
KNO3   Potassium nitrate 
λ   Wavelength 




L-NMMA  L-NG-monomethyl Arginine 
MAP   Mean arterial pressure 
mg   Milligram 
MI   Myocardial infarction 
min   Minute(s) 
mL   Millilitre 
mm   Millimetre 
mM   Millimolar 
mmHg   Millimetre of mercury 
mtNOS  Mitochondria nitric oxide synthase 
mW   Milliwatt 
N2   Nitrogen 
NADPH  Nicotinamide adenine dinucleotide phosphate 
NaNO2   Sodium nitrite 
NCD   Non communicable disease 
NEM   N-Ethylmaleimide 
nm   Nanometer 
nM   Nanomolar 
nNOS   Neuronal nitric oxide synthase 
NO   Nitric oxide 
NO2-   Nitrite 
NO3-   Nitrate 
NOS   Nitric oxide synthase 
NTD   Neural tube defect 
O2   Oxygen 
OR   Odds ratio 
PBS   Phosphate buffer saline 
PMA   Platelet monocyte aggregation 
PGA   Pteroylmonoglutamic acid 
ppb   Parts per billion 
RCF   Relative centrifugal force 




RNNO   N-nitrosamine 
RSNO   S-nitrosothiols 
SBF   Skin blood flow 
SBP   Systolic blood pressure 
SCC   Squamous cell carcinoma 
SD   Standard deviation 
sec   Second(s) 
SEM   Standard error of the mean 
SV   Stroke volume 
SVR   Systemic vascular resistance 
temp.   Temperature 
µL   Microlitre 
µm   Micrometer 
µM   Micromolar 
UK   United Kingdom 
US   United States 
UV   Ultraviolet 
UVA   Ultraviolet A 
UVB   Ultraviolet B 
UVC   Ultraviolet C 
UVR   Ultraviolet radiation 




PUBLICATIONS FROM THIS THESIS 
 
Hypothesis paper 
Feelisch M, Kolb-Bachofen V, Liu D
1. 
, Lundberg JO, Revelo LP, Suschek CV, et al. 
Is sunlight good for our heart? European Heart Journal 2010;31(9):1041-5. 
Abstracts 
D. Liu
Do skin bound NO-related species mediate the beneficial health effects of sunlight? 
Oral presentation at the 81st Scottish Skin Biology Club, Dundee, May. 2009 
, M.Morris and R.Weller. 
2. D.Liu
Skin bound NO-related species mediate the beneficial health effects of sunlight 
Poster presentation at the British Society for Investigative Dermatology, 
Edinburgh, Apr. 2010 
, J.Gallagher, M. Morris and R.Weller 
3. D. Liu
Skin bound NO-related species mediate the beneficial health effects of sunlight 
Oral presentation at the 83rd Scottish Skin Biology Club, Edinburgh, May. 2010 
, J. Gallagher, M. Morris and R. Weller 
4. D.Liu
Cardiovascular Benefits Mediated by Skin Store 
Oral presentation at the Edinburgh Taiwanese Students Society Symposia, 
Edinburgh, Dec. 2010 
 and R.Weller 
5. D. Liu
NO effect produced by UVA irradiation of skin is independent of NOS and 
temperature 
Abstract accepted for poster presentation at the 7th International Conference on the 
Biology, Chemistry and Therapeutic Application of Nitric Oxide, Edinburgh, Jul. 
2012 
, N.N. Lang, B. Fernandez, P. Dunne, K. Tinkler, K. McBride, M. Feelisch, 























1.0 General Introduction 
According to statistics published by the World Health Organization, there were 
approximately 57 million global deaths in 2008. Out of the 57 million, more than 
30% were due to cardiovascular disease (CVD) (Mendis et al., 2011), and the health 
care costs spent annually in the EU or US for CVD are more than €150 billion (Leal 
et al., 2006, Devol and Bedroussian, 2007) making cardiovascular disease not just the 
number one killer in the world, but also a heavy economic burden. 
There are many types of CVD, with high blood pressure (hypertension) being one of 
the dangerous and common CVD seen. Hypertension has been given the name “silent 
killer” due to its complications and absence of early symptoms. Studies have shown 
that hypertension is a risk factor for most of the other CVDs such as stroke (Wolff 
and Lindeman, 1966, Macmahon et al., 1990, Probstfield, 1991, Rodgers et al., 1996), 
atherosclerosis (Young et al., 1960), coronary heart disease (Macmahon and Rodgers, 
1993) and myocardial infarction (Dagostino et al., 1991, Flack et al., 1995). 
That blood pressure varies according to the season was noted by Rose as early as  
1961 (Rose, 1961), with both systolic and diastolic blood pressure lowest during 
summer and highest during winter/spring. This decrease in blood pressure seems to 
be more obvious in those with higher resting blood pressure (Brennan et al., 1982, 
Winnicki et al., 1996, Sega et al., 1998). This finding correlates with mortality of all 
causes, which was also shown to be higher during the winter season in different 
places. All cause mortality with cerebral-vascular disease being a major contributor 
(Douglas et al., 1991, Kloner et al., 1999). 
Other than seasonal variation, blood pressure and the prevalence of hypertension 
correlates with latitude, with blood pressure higher in populations further away from 
equator (Rostand, 1997). The difference in blood pressure across the globe could be 
due to confounders such as race, ethnicity, diet, living environment and geographical 
variations, but there is further evidence showing that mortality of CVD globally 




being corrected for known confounders also correlate linearly with latitude (Law and 
Morris, 1998). Another interesting fact reported by the Law & Morris study is that 
the relative risk of ischemic heart disease and stroke mortality being higher but skin 
cancer being lower in the northern area of the United Kingdom when compared to 
the south. 
As many of the research results have shown, here in this thesis I suggest that the 
correlation between latitude and season against blood pressure change is due to the 
amount of sunlight received. I further suggest that ultraviolet A mediated release of 
nitric oxide (NO) from skin plays an important role in the cardio-protective effect 
from sunlight. 
 
Figure 1.1 Concept schematic of blood pressure and cardiovascular disease mortality 





1.1 Various health effects of sunlight exposure on human well being 
1.1.1 Photomedicine : Sunlight spectrum that reaches the Earth 
Photomedicine is the study of light’s effects on health and disease, the roots of which 
can be dated back over two millennia. It was said that the first report of the 
therapeutic use of sunlight for medical purposes dates from about 1400 BC. In 
Atharva Veda, a sacred Indian book written 3400 years ago, mentions using seed 
extracts as a sunlight activation agent that deals with the treatment of leprosy and 
leukoderma (Fitzpatrick and Pathak, 1959). Heliotherapy was also widely practiced 
in ancient Egypt, Greece, and Rome (Roelandts, 2002) with anecdotal records around  
480 BC mentioning that the Romans built solaria on their houses for access to 
sunbathe (Dietrich, 1913, Feelisch et al., 2010). The importance of heliotherapy was 
highlighted in 1903 with the award of the Nobel Prize for medicine to Niels Ryberg 
Finsen in recognition of his contribution to the treatment of lupus vulgaris (cutaneous 
tuberculosis) using concentrated light radiation (Moller et al., 2005). Heliotherapy 
used for assisting the treatment of tuberculosis was also a breakthrough (Gauvain, 
1914). In the first half of the twentieth century, sunlight exposure was generally 
regarded as being beneficial to health, but with the realization that excess sun was a 
risk factor for cutaneous malignancies, there has been a shift of medical opinion to 
one in which public health messages warn against sun exposure (Roffo, 1936, Peller 
and Stephenson, 1937).  
Wavelengths of UV radiation below 200 nm are mainly absorbed by Nitrogen (N2) 
and Oxygen (O2) molecules in the upper atmosphere (Diffey, 2002, Juzeniene et al., 
2011), and the spectrum of sunlight that reaches sea level thus ranges mainly from 
280~4000 nm (ultraviolet to infrared) even when the measurement was performed 
without ozone above (Juzeniene et al., 2011). The health effect sunlight produces on 
mankind varies according to the spectrum. Sunlight affects human health via 
different mechanisms and pathways, and this thesis will focus mainly on the 
ultraviolet wavelengths of sunlight, particularly the health effect produced by 




1.1.2 Different wavelength ultraviolet light and their impact on human health 
Ultraviolet radiation (UVR, λ=100~400 nm) is involved in many aspects of human 
physiology, starting at the moment when it comes into contact with the skin, and 
produces both local effects and systemic responses. The responses produced by UVR 
can be immediate such as pigment darkening (Routaboul et al., 1999), nitric oxide 
release or delayed such as sunburn (which depends on skin type), pigment darkening 
via a different pathway (Pathak and Fanselow, 1983) and DNA damage leading to 
genetic mutation (Brash et al., 1991, Kress et al., 1992). Cumulative or long term 
effects of UVR exposure such as photoaging (Petersen et al., 1992, Fisher et al., 2002) 
and immunosuppression (Noonan et al., 1981, Molendijk et al., 1987) also occur. 
Some of the physiological effects can only be triggered by exposure to specific 
wavelengths of ultraviolet light, so research investigating different wavelengths has 
been conducted (described below). 
     1.1.2.1 Ultraviolet C 
Most ultraviolet C (UVC, λ=100~280 nm) is filtered by the atmosphere, leaving 
minimal amounts reaching the Earth’s surface. That which reaches the surface of the 
Earth (at extreme high altitude for example or through ‘holes in the ozone layer’ in 
the Antarctic) and strikes human skin and eyes will cause minimal harm and burn 
due to its short wavelength, thus very unlikely to penetrate deep into the epidermis. 
Exposure will cause temporary reddening and painful eyes (however UVC is not 
responsible for causing cataract due to inability to penetrate into the lens). UVC is 
germicidal, therefore usually used in hospitals, laboratories, or industries for 
disinfection purposes. 
     1.1.2.2 Ultraviolet B 
Ultraviolet B (UVB, λ=280-315 nm) with a longer wavelength than UVC, can 
penetrate through the atmosphere and reach human skin. Prolonged exposure to UVB 
causes sunburn (duration of exposure that leads to sunburn varies depending on 




1988). This has been well studied on account of its harmful effects as well as its role 
of treatment in many dermatological conditions, particularly the narrow band UVB 
(commonly being the TL-01 311nm unit). 
1.1.2.2.1 Clinical use of ultraviolet B 
Narrow band UVB is an effective treatment in psoriasis (Coven et al., 1997, 
Barbagallo et al., 2001, Gambichler et al., 2005), chronic atopic dermatitis (George 
et al., 1993), generalized vitiligo (Scherschun et al., 2001) and also can help in 
treating patients with polymorphic light eruption, early stages of cutaneous T-cell 
lymphoma and chronic urticaria (Ibbotson et al., 2004, Gambichler et al., 2005). 
1.2.2.2.2 Ultraviolet B and vitamin D 
UVB other than serving as a therapy in dermatological conditions, can photolyse 7-
dehydrocholesterol to cholecalciferol in the skin (Lehmann et al., 2001). 
Cholecalciferol is then hydroxylated in the liver and kidney to form 1,25-
dihydroxyvitamin D3, the most active form of vitamin D3. 
The production of vitamin D was found to regulate serum calcium level and via 
negative feedback, inactivates parathyroid hormone secretion. It was also thought by 
many that vitamin D plays a key role in reduction of blood pressure (Krause et al., 
1998, Pfeifer et al., 2001). As there are data showing serum vitamin D correlates 
with season as well as latitude (Webb et al., 1988), seasonal variation in blood 
pressure has been therefore suggested to be vitamin D dependent. There are also data 
supporting the fact that vitamin D increment associates with a reduction in total 
cancer incidence (Giovannucci et al., 2006). 
Margolis et al in 2008 published the results of a vitamin D supplement study, in 
which daily supplement of 1000 mg elemental calcium plus 400 IU of vitamin D3 or 
placebo was given to 36,282 postmenopausal women. The subjects were followed up 




incidence of hypertension between the treated versus control group (Margolis et al., 
2008). 
Recently, Pittas and colleagues reviewed ten studies of vitamin D supplementation 
investigating blood pressure outcome and four studies that looked into the relative 
risk of cardiovascular diseases/events (including stroke, coronary heart disease and 
ischaemic heart disease). The majority of the studies that studies blood pressure as an 
outcome showed no significant reduction in both systolic and diastolic blood 
pressure (Pittas et al., 2010). Vitamin D supplement was also not found to be 
protective against the development of cardiovascular diseases (Trivedi et al., 2003, 
Brazier et al., 2005, Hsia et al., 2007, Prince et al., 2008, LaCroix et al., 2009). With 
inconsistent results in vitamin D supplementation studies and insignificant blood 
pressure lowering effect by vitamin D through long term UVB irradiation (Scragg et 
al., 2011), suggests the variation of blood pressure and cardiovascular mortality in 
season and latitude might be vitamin D independent. 
1.2.2.2.3 Ultraviolet B and development of skin cancer 
The association of UVR exposure and skin cancer was been noted since the 
beginning of 1900’s, with an early animal study showing that repeated UV exposure 
to mice induced formation of skin cancer (Findlay, 1928). Basal cell carcinoma and 
squamous cell carcinoma are known to develop via mutation of various genes, with 
p53 tumour suppressor gene found to play a role in both types of carcinoma. The 
pathophysiology in formation of non-melanotic carcinoma of the skin have been well 
investigated and reviewed with solid evidence suggesting UVB being the most potent 
spectrum in the initiation of p53 mutation with UVA having additional effects (Brash 
et al., 1991, Kress et al., 1992, Rady et al., 1992, deGruijl et al., 1993, Ziegler et al., 
1993, de Gruijl et al., 2001, Rigel, 2008). UVR associated immunosuppression of T-
lymphocytes was also suggested to play an important role in carcinogenesis 
(Spellman and Daynes, 1977, Fisher and Kripke, 1982). UVR causes the mutation 
mainly by formation of thymidine dimers resulting in a CC to TT double base change 




will undergo clonal expansion and lose their ability to regulate cell growth, resulting 
in uncontrolled proliferation of cells and finally the abnormal cells developing into 
squamous cell carcinoma in situ (Alam and Ratner, 2001). Recent evidence regarding 
the carcinogenic effect of UVB irradiation suggests that UVB not only involves in 
the mutation of p53, but might also play a role in the down regulation of other 
tumour suppressor genes, such as PTEN, encouraging tumour initiation and 
progression (Ming et al., 2011). 
     1.1.2.3 Ultraviolet A 
Ultraviolet A (UVA, λ=315-400 nm), having the longest wavelength within the UV 
spectrum penetrates through the atmosphere and can penetrate about 500 µm into the 
skin (Tuchin, 1993), deep into human’s dermal layer where microcirculations are 
present (average epidermis thickness is 83.7 µm (Sandby-Moller et al., 2003)). 
1.1.2.3.1 Clinical use of Ultraviolet A 
UVA was commonly used along with psoralen application or ingestion as the 
treatment of psoriasis, however, along with evidence showing psoralen UVA therapy 
increase risk of skin cancer (Nataraj et al., 1997) and that narrow band UVB might 
be equally or even more effective with lesser side effects, (Barbagallo et al., 2001) 
the treatment of psoriasis has changed, but the treatment of choice is still under 
considerable debate (Gambichler et al., 2005). 
1.1.2.3.2 Ultraviolet A and folate 
UVA irradiation was noted to decrease serum folate level by Branda & Eaton in 
1978 both in vitro and in vivo (Branda and Eaton, 1978). Folate is an important 
vitamin that is needed during pregnancy for prevention of neural tube defects (NTD) 
and this raised concerns that an increased incidence of NTD might occur in pregnant 
women exposed to UV radiation (Jablonski, 1999). However a randomized 
controlled trial from 2001 showed a different result. Gambichler and colleagues gave 




significant change in serum folate was observed, concluding that the NTD thought to 
occur after periconceptual UVA exposure are probably not due to UVA induced 
folate catabolism (Gambichler et al., 2001). Later in 2006, Steindal and colleagues 
found that pteroylmonoglutamic acid (PGA), the synthetic form of folate actually 
absorb more UVA than 5-methyltetrahydrofolate (5-MTHF) (Steindal et al., 2006), 
the reduced form, also the major form of folate in the blood stream. In 2009, 
Fukuwatari et al proved that 5-MTHF will not be destroyed by exposure to sunlight, 
and blood folate concentration will not be reduced unless humans are taking PGA 
(Fukuwatari et al., 2009). 
1.1.2.3.3 Ultraviolet A in cosmetic usage 
One of the effects caused by cumulative UVA exposure that discourage people from 
going under the sun is cosmetic related. UVA stimulates the expression of matrix 
metallopeptidase 1 gene, which degrades type I and III collagen (Fisher et al., 2002) 
as well as down regulating type I and type III procollagen gene expression (Fisher et 
al., 2000). The final result of decrease collagen synthesis is photoaging. 
Nowadays, UVA is been widely used in tanning salons in tanning lamps due to its 
immediate pigment darkening effect, (Honigsmann et al., 1986) which is probably 
caused by oxidising pre-existing melanin or melanogenic precursors. 
1.1.2.3.4 Ultraviolet A and nitric oxide 
UVA is known to photodecompose nitrite to form nitric oxide (equation below) 
(Treinin and Hayon, 1970, Zafiriou and Bonneau, 1987). 
NO2− + ℎ𝑣𝑣(+H+) → NO + OH (Fischer and Warneck, 1996) 
Combined with evidence showing increased circulatory nitrite post UVA irradiation 
on human skin (Paunel et al., 2005, Mowbray et al., 2009), this suggests that the 




UVA photolysis of nitrite rather than the UVB induced vitamin D synthesis (Feelisch 
et al., 2010). This hypothesis was been strengthen by the Oplander study 
investigating blood pressure change post UVA irradiation (Oplander et al., 2009). 
*Wavelength classification based on the ISO 21348 Process for Determining Solar 
Irradiances (2007) (Standardization, 2007). 
 
Figure 1.2 Summary schematic of a brief overview regarding health effects 




1.2 Overview of nitric oxide and related species 
1.2.1 Nitric Oxide 
Nitric oxide, originally known as endothelium derived relaxing factor (EDRF) is a 
gaseous molecule that is synthesized from L-arginine by one of the nitric oxide 
synthase (NOS) enzymes (Palmer et al., 1988a). Nitric oxide is particularly well 
known for its vasodilatatory (Furchgott, 1991) and anti-inflammatory effects; 
additionally its role in neurotransmission, platelet aggregation (Radomski et al., 1987, 
Radomski et al., 1990), and regulation of apoptosis has been explored by other 
research groups and reviewed by different people (Moncada et al., 1991, Moncada 
and Higgs, 1993, Alderton et al., 2001, Taylor et al., 2003, Moncada and Higgs, 
2006). 
     1.2.1.1 L-Arginine Nitric Oxide Pathway 
Nitric oxide is synthesized as a co-product by NOS during the conversion of L-
arginine and oxygen to citrulline (Palmer et al., 1988a, Palmer et al., 1988b), and this 
pathway is NADPH and calmodulin dependent  (Bredt and Snyder, 1990). Several  
types of NOS have been identified, named by the tissue in which they were first 
found neuronal, inducible, and endothelial NOS, also known as NOS-I, NOS-II, and 
NOS-III. 
     1.2.1.2 Nitric Oxide Metabolism 
Nitric oxide activity in human can be difficult to detect as nitric oxide has a very 
short half-life of a few seconds due to its rapid reaction with haemoglobin and 
oxygen (Hakim et al., 1996). The oxidized end product of nitric oxide, nitrite is more 




1.2.2 Nitric oxide synthase 
     1.2.2.1 neuronal Nitric Oxide Synthase (nNOS) 
nNOS, being the first NOS sequenced is known to be a constitutive NOS that is 
highly expressed in human and animal brain tissue (Bredt et al., 1990, Salter et al., 
1991, Nakane et al., 1993). nNOS, was found to be calmodulin dependent thus 
remains inactive until the intracellular calcium levels increase. In the presence of the 
calcium-binding protein calmodulin, it binds to intracellular calcium forming the 
calcium calmodulin complex and activates the activity of nitric oxide synthase 
releasing nitric oxide. Studies have also shown formation of nitric oxide after UV 
irradiation of human keratinocytes via activation of nNOS (RomeroGraillet et al., 
1997). 
     1.2.2.2 inducible Nitric Oxide Synthase (iNOS) 
iNOS, being inducible by many tissue and cells such as macrophages, hepatocytes, 
endothelial kidney cells and even vascular smooth muscle, can remain active even 
without the calcium calmodulin complex. The calcium independent activity of iNOS 
was found to be due to the calmodulin tightly bound to the enzyme (Cho et al., 1992). 
As the expression of iNOS is induced upon stimulation of cells with cytokines or 
endotoxins, it becomes fully active even when calcium levels in cells are low, thus 
plays a major role in the over production of nitric oxide in endotoxin shock 
(Macmicking et al., 1995). Recent studies also suggest iNOS involvement in 
carcinogenesis by increasing tumour blood flow, and have shown evidences that 
iNOS inhibition could limit tumour growth (Fukumura et al., 1997). 
     1.2.2.3 endothelial Nitric Oxide Synthase (eNOS) 
Endothelial NOS, also found to be a type of constitutive NOS, plays an extremely 
vital role in the regulation of vascular function, specifically well known for its 
vasodilatory property. After acetylcholine binds with its receptor on the surface of 
the endothelial cell, the calcium channel is opened up for the influx of the calcium, 




complex binds with eNOS to allow the conversion of L-arginine to citrulline, 
forming nitric oxide (Knowles and Moncada, 1994).  
     1.2.2.4 mitochondrial Nitric Oxide Synthase (mtNOS) 
During the 1990’s, two different laboratories described the existence of a new type of 
NOS which is located in the mitrochondria (Ghafourifar and Richter, 1997, Giulivi et 
al., 1998). However, it was later proposed in different studies that all three types of 
NOS isoforms could be the actual form of mtNOS (Hotta et al., 1999, French et al., 
2001, Kanai et al., 2001) with nNOS being the primary candidate (Dedkova and 
Blatter, 2009). 
     1.2.2.5 Nitric Oxide Synthase Inhibitors 
Various types of NOS inhibitors are available, which are usually arginine analogues 
and competitive inhibitors of the NOS enzymes, however none are completely 
specific for any NOS isotypes. L-NG-monomethyl Arginine (L-NMMA) being the 
first NOS inhibitor identified (Palmer et al., 1988b) has been investigated for its 
property and safety, and results from different studies concluded that L-NMMA is  a 
non-selective NOS inhibitor which inhibits all three types of NOS (Moncada et al., 
1991). Even though L-NMMA is not a licensed drug by the FDA, and was shown to 
have a trend for increased mortality in treating septic shock patients during a phase 
three trial held in 1997 by Glaxo Wellcome (Ignarro, 2000), it is still widely use in 
approved clinical trials and phase I/II studies under careful administration. Other 
NOS inhibitors such as N (G)-nitro-L- arginine methyl ester (L-NAME) inhibits 
eNOS and nNOS, and with high doses inhibits iNOS as well, but it is more effective 
than L-NMMA in eNOS inhibition (Rees et al., 1989a, Mulsch and Busse, 1990, 
Pfeiffer et al., 1996, Furfine et al., 1997).  
1.2.3 Nitric oxide related species 
     1.2.3.1 Nitrite 




nitric oxide is synthesized from NOS during the conversion of L-arginine to 
citrulline, nitric oxide formed from this process can go through oxidation, forming 
nitrite as one of its end product. Nitrite can also be produced during food 
consumption that contains nitrate, as the oral bacteria reduces nitrate to nitrite 
(Tannenbaum et al., 1976). With the nitrite form from oral bacteria reduction of 
nitrate gets ingested and enter the gastric cavity, acidification of nitrite will form 
nitrous acid and then dinitrogen trioxide, later forming nitric oxide, which plays an 
important role in the defence mechanism against the swallowed pathogens (Benjamin 
et al., 1994, Duncan et al., 1995). 
Nitrite was once thought to be a non-biologically active product of nitric oxide 
metabolism as studies have shown an extremely short half-life (±110 seconds) of 
nitrite after addition of sodium nitrite into whole blood, it was found that more than 
95% of the nitrite was oxidized to nitrate within one hour (Moshage et al., 1995), and 
this rapid process of oxidization was shown to be due to the oxyhaemoglobin in 
erythrocytes (Wennmalm et al., 1993). Regardless of nitrite’s short half-life in whole 
blood, nitrite is now known to produce nitric oxide like activity after reduction. 
Nitrite was found to generate nitric oxide in the acidic conditions of the stomach 
(Benjamin et al., 1994) and also in hypoxic environments where low pH and 
deoxyhaemoglobin (Cosby et al., 2003) serve as a nitrite reductase. Nitrite can also 
act as a nitric oxide reservoir that can be found in the circulation or stored in skin 
(Mowbray et al., 2009) and serves as a stable endocrine carrier and transducer of 
nitric oxide-like bioactivities in body circulation (Schechter and Gladwin, 2003). 
Thus one can conclude that nitrite plays an important role in NOS independent 
synthesis of nitric oxide in acidic and hypoxic environment (Zweier et al., 1995). 
Other than producing nitric oxide in hypoxic conditions, recent studies have shown 
production of nitric oxide from nitrite photolysis via UVA irradiation (Singh et al., 




     1.2.3.2 Nitrate 
Nitrate (NO3-), which is the ultimate biological oxidation end product of nitric oxide 
and nitrite, forms the largest store of nitro-species present in the skin and circulation 
(Mowbray et al., 2009). As mammals do not produce the enzyme nitrate reductase 
this has been thought to render nitrate biologically inactive compared to nitrite. The 
fate for a big portion of nitrate (60 %) in the circulation was found to be excreted 
from kidney along with urine (Green et al., 1981), and the rest remains unknown. 
1.2.3.2.1 Nitrate reduction by nitrate reductase 
Even though mammals do not synthesize nitrate reductase, nitrate can generate nitric 
oxide and NO2- via other routes. Oral nitrate consumption increases salivary nitrite 
(Goaz and Biswell, 1961, Tannenbaum et al., 1976) via reduction of nitrate to nitrite 
by oral micro-flora such as the Veillonella species (V.atypica and V.dispar), 
Actinomyces species (A.odontolyticus and A.naeslundii), Rothia species 
(R.mucilaginosa and R.dentocariosa) and S.epidermis (Doel et al., 2005). This nitrite 
was further reduced to nitric oxide in the acid conditions of the stomach after being 
swallowed. The normal flora on the skin (S.aureus, S.epidermis, Nitrosomonas spp.) 
also produce nitrate reductase to release nitric oxide on the skin surface by reducing 
sweat nitrate (Weller et al., 1996). 
1.2.3.2.2 Enzyme independent reduction of nitrate 
Keratin, produced by keratinocytes is an important protein for making up human skin, 
hair and nails (Birbeck and Mercer, 1957). Keratin in human skin contains about 5 % 
cysteine (Fraser et al., 1988) and keratin in human hair contain about 15 % of 
cysteine (Block et al., 1939). 
Production of nitric oxide from nitrate can be enzyme independent. Dejam and 
colleagues showed that upon UV irradiation, thiols (which are a major component of 
cysteine and glutathione) allow non-enzymatic conversion of nitrate to nitric oxide 




common cell type found in the epidermis (Wickert and Visscher, 2006), thiols in 
keratin may be involved in the non-enzymatic conversion of epidermal stored nitrate 
in the presence of UVA. A schematic of where nitrate might be reduced to nitrite and 
nitrite being photo-decomposed in the epidermis is shown below (figure 3.1). Further 
discussion about the mechanism will be described in chapter 5. 
  
Figure 1.3 Schematic of where nitric oxide might be formed in epidermis 
 
     1.2.3.3 Nitrosothiols 
S-nitrosothiols (RSNO) are derivatives of nitric oxide, formed by S-nitrosation of 
thiols. In the chemical formula of RSNO, R is either a protein, a peptide or an amino 
acid, whereas S represents sulphur atom (Al-Sa'doni and Ferro, 2004). RSNO are 
compounds that can be degraded by heat, UV irradiation, vitamin C and trace amount 
of copper ions to produce nitric oxide via breaking the sulphur nitrogen bond 




2RSNO → RSSR + 2NO 
Significant stores of RSNO are found in the skin, with a magnitude about 300 fold 
more than those in circulation (Paunel et al., 2005), thus RSNO acting as a nitric 
oxide donor via UV photo-decomposition (Singh et al., 1996) might play an 
important role in the increased nitric oxide activity after UV irradiation. 
1.2.4 Detection of nitric oxide activity 
Nitric oxide has a short half-life in whole blood due to its reaction with haemoglobin 
(equation below), thus detection of nitric oxide activity depends on the measurement 
of nitrite, nitrate and the nitrosothiols. 
NO + HbO2 → Hb+ + NO3− 
 Nitric Oxide + Oxyhaemoglobin → Methagmoglobin + Nitrate 
The most sensitive widely available method for nitric oxide related species detection 
is gas phase chemiluminescence. Other methods such as Griess assay (Griess, 1879, 
Green et al., 1982) that detects nitrite is widely used, but this only assays nitrite, the 
oxidation product of nitric oxide in aqueous solution, at concentrations about 10 to 




1.3 Cardiovascular health in association with nitric oxide & sunlight exposure 
1.3.1 Brief overview of cardiovascular homeostasis 
The human cardiovascular system is tightly regulated, and must deliver sufficient 
oxygen to all tissues. This regulation of the cardiovascular system can be break down 
to three main factors, being the blood flow, blood pressure and vascular resistance 
(determine by blood viscosity, radius and length of vessel) (Klabunde, 2005). 





1.3.2 Impact of nitric oxide in cardiovascular diseases 
As mentioned earlier in the general introduction, cardiovascular mortality correlates 
linearly with latitude and appear to be higher in winter seasons. This suggests that the 
amount of sun exposure to individuals plays a part. Previous hypotheses have been 
that this might be due to temperature or to vitamin D. However, I believe that UVA 
formed nitric oxide plays an important role. 
     1.3.2.1 Nitric oxide associated abnormality in cardiovascular diseases 
Knowing that nitric oxide plays a vital role in cardiovascular physiology (Rees et al., 
1989b, Han et al., 1994), it is not surprising to find abnormal nitric oxide synthesis in 
some cardiovascular diseases. As early as in 1990, by using the venous occlusive 
plethysmography technique, Linder and Panza found that endothelial dependent 
vascular relaxation is abnormal in patients presenting with essential hypertension as 




(Linder et al., 1990, Panza et al., 1990). However, this finding is debatable after the 
Cockcroft study. Cockcroft, with a bigger population size found that forearm blood 
flow (FBF) showed no significant difference upon infusion of acetylcholine in 
untreated hypertensive patients (Cockcroft et al., 1994). 
Further research by Cadwgan & Benjamin demonstrated L-NMMA significantly 
increase platelet aggregation in healthy volunteers but not as much in hypertensive 
patients, showing evidence that nitric oxide production in platelets of hypertensive 
patients are reduced (Cadwgan and Benjamin, 1993). It was later demonstrated that 
there is a reduced expression of eNOS in the lung with those that have pulmonary 
hypertension (Giaid and Saleh, 1995), a decreased basal nitric oxide production in 
humans with essential hypertension (Forte et al., 1997) and a decreased expression of 
NOS gene in hypertensive rodents (Huang et al., 1995, Chou et al., 1998). 
It was been suggested that there is no sufficient evidence to state whether the 
abnormal basal level of nitric oxide or expression of NOS in hypertensive patients is 
a cause or a result of high blood pressure (Forte et al., 1997). 
     1.3.2.2 Clinical application of nitric oxide related species 
Considerable research has gone into methods of increasing circulatory nitric oxide 
activity, aiming to find new treatments for high blood pressure and other vascular 
related disorders. Inhalation of nitric oxide as a treatment for pulmonary 
hypertension has been practiced since 1991 (Pepke-Zaba et al., 1991) and has shown 
good response in selectively reducing pulmonary artery pressure (Rossaint et al., 
1993) although effects on overall mortality have been disappointing (Adhikari et al., 
2007). A widely used clinical use of increasing circulatory nitric oxide activity was 
identified in 1996. Sildenafil, a cyclic GMP-specific phosphodiesterase inhibitor was 
shown to improve erectile dysfunction (Boolell et al., 1996). 
A diet high in fruit and vegetables was found to lower blood pressure (Rouse et al., 




disease (Hu and Willett, 2002), myocardial infarction (Hung et al., 2004) and stroke 
(Joshipura et al., 1999, Hung et al., 2004). Green vegetables are high in nitrate 
content, and it has been suggested that this might account for their cardio-protective 
effects. Webb and colleagues gave their volunteers 500 ml of beetroot juice (which is 
rich in nitrate) and found a significant drop of blood pressure three hours after 
ingestion. This was accompanied by an inhibition of platelet aggregation and an 
increase in circulatory nitrite and nitrate (Webb et al., 2008). 
1.3.3 Temperature effect on blood pressure 
Temperature plays a vital role in regulation of blood pressure via the neuroendocrine 
system (Gale, 1973), particularly via the pre-optic area of the anterior hypothalamus. 
It was also suggested by many groups that the seasonal variation of blood pressure 
and cardiovascular mortality is due to temperature change (Woodhouse et al., 1993, 
Alperovitch et al., 2009). This hypothesis was supported by different studies 
investigating the cardiovascular response against change in outdoor (Barnett et al., 
2007, Halonen et al., 2011), ambient (Woodhouse et al., 1993, Barnett et al., 2007), 
and skin temperature (Namsawang and Rattanathongkom, 2008) as all research 
groups showed an inverse correlation between blood pressure and temperature. 
However recent studies have been suggesting that other than regulation of blood 
pressure by the neuroendocrine system, nitric oxide might be involved in the 
regulation of blood pressure via at least two different pathways. Kellogg et al  
showed L-NAME infusion reduces skin blood flow (SBF) (Kellogg et al., 1999) and 
attenuates thermoregulatory reflex-mediated vasodilation during local warming of 
the skin in human (Kellogg et al., 1998), suggesting eNOS involvement in 
temperature induced vasodilatation during local warming, and this was verified by 
further study (Kellogg et al., 2008a). 
Another study done by Kellogg looking for nitric oxide involvement in 
thermoregulation of blood flow showed nNOS being involved in the 




Kellogg et al., 2009). These studies suggest blood pressure regulation by temperature 





Geographical and seasonal variations in blood pressure and cardiovascular mortality 
have been known of for many years, and demonstrated by different studies. Hitherto 
it has been suggested by most authors that vitamin D and/or temperature are 
responsible for these major cardio-protective effects. However, vitamin D 
supplement studies have shown inconsistent effects. 
All three types of NOS isoform are found in human dermis and epidermis (Bruch-
Gerharz et al., 1998). In addition to this, there is a significant store of nitric oxide 
related species in human skin (Paunel et al., 2005, Mowbray et al., 2009) and when 
compared to the circulatory system, the nitrite and S-nitrosothiols have 
concentrations 25 or 360 fold higher than those found in plasma (Paunel et al., 2005). 
This significant store of nitric oxide related species in the skin seems to mobilize into 
the circulation after UVA irradiation. The exact site where nitric oxide is formed in 
the skin upon UVA irradiation is uncertain, but may involve the keratins found in 
epidermal keratinocytes (RomeroGraillet et al., 1997). As keratins contain thiol rich 
cysteine, the reduction of nitrate into nitrite might take place at the epidermis. Nitric 
oxide was shown to have high diffusion gradient, and was suggested to be able to 
diffuse 1±3 mm through the skin to the pre-capillary sphincters without being 
oxidized (Hardwick et al., 2001). This provides the possibility that nitric oxide 
formed in the epidermis may enter the dermal microcirculation, and possibly the 
systemic circulation where it produces a vasodilatory effect (Figure 1.3). 
I thus suggest that nitric oxide released from skin upon UVA irradiation can induce 
sufficient nitric oxide activity to alter our cardiovascular physiology. I further 
hypothesize the nitric oxide release upon UVA irradiation plays a vital role in the 




1.5 Overview of thesis 
To test this hypothesis, I have measured various systemic cardiovascular parameters 
in healthy volunteers before and after whole body UVA irradiation. Sham irradiation 
was done to control for core and skin temperature, as this will help in ruling out any 
NOS dependent and neuro-endocrine thermoregulatory effect. Blood samples were 
taken from the volunteers to measure nitric oxide activity in the vasculature. 
To confirm the increased circulatory nitro-species post UVA irradiation is NOS 
independent, I have also measured the local vascular response before and after UVA 
by forearm venous occlusive plethysmography post infusion of L-NMMA in the 
brachial artery. Skin temperature control was carried out by using electric fans. 
Blood samples were again taken from the volunteers to measure nitric oxide activity 
in the vasculature. 
In-vitro studies were conducted to identify the wavelengths for nitrite photo-
decomposition. Using a similar model, the ratio of nitric oxide release from UV of 
the sun at different latitude and months were estimated. Further studies were 
conducted to explore the role of thiols in nitrate reduction. 
Lastly, using the development of non-melanoma carcinoma of the skin, particularly 
squamous cell carcinoma of the skin as an indication for total life time sun exposure, 
a matched cohort study was performed attempting to investigate the relative risk in 























2.1 In vivo studies 
2.1.1 Human studies and general consumables 
     2.1.1.1 Volunteer recruitment 
All studies were approved by the Lothian Research Ethics Committee. Volunteers for 
the blood pressure (other than the Indigo sun study, who were recruited from the 
Edinburgh city population), SBF, FBF, and bleeding time study were recruited from 
the University of Edinburgh population. An advertisement that briefly described the 
study was placed on the medical student’s notice board on EEMEC, and details given 
for volunteers who were interested in the study to contact the project investigators. 
Depending on the protocol, volunteers were then screened to ensure that they met the 
inclusion and exclusion criteria. They were then provided with a volunteer 
information sheet explaining the study in layman’s terms. Having had at least 24 
hours to consider entering the study, volunteers then signed a consent form prior to 
the start of the study. 
For inclusion in the study the subjects had to be healthy volunteers between the ages 
of 16 and 75 years unless otherwise specified.  
The exclusion criteria for the recruitment are as follow unless otherwise specified: 
- Subjects with primary or secondary hypertension 
- Subjects with other systemic diseases 
- Subjects who were on any medications that could influence blood pressure 
- Subjects who have contraindications to UVA treatment 
- Subjects allergic to any drugs used in the study 
- Subjects with peripheral vascular disease or bleeding disorders 
- Lack of informed consent 
- Current involvement in a clinical trial 





     2.1.1.2 Materials 
N-Ethylmaleimide 
Chemicals / Solutions / Kits 
Sigma Aldrich, Dorset, United Kingdom 
Nitric oxide quantitation kit Active Motif, Carlsbad, United Kingdom 
Phosphate Buffered Saline Sigma Aldrich, Dorset, United Kingdom 
Potassium nitrate, 99+% 





Clinalfa, Bachem, Weil am Rhein, Germany 
Lidocaine Hydrochloride 2% Hameln, Gloucester, United Kingdom 
Normal saline Baxter, Berkshire, United Kingdom 




BD Connecta, Oxford, United Kingdom 
Membrane adapter Sarstedt, Leicester, United Kingdom 
Monovette Sarstedt, Leicester, United Kingdom 
Multi adapter Sarstedt, Leicester, United Kingdom 
Surgical gloves (Biogel) 
Molnlycke Health Care, Manchester, United 
Kingdom 
Surgicutt & Blotting Paper 
ITC Medical, Edison, United States of 
America 
Syringe BD Plastipak, Oxford, United Kingdom 
Venflon B.Braun, Sheffield, United Kingdom 
 
Arm cuff (SC12) 
Equipment (non-disposable) 
Hokanson, Berkshire, United Kingdom 
Bioimpedance (Modular HOTMAN BAS 
System) 
Hemo Sapiens, Sedona, United States of 
America 
Blood pressure machine (705IT) 
OMRON Healthcare, Milton Keynes, United 
Kingdom 





Centrifuge (Sigma 4K15) 
Sigma Laboratory, Buckinghamshire, United 
Kingdom 
Cuff inflator air source (AG101) Hokanson, Berkshire, United Kingdom 
Faceshield (SV9A/5W & SB600) Pulsafe, Surrey, United Kingdom 
Infrared lamp (IR-812) 
Efbe Elektrogeräte, Bad Blankenburg, 
Germany 
Laser Doppler optic probes (MP1 / 7-V2) Moor Instruments, Devon, United Kingdom 
Microplate photometer (Multiskan EX) Thermo Electron, Essex, United Kingdom 
moorLAB™ server ( DRT4™) Moor Instruments, Devon, United Kingdom 
Plethysmograph (EC6) Hokanson, Berkshire, United Kingdom 
PowerLab 4/20 PowerLab, Christchurch, New Zealand 
Rapid cuff inflator (E20) Hokanson, Berkshire, United Kingdom 
Mercury in silastic strain gauge Hokanson, Berkshire, United Kingdom 
Sphygmomanometer (boso-classic) 
BOSCH + SOHN GMBH, Jungingen, 
Germany 
Temperature Probe (MLT422/A) ADInstruments, Chalgrove, United Kingdom 
Thermistor Pod (M309) ADInstruments, Chalgrove, United Kingdom 
Tympanic thermometer (GeniusTM 2) 
Tyco Healthcare, Hampshire, United 
Kingdom 
Ultra violet A source (Ergoline 
Excellence 800 turbo), 
Cosmedico VHR 9K90 bulbs 
(310~410 nm, max at 365 nm) – refer to 
page 213 for spectral distribution 
Ergoline GmbH, Windhagen, Germany 
 
Cosmedico GmbH, Stuttgart, Germany 
 
 
Ultra violet A source (Waldmann GH-
8st), 
8 Waldmann F851 100W bulbs 
(320~410 nm, max at 351 nm) – refer to 
page 214 for spectral distribution 
Herbert Waldmann GmbH, Villingen-
Schwenningen, Germany 
Herbert Waldmann GmbH, Villingen-
Schwenningen, Germany 
 





2.1.2 Blood pressure studies 
     2.1.2.1 RIECRF blood pressure study 
2.1.2.1.1 Study protocols 
The study protocol (version 2b) was approved by the South East Scotland Research 
Ethics Committee 02, with the LREC reference of 08/S1102/6 and conducted under 
compliance with the Declaration of Helsinki principles. 6 healthy male and 6 healthy 
female volunteers aged between 21~28 years old (mean 22.83±0.55) were recruited 
to participate in this study. All volunteers were provided with a volunteer 
information sheet 24 hours prior to signing the consent form. This study took place in 
the Royal Infirmary of Edinburgh Clinical Research Facility (RIECRF). 
Volunteers were asked to come for two visits in this study. In one visit, a low nitrate 
diet was provided to the volunteers for two days before the measurements. In the 
other visit, the diet was not controlled, and an oral nitrate load was consumed about 
five minutes before study commenced (which in this thesis will be described as high 
nitrate diet visit). The order of low nitrate diet and high nitrate diet visits were 
randomized. The low nitrate diet was determined by liquefying various types of 
foods with a kitchen blender and obtaining its supernatant after centrifugation. The 
nitrate and nitrite content was measured using the Griess assay as described in 
2.1.2.1.2. A menu was designed according to the foods that contain low nitrate and 
nitrite, aiming to provide the volunteers less than 20 μmol of nitrite and 40 μmol of 
nitrate per day, (refer to page 220 for the nitrite and nitrate content of the foods 
given).  
The study took place in a quiet room with comfortable lighting and constant 
temperature (22~24 °C). After signing a written consent, volunteers were requested 
to wear underwear only and lie on a bed. A cannula was inserted into the ante-cubital 
vein, and they were covered by a sheet or blanket (depending on the volunteers’ 
preference) which was only removed during the UVA irradiation. Volunteers lay 




This was immediately followed by a sham irradiation during which they were 
covered by a foil ‘space blanket’ to prevent UV rays reaching the skin. After the 
sham irradiation, volunteers were monitored for one hour immediately followed by 
an active irradiation, during which no obstructive coverings were used. Volunteers 
were monitored for a further hour after UV irradiation. A flow chart of the study is 
shown as below. 
 
Figure 2.1 RIECRF protocol flowchart 
 
2.1.2.1.2 Measurements and interventions 
Nitric oxide quantification was done using the nitric oxide quantitation kit (Active 
Motif) on different food products including cereal, bread, butter, jam, pasta, sauce, 
Griess Reagent Assay 
Various methods have been suggested for the quantification of nitrite and nitrate, 
with Griess reagent assay being one of the fastest and simplest methods for multiple 
sampling. This method, suitable to detect nitrite and indirectly measures nitrate with 
a concentration as low as 0.5 µM was first described by Griess in 1879 (Griess, 
1879). Treatment of nitrite with sulphanilamide forms diazonium salt and the 
addition of N-naphthyl-ethylenediamine to the treated nitrite will then form an azo 




cheese, apple, orange, banana, milk, and water (tap and distilled). All solid food 
products were prepared by mixing 20 grams of the sample along with 100 ml of 
distilled water, and homogenized. The liquefied product was then centrifuged and the 
supernatant was used for quantification of nitrite and nitrate. 
To measure nitrite, 100 µL of standards and samples were loaded into a 96 well plate 
followed by the addition 50 µL of Griess reagent A (sulphanilamide) and 50 µL of 
Griess reagent B (N-naphthyl-ethylenediamine). The plate was read by microplate 
photometer (Thermo Electron) 20 minutes later with a 540 nm absorbance.  
To quantify nitrate an initial reduction step to nitrite was added. 70 µL of standards 
and samples were loaded into the 96 well plate according to the manufacturer’s 
protocol. This was followed by addition of 20 µL cofactor (NADPH) and 10 µL of 
nitrate reductase (Active Motif reagent kit). The plate was then shaken by a rocking 
platform at 150 rpm for one minute and incubated in a dark room for thirty minutes, 
to allow reduction of nitrate to nitrite and the nitrite assay was performed as above. 
Oral nitrate load 
Oral nitrate load was prepared by dissolving 500 mg of potassium nitrate in 50 ml of 
distilled water and later mixed with 100 ml orange juice to disguise the taste. 
Blood pressure 
Blood pressure was measured every 10 minutes by an ambulatory blood pressure 
machine, Omron 705 IT (OMRON Healthcare) throughout the study. 
Body core temperature was monitored by a tympanic thermometer (Tyco Healthcare) 
every 10 minutes or continuously by a computer program “Chart 5 For Windows” 
used in conjunction with the M309 Thermistor Pod (ADInstruments) along with the 
MLT422/A Temperature Probe (ADInstruments). The probe was placed by the axilla 






Bioimpedance (Hemo Sapiens) was performed to measure various cardiac 
parameters including cardiac index, cardiac output, heart rate, stroke index and 
stroke systemic vascular resistance index. Eight solid gel electrodes were placed over 
the neck (one pair at the side and one pair at the root of the neck) and lower thorax 
(one pair at the side of the thorax at the level of xiphoid process and one pair below it) 
as suggested by the manufacturer. The measurement of different cardiovascular 
parameters were done by sending a current passing through the thorax by the pair of 
electrodes placed on side of the neck and the pair of electrodes placed below the 
xiphoid process. The current on its way through the thorax seeks the shortest and the 
most conductive pathway, thus flowing mainly through the thoracic aorta and vena 
cava. This current then produces a high-frequency voltage across the impedance of 
the thorax, which is sensed by the two other pairs of electrodes placed inside the 
current path (the pair of electrodes placed at the root of the neck and the pair place at 
the side of thorax at the level of the xiphoid process). Unfortunately it was not 
possible to measure these data as the UV radiation source interfered with the delicate 
electrical measurements and meaningful data could not be collected. Data obtained 
via bioimpedance presented with values exceeding normal range (figure 3.2-B, 
normal stroke volume range from 70~100 mL), however, can act as an indicator for 
changes in cardiovascular parameter during the study. 
An intravenous cannula sized 18 G (B.Braun) was inserted into the left antecubital 
fossae before the study commenced. A luer lock tube (BD Connecta) along with 
membrane adaptor (Sarstedt) was connected to the cannula for the easiness of 
multiple blood sampling. Venous blood samples were collected immediately prior to, 
immediately after and every twenty minutes after irradiation for the measurement of 
nitro-species. After collection of venous blood samples in 9 ml EDTA tubes 
(Sarstedt), 0.9 ml of N-Ethylmaleimide (NEM) solution was added to the sample (to 
prevent degradation of RSNO) (Rassaf et al., 2004) to achieve 10 mM NEM final 
concentration and gently inverted five times to ensure adequate mixing, then the 





centrifugal force (RCF). Immediately after centrifugation, plasma was collected by 
carefully pipetting off the supernatant without disturbing the buffy coat and 
transferred into fresh Eppendorf tubes. The samples were then snap frozen in dry ice, 
and then placed into a -80 °C freezer until analyzed by Dr Fernandez at the 
University of Warwick. Vitamin D blood samples were collected using a plain tube 
from the volunteers 60 minutes before, immediately after and 24 hours after active 
irradiation. Vitamin D samples were analysed by the NHS laboratory using the high-
pressure liquid chromatography-atmospheric pressure chemical ionization-mass 
spectrometry (HPLC-APCI-MS) (Knox et al., 2009). This method has been reviewed 
recently by Snellman and colleagues in comparison with other available commercial 
assays. They suggest HPLC-APCI-MS being the method with highest accuracy in 
analyzing 25-hydroxyvitamin D (Snellman et al., 2010). However, whether the 
method performed by the NHS laboratory was up to standard is not known. 
NEM (N-Ethylmaleimide) solution 
NEM solution was created by dissolving 2.5 gram of NEM into 200 ml of phosphate 
buffer saline solution, reaching a final concentration of 0.1 M. 
The UVA lamp used to irradiate the WTCRF group volunteers was the Waldmann 
GH-8st unit with 8 F851 100W bulbs (Herbert Waldmann). This lamp was calibrated 
by the department of medical physics (Ms. Karne McBride) for safety and 
calculation of the time required to deliver 20 J/cm2 of energy. A Macam UV203 
(#6191) meter and UVA head (#843) was used for the measurement according to 
national standard (refer to page 215 for the detail measurement report). A total 
energy of 20 J/cm2 was delivered to all the volunteers by placing the lamp 21 cm 
above their chest for 22 minutes. Aluminium foil was taped as a ‘curtain’ around the 
sides of the lamp to prevent UV spilling out. Eye protection consisting of UV 






     2.1.2.2 Indigo sun blood pressure study 
2.1.2.2.1 Study protocol 
The study protocol (version 3) was approved by the South East Scotland Research 
Ethics Committee 02, with the LREC reference of 08/S1102/6 and conducted under 
compliance with the Declaration of Helsinki principles. 3 healthy male and 6 healthy 
female volunteers aged between 33~67 years old (mean 51±4.02) were recruited to 
participate in this study from the Edinburgh city population. All volunteers were 
provided a volunteer information sheet 24 hours prior to signing consent. The main 
difference of this study from the previous one was no control in diet, irradiation of 
bigger surface area, older age group and separate visits for active and sham 
irradiation. 
The study took place at a tanning salon situated in Edinburgh City (134 Lothian 
Road), this site was been approved by the South East Scotland Research Ethics 
Committee 02. Volunteers were requested to come for two visits in this study, one 
for active and one for sham irradiation. The orders of these visits were randomised. 
After signing the consent, a cannula was inserted in the left ante cubital vein and 
volunteers were treated the same as the previous study, in which they lay quietly for 
30 minutes in their underwear with blankets on the ‘tanning bed’ that have 44 bulbs 
before the sham or active irradiation. Unfortunately according to the tanning salon’s 
regulation of erythema, 20 J/cm2 of energy were not allowed to be given to the 
volunteers and they received 12 or 16 J/cm2 depending on their skin type and past 
tanning experience. Data monitoring was continued for one hour following 





Figure 2.2 Indigo Sun protocol flowchart 
 
2.1.2.2.2 Measurements and interventions 
Blood Pressure 
Blood pressure was measured by an ambulatory blood pressure machine, Omron 705 
IT every 15 minutes throughout the study. To minimize possible measurement errors, 
three measurements were performed and the average of the three measurements was 
taken as the final record. 
Temperature 
Body core temperature were monitored continuously by the skin temperature probe 
mentioned in the RIECRF study, the probe was placed at the axilla region to 
determine temperature change. 
An intravenous cannula sized 20 G was inserted into the left cubital fossae before the 
study commenced, blood sampling procedure is same as described in the RIECRF 
study. After obtaining the blood samples by the 4.7 ml EDTA tubes, 0.47 ml of NEM 
was added to the sample where same procedure was then followed, samples collected 
in this study were snap froze by liquid nitrogen, which then placed into a -20 °C 





The UVA source of this study was the Ergoline Excellence 800 turbo sun bed along 
with the Cosmedico VHR 9K90 bulbs. The spectral output of the unit was measured 
by Ms. Karne McBride with a Macam SR9910-v7 double monochromator 
spectroradiometer and Macam UV203 (#6191) meter with UVA head (#843) (refer 
to page 217 for detail measurement report). In compliance with the tanning salon’s 
regulation, 12 J/cm2 (6 min under the tanning lamp) was delivered to skin type II 






     2.1.2.3 Lauriston blood pressure study 
2.1.2.3.1 Study protocol 
This study is a repetition of the previous RIECRF blood pressure study, which took 
place in Lauriston Building clinical examination room. I repeated the high nitrate diet 
visit but gave no oral nitrate load before the study commence, as this will bias the 
blood pressure. 12 healthy male volunteers aged between 20~23 years old with the 
mean of 21.75±0.25 were recruited to participate in this study. All volunteers were 
provided a volunteer information sheet 24 hours prior to signing consent. As the 
finding in RIECRF study was small, this study aimed to increase the sample size and 
repeat the high nitrate diet visit mentioned in the RIECRF study but without oral 
nitrate load and blood sampling. 
Exactly the same protocol as described in the RIECRF study was followed but 
without blood sampling. Skin temperature instead of core temperature were 
monitored, simplified protocol flow chart is shown as below. 
 





2.1.2.3.2 Measurements and interventions 
Blood Pressure 
Blood pressure was measured in the same way as mentioned in the RIECRF study, 
but instead of one measurement, three measurements were performed. 
Temperature 
As no change in core temperature was observed in the RIECRF study, skin 
temperature was monitored by temperature probes from two different sites (chest and 
back), the average of the two measurements were used for analysis. 
 
UVA Irradiation 




2.1.3 Blood flow studies 
     2.1.3.1 Skin blood flow study 
2.1.3.1.1 Study protocol 
The study protocol (version 3) was approved by the South East Scotland Research 
Ethics Committee 03, with the LREC reference of 10/S1103/52 and conducted under 
compliance with the Declaration of Helsinki principles. The study was performed on 
4 male volunteers aged between 23~48 years (mean 32.5±5.84) to test for UVA’s 
effect on SBF. 
The study took place in a quiet room with comfortable lighting and constant 
temperature (22~24 °C). During the day of the study, volunteers were been requested 
to undress till underwear and lie on the bed. A sheet or blanket was provided to keep 
the volunteers warm which was only removed during the UVA irradiation. Once all 
equipment was in place, the minimal and maximal SBF was determined by inflating 
a blood pressure cuff to 300 mmHg for five minutes. This was followed by a period 
of resting time, UVA irradiation, and twenty minutes of SBF observation. 
 




2.1.3.1.2 Measurements and interventions 
Skin Blood Flow 
Laser Doppler flowmetry was used to measure SBF at non-UVA irradiated site. Prior 
to any interventions, three laser Doppler probes (Moor Instruments) were been 
attached to the ventral aspect of the left forearm, with each probe at least one cm 
apart from the other. As the data generated by laser Doppler flowmetry is relative 
and not absolute, to record data which could be compared between individuals it was 
necessary to first know the maximum and minimum SBF. This was done by applying 
a sphygmomanometer cuff (BOSCH + SOHN GMBH) to the left arm and inflating 
the cuff to 300 mmHg for five minutes and then deflating it. The minimal blood flow 
was calculated by using the mean value of the last minute during occlusion, and the 
maximal blood flow was determined by taking the mean value of the peak blood 
flow over a duration of twenty seconds during reactive vasodilatation. To assure that 
the temperature generated by UVA lamp did not influence the SBF at the measuring 
site, we occluded the measuring site with aluminium foil. 
Temperature 
Skin temperature probe was placed at the ventral aspect of the left forearm next to 
the area where laser Doppler probes were placed, and temperature measured 
continuously using the skin temperature probe system described earlier in the blood 
pressure study. 
The UVA source (Waldmann GH-8st with 8 F851 100W bulbs), dose and method of 
delivery is the same as mentioned in the RIECRF blood pressure study. The only 





     2.1.3.2 Forearm blood flow study – Phase 1 (Infrared & UVA) 
2.1.3.2.1 Study protocol 
The study protocol (version 5b) was approved by the South East Scotland Research 
Ethics Committee 02, with the LREC reference 08/S1102/6 and conducted under 
compliance with the Declaration of Helsinki principles. 12 healthy male volunteers 
aged between 20~48 years old with the mean of 24.75±2.27 were recruited to 
participate in this study. All volunteers were provided with a volunteer information 
sheet 24 hours prior to signing consent. 
The study took place in a quiet room with comfortable lighting and constant 
temperature (22-24 °C). Volunteers were been asked to come for one visit, which 
during the day of the study, they were been requested to expose both of their arms 
and relax on a comfortable bed. Prior the study commence, one cannula was inserted 
in both the left and right arm. 
After forty minutes of resting period, the right arm of the volunteer was irradiated 
with the UVA lamp and the left arm by the infrared lamp for twenty two minutes. 
Data collection was continued for one hour thereafter. A flow chart of the study is 
shown below. 
 




2.1.3.2.2 Measurements and interventions 
Forearm Blood Flow 
Venous occlusion plethysmography is a non-invasive technique to determine FBF. 
FBF was measured in both the left and right arm by applying one blood pressure 
cuffs around the upper arm (Hokanson) and a second cuff around the wrist (Hokanson) 
of each limb. In between the two cuffs, a mercury in silastic strain gauge (Hokanson) 
was fastened around the forearm. The size of the mercury in silastic strain gauge 
used in each volunteer was determined by measuring the forearm circumference of 
the volunteers, and using a strain gauge 2 cm shorter than this. FBF was measured 
every twenty minutes before UVA irradiation and every fifteen minutes after 
irradiation. Before the study commenced, the strain gauge was calibrated 
electronically so that 1 % change in voltage equals to a 1 % change in limb volume. 
Each set of measurements lasted three minutes, and during this period the arm cuff 
was inflated to 40 mmHg for nine seconds and deflated for three seconds, the cycle 
being repeated for three minutes. The wrist cuff was inflated to 200 mmHg and 
remained inflated throughout the three minutes measurement period. During the nine 
seconds that upper-arm cuff was inflated to 40 mmHg, venous return from the 
forearm to the arm was blocked and as the writs cuff was inflated to 200 mmHg, this 
prevents the arterial blood to exit from forearm into the hand, making the forearm an 
isolated chamber which only allows arterial inflow from the arm. During the nine 
seconds that venous return was blocked the increase in forearm circumference is 
directly related to arterial blood flow into the arm. This dilation caused by the arterial 
inflow stretches the mercury in silastic strain gauges, where this stretch was 
converted to an electric voltage and was recorded by Chart 5 for Windows, this 
allows us to further analyze the FBF. 
A 20 G cannula was inserted into the left and right antecubital fossa before the study 
started. Venous blood samples were collected simultaneously from both arms twenty 





the study ended. Method of blood sampling and processing is the same as mentioned 
in the RIECRF study. Samples were stored in a -80 °C freezer until analysed by Dr. 
Fernandez at the University of Warwick. 
Temperature monitoring and control 
Skin temperature was continuously monitored using the same system mentioned in 
the blood pressure study. One temperature probe was placed a centimetre above the 
wrist cuff of the right forearm and the other temperature probe was placed one 
centimetre above the wrist cuff of the left forearm to determine the skin temperature 
change caused by the UVA or IR lamp. 
With two temperature probes, I was able to monitor the skin temperature at both arm 
simultaneously, thus the infrared lamp was moved closer and further away from the 
irradiating site during the irradiation, mimicking the same temperature rise produced 
by the UVA lamp. 
UVA source 
The UVA source being the same as RIECRF study (Waldmann GH-8st with 8 F851 
100W bulbs), and a total energy of 20 J/cm2 was delivered to all the volunteers, with 
the lamp placed 21 cm above the volunteers’ right upper limb for 22 minutes. 
Irradiation was been given to the volunteers’ right upper limb with nothing (except 
the venous occlusion plethysmography cuffs) covering the limb. 
An infrared lamp (Efbe Elektrogeräte) used to irradiate the volunteers’ left arm was 
tested by the medical physic department in Western General Hospital for safety and 
to exclude overlapping of UVA spectrum. The infrared lamp was been shifted back 
and forth during the irradiation period to generate a similar temperature rise caused 





     2.1.3.3 Forearm blood flow study – Phase 2 (L-NMMA) 
2.1.3.3.1 Study protocol 
The study protocol (version 2) was approved by the South East Scotland Research 
Ethics Committee, with the LREC reference of 11/AL/0130 and conducted in 
compliance with the Declaration of Helsinki principles. 12 healthy male volunteers 
aged between 19~30 years old (mean 22.42±0.82) took part in this study. All 
volunteers were provided with a volunteer information sheet 24 hours prior to 
signing consent. 
The study took place in a quiet room with comfortable lighting and constant 
temperature (22~24 °C). Volunteers were asked to come for two visits, during which, 
exposed both of their arms and relaxed on a bed. Before the study commenced, 
cannulae were inserted in both the left and right arm. 
Volunteers attended twice, with at least one week between visits. During one visit, 
they received active UVA irradiation just to the arm that was given L-NMMA 
infusion, and on the other visit sham UVA irradiation along with L-NMMA infusion. 
For the sham irradiation they were covered by a space blanket during the UVA 
irradiation. During the active irradiation an electric fan was used to control the skin 
temperature of the irradiated site, keeping it as close as possible to baseline. 
During the day of the study, participants underwent cannulation of the brachial artery 
in the non-dominant arm with a sterile 27G standard wire gauge steel needle. Study 
drugs were infused via this cannula. 17 G venous cannulae were inserted under local 
anaesthetic into both ante-cubital fossae for blood sampling. A twenty minute period 
of equilibration took place during which period intra-arterial saline was administered 
at a rate of 1 mL/min. Subsequently, intra-arterial L-NMMA was infused at a rate of 
8 µmol/min (this was approached by reconstituting one vial of L-NMMA (1006 




Twenty minutes after the L-NMMA infusion commenced, volunteers were irradiated 
over their L-NMMA infused arm. Observations carried on for forty-five minutes 
after the irradiation. A flow chart of the study is shown below. 
 
Figure 2.6 Forearm blood flow (phase – 2) protocol flowchart 
 
2.1.3.3.2 Measurements and interventions 
1. Identify the tendon of the biceps and palpate medial to the tendon for the 
brachial artery pulsation to decide for the site of needle insertion. 
Brachial artery cannulation 
Brachial artery cannulation was performed on all participants to allow drug infusion. 
This procedure was done by trained cardiologists according to the following steps. 
2. Clean the site of insertion with alcohol swabs (sterile gloves (Molnlycke 
Health Care) were worn). 
3. 2 % lidocaine hydrochloride (Hameln) was injected subcutaneously at the site 
for local anaesthetic. 




5. Insertion of the 27 standard wire gauge steel needle at a 45° angle where the 
brachial artery was palpated, when the needle is above the artery, pulsation of 
the artery can be felt vibrating through the needle. 
6. Once the distal needle is in the artery (confirm by flashback of blood into the 
catheter), the proximal end was connected to the infusion pump. 
7. Secure the catheter and place the volunteer’s arm into the position in which it 
will remain for the rest of the study. 
8. Check for reflow of the catheter again before the study commences. 
9. Normal saline (Baxter) was infused for the first twenty minutes and L-
NMMA (Clinalfa) thereafter until the study finishes.  
 
Forearm Blood Flow (FBF) 
Venous occlusion plethysmography, the exact same method used to measure FBF in 
the previous UVA/IR study was used in this study. FBF was measured every twenty 
minutes before UVA irradiation and every fifteen minutes post irradiation. 
Blood samples 
A 17 G cannula was inserted into the left and right ante-cubital fossae before the 
study commenced. Venous blood samples were collected simultaneously from both 
arms twenty minutes before the UVA irradiation and thereafter at twenty minutes 
interval until the study ended. Method of blood sampling and processing is exactly 
the same as that of RIECRF study. Samples were stored in a -80 °C freezer until 
analysed by Dr. Fernandez in the University of Warwick. 
Body temperature was continuously monitored by a computer program “Chart 5 For 
Windows” use in coordination with M309 Thermistor Pod along with the MLT422/A 
Temperature Probe. One temperature probe was placed one cm proximal to the wrist 
cuff of the right forearm and the other temperature probe was placed at one cm 




proximal to the wrist cuff of the left forearm to determine the skin temperature 
change caused by the UVA lamp. 
As the computer program “Chart 5 for Windows” instantly records the skin 
temperature change, during the active irradiation visit of the study an electric fan was 
placed next to the forearm which was switched on and off to control the skin 
temperature change during active irradiation as close as possible to that of pre-
irradiation. 
The UVA lamp used in this study was the Waldmann GH-8st unit with 8 F851 100W 
bulbs, a total energy of 20 J/cm2, was delivered to all the volunteers, with the lamp 
placed 21 cm above the volunteers’ right upper limb for 22 minutes. During active 
irradiation the volunteer’s right upper limb (which is also the L-NMMA infused limb) 
was exposed to the UVA source directly (except the venous occlusion 
plethysmography cuffs) and during sham irradiation a sheet of silver foil was placed 
in-between the lamp and the L-NMMA infused arm to prevent direct exposure. The 
contra-lateral arm (non-infused arm) was not exposed to UVA at all during both 





2.1.4 Bleeding time study 
     2.1.4.1 Study protocol 
The study protocol (version 2.1) was approved by the South East Scotland Research 
Ethics Committee, with the LREC reference of 11/AL/0131 and conducted in 
compliance with the Declaration of Helsinki principles. 6 healthy male and 6 healthy 
female volunteers aged between 21~49 years old (mean 23.83±2.29) were recruited 
to participate in this study. All volunteers were provided with a volunteer 
information sheet 24 hours prior to signing consent. 
In this study, the volunteers came for two visits (at least one week apart). During one 
visit they received whole body UVA irradiation without space blanket (active 
irradiation) and the other visit with space blanket covering them during UVA 
irradiation (sham irradiation). The study took place in a quiet room with comfortable 
lighting and constant temperature (22~24 °C). After signing a written consent, 
volunteers were requested to undress till underwear and lie on a bed, with a blanket 
(which was removed during irradiation) covering them. Thirty minutes of resting 
time was given to allow blood pressure to settle, this was followed by 22 minutes of 
UVA irradiation and one hour of data collection. A flow chart of the study is shown 
below. 
 




     2.1.4.2 Measurements and interventions 
Bleeding time 
Measurements of bleeding time were performed by Surgicutt (ITC Medical), an 
automatic disposable device that makes an incision with the depth of 1 mm and 
length of 5 mm every time. During the measurement, the volunteer’s arm was placed 
on a steady support with the volar surface exposed. A sphygmomanometer cuff 
(BOSCH + SOHN GMBH) was wrapped around the upper arm and inflated to 40 
mmHg, within 60 seconds, the site of incision was cleaned with alcohol swabs and 
an incision was made by the surgicutt blade. Every 30 seconds, the blood was wicked 
away with blotting paper (ITC Medical) until the bleeding stops. Bleeding time was 
recorded as the time from which the incision was made until the bleeding stops 
(bleeding time was measured before UVA irradiation, immediately after irradiation 
and at twenty minutes post irradiation). 
Temperature monitoring and control 
The same system was used to measure skin temperature. This time I placed one 
temperature probe over the anterior surface of the thigh and the other temperature 
probe close to the site where incisions for bleeding time measurement were 
performed. Skin temperature control was achieved by using two electronic fans 
blowing at the volunteer’s body from different direction to assure whole body 
cooling. 
The UVA source (Waldmann GH-8st with 8 F851 100W bulbs), dose and method of 





2.2 in vitro studies 
2.2.1 Materials 
Hydrochloric acid 
Chemicals / Solutions / Kits 
Thermo Fisher Scientific, Leicestershire, 
United Kingdom 
L-Cysteine hydorcholride 1-hydrate BDH Merck, Poole Dorset, United Kingdom 
Nitrogen (Oxygen-Free) BOC Tradequip, Edinburgh, United Kingdom 
Phosphate Buffered Saline Sigma Aldrich, Dorset, United Kingdom 
Potassium nitrate, 99+% 
Thermo Fisher Scientific, Leicestershire, 
United Kingdom 
Sodium hydroxide 
Thermo Fisher Scientific, Leicestershire, 
United Kingdom 
Sodium nitrite Analar Standards, Dorset, United Kingdom 
Sulphanilamide Sigma Aldrich, Dorset, United Kingdom 
 
Chemiluminescence (42C NO-NO2-NOx 
Analyzer) 
Equipments (non-disposable) 
Thermo Environmental Instruments, Franklin, 
MA, United States 
PowerLab 4/20 PowerLab, Christchurch, New Zealand 
Monochromator (model 66921, Xe and 
Hg(Xe) DC arc lamp, 200~2500 nm) 
Oriel Instruments, Stratford, Connecticut, 
United States of America 
Syringes for sample injection (µL 
syringes) 
SGE Analytical Science, Ringwood, Australia 
Ultra violet A source (UVA cabinet), 
 
 
12 Philips TLK 40W/10R bulbs 
(350~400 nm, max at 360 nm) – refer to 
page 214 for spectral distribution 
Department of Medical Physics & 
Engineering, Royal Infirmary Edinburgh, 
United Kingdom 








Determination of nitrite and nitrate by gas phase chemiluminescence (Thermo 
Environmental Instruments) was described by Cox as early as 1980 (Cox, 1980). 
Different solutions for reduction of nitrite and nitrate into nitric oxide have been 
suggested (Cox, 1980, Braman and Hendrix, 1989, Feelisch et al., 2002), but the 
setup of the equipment remains more or less the same. 
To determine nitrate and nitrite concentration by gas phase chemiluminescence, 
nitrate and nitrite need to be first reduced to nitric oxide. This process is completed 
in the stripping vessel. Once the nitric oxide carried by the nitrogen gas enters the 
reaction chamber, it rapidly reacts with ozone (O3) releasing nitrogen dioxide. This 
nitrogen dioxide released during the reaction of nitric oxide and O3 arises in an 
electronically excited state (NO2*) (Greaves and Garvin, 1959), which on decay to its 
ground state, emits light in the near-infrared region and can be quantified by a 
photomultiplier (Clough and Thrush, 1967). 
1 M of Sodium hydroxide was connected between the stripping vessel and the 
reaction chamber for trapping traces of acid and iodine from entering the detector. 
A gas reservoir bag was connected between the N2 gas cylinder (BOC Tradequip) 
and the stripping vessel to replace a flow control valve. Since the rate of the suction 
pump is fixed, the gas reservoir bag was filled with N2 all the time, and any extra N2 
gas will exit the reservoir bag via the valve, thus keeping the flow constant. 
Sodium hydroxide solution 
NaOH solution was prepared by mixing 40 g of NaOH (Thermo Fisher Scientific) 





Figure 2.8 Chemiluminescence setup 
 
2.2.3 Monochromator study 
A monochromator that can generate specific wavelength within the range of 200 ~ 
2500 nm was used to determine the max release of nitric oxide from sodium nitrite 
solution. The monochromator lamp was calibrated and the duration required by each 
wavelength to deliver 1 J was determined by the Ms. Karne McBride using the Ophir 
3AP (refer to page 219 for detail measurement report). The study took place in a dark 





Figure 2.9 Monochromator setup (chemiluminescence system simplified) 
 
 




     2.2.3.1 Nitric oxide release from nitrite by different wavelength 
Once the chemiluminescence analyser was prepared, 4.5 ml of phosphate buffered 
saline and 0.5 ml of 0.1 M sodium nitrite were injected into the stripping vessel. 
With the monochromator set to a specific wavelength (ranging from 260~400 nm 
with an interval of 10 nm) and switched on for irradiation of nitrite solution and the 
amount of nitric oxide release was measured by chemiluminescence. The irradiation 
of nitrite solution was done by placing the light guide against a piece of quartz plate 
(to allow the full transmission of UV radiation through the stripping vessel and 
prevent absorbance of wavelength by normal glass. The lower part of the vessel was 
modified by the glass blower in the University of Edinburgh Chemistry department 
to incorporate a piece of quartz cuvette) that replaced the original glass of the 
stripping vessel. Every time a new measurement was made, the stripping vessel was 
cleaned and new aqueous nitrite solution was added. 
One joule of energy was delivered at each wavelength. The duration of irradiation for 
each wavelength varied since the irradiance of each wavelength is different (refer to 
chapter 5.2.1 (table 5.1) for the exact time required to deliver 1 J of energy at each 
particular wavelength). The data collected was then presented as area under the curve. 
     2.2.3.2 Dose response of nitrite photolysis 
With the same monochromator setting used in the wavelength study, 340 nm was 
chosen to conduct a dose response on both the irradiation time and sodium nitrite 
concentration. 
5 ml of 0.001 M or 0.01 M of sodium nitrite was injected into the stripping vessel 
and irradiated for 10, 20, 40, 80, 160, 320 and 640 seconds. The data collected was 
then presented as area under the curve. 
200 ml of Phosphate buffer saline is made by dissolving one PBS tablet (Sigma 




Aldrich) into 200 ml of distilled water. After they were made, they were stored in a 
2~5 °C refrigerator and discarded when turbidity was seen. 
Aqueous nitrite solution 
The different concentration of nitrite solution used for the laboratory study was a 
mixture of sodium nitrite (NaNO2) (Analar Standards) with phosphate buffered 
saline, aiming to maintain the neutral pH. 
2.2.4 Thiol study 
UVA source 
The UVA source used is the monochromator lamp (Oriel Instruments) that allows 
wavelength to be set at a particular wavelength ranging from 200~2500 nm. 
Irradiation time varies at each wavelength depending on the irradiance. 
After setting up the chemiluminescence, 10 ml of cysteine solution was injected into 
the stripping vessel before each measurement, this was followed by the following 
procedure. 
1. Addition of 1 ml of 0.01 M potassium nitrate into the cysteine solution 
2. Addition of 1 ml of 0.01 M potassium nitrate into the cysteine solution 
followed by broad spectrum UVA irradiation 
3. Addition of 2 ml of sulphanilamide / hydrochloric acid mixture then 1 ml of 
0.01 M potassium nitrate into the cysteine solution, this allows binding to 
nitrite as explained earlier. 
4. Addition of 2 ml of sulphanilamide / hydrochloric acid mixture then 1 ml of 
0.01 M potassium nitrate into the cysteine solution followed by broad 




5. Addition of 1 ml of 0.01 M potassium nitrate followed by broad spectrum 
UVA irradiation then 2 ml of sulphanilamide / hydrochloric acid mixture 
during the irradiation 
6. Addition of 1 ml of 0.01 M potassium nitrate then 2 ml of sulphanilamide / 
hydrochloric acid mixture into the cysteine solution followed by broad 
spectrum UVA irradiation 
 
Aqueous nitrate solution 
The different concentration of nitrate solution used for the laboratory study was a 
mixture of potassium nitrate (KNO3) (Thermo Fisher Scientific) with phosphate 
buffered saline, depending on the protocol of the study. 
Aqueous cysteine solution 
Cysteine solution was prepared into 0.05 M solutions by mixing L-Cysteine 
hydorcholride 1-hydrate (BDH Merck) with phosphate buffered saline. 
Sulphanilamide / Hydrochloric acid mixture 
Laboratory use of sulphanilamide / hydrochloric acid mixture was prepared into 5 % 
weight by volume, usually done by adding 1.5 gram of sulphanilamide (Sigma 
Aldrich) into 30 ml of 1 M hydrochloric acid. Treating solution/samples with 
sulphanilamide allows reaction with nitrite to form diazonium salt, thus preventing 
nitrite to be reduced to nitric oxide. 
 
UVA source 
The UVA source that was used for the cysteine study was a bespoke cabinet 
containing a panel of 12 Philips TLK 40W/10R bulbs (350~400 nm, max at 360 nm) 





2.3 Primary Care Clinical Information Unit (PCCIU) Database study 
The PCCIU collects patient data from more than 200 practices and has about one 
million patients’ data recorded. Data on patients who had been diagnosed with 
squamous cell carcinoma of the skin were been requested. Each patient was matched 
with 3 controls matched for age, gender, and practice. The database was cleaned to 
exclude obvious input errors (for example typing mistakes) and classified into groups 
using the date skin cancer was diagnosed as a cut-off point. Using the group of 
individuals that developed cardiovascular diseases before the diagnosis of squamous 
cell carcinoma I was able to conduct a case-control study by observing whether the 
presence of cardiovascular diseases increase / decrease the odds of developing 
squamous cell carcinoma. Conditional logistic regression was used as the method of 
analysis for this study as this measures the relationship between an outcome and a set 
of prognostic factors in matched case-control (So and Sas Users Grp, 1993). Using 
the group of individuals that developed cardiovascular diseases after the diagnosis of 
squamous cell carcinoma, I was able to conduct a retrospective cohort study by 
observing whether the presence of squamous cell carcinoma increases or decreases 
the risk of various cardiovascular diseases in the future. 
Inclusion criteria 
Cases were defined as those that were diagnosed with SCC of the skin. SCC cases 
were chosen specifically for this study as SCC of the skin in the epidemiology shows 
a direct correlation between total lifetime sun exposure. Bowen’s disease was also 
included as it can be a precursor to SCC.  
Three matched controls were selected by to match each case’s age, gender and 
general practice they have attended (living environment). Those that presented with 
other non-SCC skin neoplasms were excluded to be selected as there are still some 
positive correlations with sun exposure.  





- Subjects on immunosuppressive drugs, as this increase the risks of 
developing SCC. 
- Subjects who have had organ transplants, as they will likely to be put on 
immunosuppressive drugs. 
- Subjects with chronic (>6 months) venous ulcers, as this predispose to 
Marjolin’s ulcers, which is a form of SCC. 
- Subjects infected with human immunodeficiency virus as immune-
compromised individuals are more prone to develop skin cancer. 
- Subjects with psoriasis, as they have a higher incidence of developing 





2.4 Software programs and statistic packages 
GraphPad Prism (v5.01) 
GraphPad Software, La Jolla, California, 
United States of America 
LabChart 5 ADInstruments, Chalgrove, United Kingdom 
LabChart 7 (v7.3.1) ADInstruments, Chalgrove, United Kingdom 
Microsoft Office 2007 
Microsoft, Waverley Gate, Edinburgh, United 
Kingdom 
moorLAB (v1.31) Moor Instruments, Devon, United Kingdom 
R (v2.13.2) 
R Development Core Team (2012). R: A 
language and environment for statistical 
computing. R Foundation for Statistical 
Computing, Vienna, Austria. ISBN 3-900051-
07-0, URL http://www.R-project.org/. 
SPSS (v17.0) 
IBM Corporation, Armonk, New York, 




2.5 Statistical analysis 
All data were processed and organized in Microsoft® Excel except for the PCCIU 
database, which was organized in SPSS; statistical analysis was done by using the 
statistic packages GraphPad Prism 5, SPSS, or R. Shapiro-Wilk test, paired Student’s 
t-tests, Pearson correlation, one-way repeated measures analysis of variance 
(ANOVA) with post hoc test (Bonferroni’s Multiple Comparison Test), Friedman 
test with post hoc test (Dunn’s multiple comparison test), two-way ANOVA and 
conditional logistic regression along with Wald’s test were performed where 
appropriate according to the data type. Area under the curve and the slope data were 
obtained from the program that quantifies nitric oxide releases, Chart 5/7 for 
Windows. All data are presented as mean ± standard error of the mean unless 
otherwise specified. P value of less than 0.05 was considered significant. 
1. Shapiro-Wilk test was used to determine dataset for Gaussian distribution. 
2. Paired Student’s t-test was used when comparing two groups of Gaussian 
distributed data with one measure. This test was performed in GraphPad 
Prism, measuring within subjects test group vary over 2 test conditions. 
3. One-way repeated measures analysis of variance ANOVA with post hoc test 
(Bonferroni's multiple comparison test) was used when looking for 
significance between different time points within a group of Gaussian 
distributed data that have multiple measures. In SPSS, within subject factor 
for one-way repeated measures ANOVA was determined by the effect of 
UVA on the primary outcome (e.g. blood pressure, FBF, heart rate). The level 
was defined by the number of time points performed in the study (e.g. if 
blood pressure was measured 6 times, the level equals to 6). 
4. Friedman test with post hoc test (Dunn’s multiple comparison test) was used 
when looking for significance between different time points within a group of 
non-Gaussian distributed data that have multiple measures. GraphPad Prism 
was used to perform this analysis, within subject factor and levels were 
determined the same way as that of one-way repeated measures ANOVA. 
5. Two-way repeated measures ANOVA was used when comparing two or 




performed by GraphPad Prism. Two-way repeated-measures ANOVA was 
used to analyze the effect of UVA (between-subject) and time (within-subject) 
variables on the primary outcome (blood pressure, heart rate etc). Three types 
of interactions were tested. First, the interaction of time course with UVA 
irradiation. Second, the interaction of sham and active UVA irradiation. Third, 
the interaction of the time course. 
6. Conditional logistic regression and Wald’s test was used to investigate the 
relationship between the outcome of matched cases and controls with a set of 
prognostic factors. This statistic test was performed by the statistic package R. 




















SYSTEMIC CARDIOVASCULAR RESPONSE TOWARD 





Cardiovascular diseases inflict a heavy economic burden (Leal et al., 2006, Devol 
and Bedroussian, 2007) and caused more than thirty percent of global deaths in 2008 
(Mendis et al., 2011). Hypertension was shown to be a risk factor of many other 
cardiovascular diseases such as stroke (Wolff and Lindeman, 1966, Macmahon et al., 
1990, Probstfield, 1991, Rodgers et al., 1996), atherosclerosis (Young et al., 1960), 
coronary heart disease (Macmahon and Rodgers, 1993) and myocardial infarction 
(Dagostino et al., 1991, Flack et al., 1995). Macmahon and colleagues showed a 
reduction of diastolic blood pressure (DBP) by 5 mmHg decreases risk for stroke by 
34% and coronary heart disease (CHD) by 21%. Lewington et al., reported that a 
reduction of systolic blood pressure (SBP) by 20 mmHg to 115 mmHg or DBP by 10 
mmHg to 75 mmHg will lead to a twofold decrease in mortality due to stroke, 
ischaemic heart disease, and other vascular diseases in both men and women aged 40 
to 69 years (Macmahon et al., 1990, Lewington et al., 2002). Thus any form of blood 
pressure reduction in those with blood pressure higher than 115/75 mmHg would 
improve their cardiovascular mortality and lighten economy burden. 
Blood pressure and cardiovascular events correlate linearly with latitude (Rostand, 
1997, Law and Morris, 1998) and also vary according to seasonal changes (Brennan 
et al., 1982, Winnicki et al., 1996, Sega et al., 1998). As vitamin D also correlates 
with season and latitude (Webb et al., 1988), seasonal variations in blood pressure 
and cardiovascular events have been suggested to be vitamin D dependent, especially 
when UVB was found to photolyse 7-dehydrocholesterol to cholecalciferol in the 
skin (Lehmann et al., 2001). Cholecalciferol is then hydroxylated in the liver and 
kidney to form 1,25-dihydroxyvitamin D3, the most active form of vitamin D3. 
Studies on Vitamin D supplementation have however, refuted the hypothesis that 
temperature and vitamin D account for the higher cardiovascular mortality and blood 
pressure in places with little sunshine. Most studies suggest that vitamin D 
supplement is not protective against hypertension (Margolis et al., 2008, Pittas et al., 




al., 2005, Hsia et al., 2007, Prince et al., 2008, LaCroix et al., 2009). 
Recently, I, my supervisor, and others have proposed an alternative hypothesis to 
explain the lower blood pressure and risk of developing cardiovascular disease in 
summer and closer to the equator (Feelisch et al., 2010). Nitric oxide generated either 
by nitric oxide synthase mediated oxidation of L-arginine or by reduction of nitrate, 
is a potent vasodilator. Nitrite in the epidermis alone is approximately 135 µmoles, 
while total nitrite in blood rarely exceeds 13~15 µmoles (Mowbray et al., 2009), 
after calculation, nitrite stored in the skin is one to two orders of magnitude higher 
than those in circulation (Paunel et al., 2005, Mowbray et al., 2009). UVA can photo-
decompose nitrite to form nitric oxide (Treinin and Hayon, 1970, Zafiriou and 
Bonneau, 1987) and can penetrate up to 500 µm in human skin (Tuchin, 1993) thus 
will be able to pass through the epidermis (83.7±16.6 µm) (Sandby-Moller et al., 
2003) and reach the dermal layer. The increased circulatory nitrite post UVA 
irradiation of human skin (Paunel et al., 2005, Mowbray et al., 2009), suggests that 
the cardio-protective effects of sunlight might be due to UVA induced nitric oxide 
release rather than UVB induced vitamin D synthesis (Feelisch et al., 2010). This 
hypothesis has been strengthened by the Oplander study confirming that blood 





I hypothesize that UVA irradiation of human skin will photo-decompose the skin 
store and circulatory nitrite releasing nitric oxide. The nitric oxide released will then 
produce a blood pressure reduction effect. 
3.1.2 Aim 
This study had two main aims. I first set out to confirm the findings of Oplander and 
colleagues that UVA irradiation of human skin will reduce blood pressure and alter 
cardiovascular parameters independently of temperature change. I then wished to 





3.2.1 RIECRF & Lauriston blood pressure study (1st blood pressure study) 
In the Royal Infirmary of Edinburgh Clinical Research Facility (RIECRF) blood 
pressure study, 12 healthy volunteers were recruited and requested to come for two 
visits. During one visit, a low nitrate diet (as explained in chapter 2.1.2.1) was 
provided to the volunteers and they ate only this for two days before the study. In the 
other visit, they had a normal daily diet, but 5 minutes before the study started, they 
were given a nitrate load of 500 mg potassium nitrate. The order of the visits was 
randomized. 
On the day of the study all volunteers relaxed on a comfortable bed wearing only 
underwear. After 30 minutes of rest allowing blood pressure to settle to baseline, a 
sham UVA irradiation (in which volunteers were covered with a silver foil blanket 
that blocked UVA penetration) was given for 22 minutes followed by 60 minutes 
more of data collection. Immediately after the 60 minutes monitoring period, an 
active irradiation (where the ventral side of the volunteer was directly irradiated by 
an eight bulb UVA lamp with 20 J/cm2) was given for 22 minutes, and data was 
again collected for 60 minutes. 
Blood pressure, heart rate (HR), body core temperature (measured by tympanic 
thermometer or skin temperature probes placed at axilla), stroke volume and cardiac 
output were recorded at 10 minutes intervals. During the recording time, all 
movement was discouraged other than stretching. Blood samples for circulatory 
nitro-species were collected at a 20 minutes interval. Blood samples for 25-
Hydroxyvitamin D3 were collected before and 24 hours post active UVA irradiation. 
Blood pressure and blood sample data collected during the high nitrate diet visit in 
the RIECRF study will not be presented or discussed as the ingestion of oral nitrate 
load alone increases circulatory nitrate/nitrite and also produces a blood pressure 
reduction via the oral bacteria situated on the surface of the tongue (Webb et al., 




Providing an oral nitrate load to the volunteers before the study interfered with the 
result of circulatory nitro-species and alters blood pressure. Therefore, the Lauriston 
blood pressure study was conducted to replace the RIECRF study’s high nitrate diet 
visit. 
Twelve volunteers were recruited to participate in this study, with the same settings 
and protocol, the only difference in this study was no blood sampling and 
measurement of skin instead of core temperature. Refer to page 28 and 36 for detail 
of the protocol. 
3.2.2 Indigo Sun blood pressure study (2nd blood pressure study) 
To try and increase the response to UV, the decision to irradiate both sides of the 
body was made. This required a larger lamp than the one that was available in the 
clinical research facility. Commercial tanning lamps contain 44 bulbs and irradiate 
the whole body, emitting UVA and slight UVB irradiation. Another blood pressure 
study was then carried out in a commercial tanning salon (Indigo Sun) (not a 
temperature controlled environment). The purpose of this study is to reproduce the 
result shown by the Oplander group (Oplander et al., 2009). 
9 volunteers were recruited for this study and as the main aim was to confirm 
Oplander’s study result (Oplander et al., 2009), the original protocol was modified. 
Volunteers recruited to this study were older than that of the RIECRF study with a 
higher resting blood pressure. Volunteers came for two visits, during one of the visits 
they received sham irradiation and on the other active irradiation. The order of the 
visits was randomized. 
During the day of the study, volunteers lay in their underwear on the tanning bed for 
30 minutes to allow blood pressure to settle. In compliance with the tanning salon’s 
regulation, 12 J/cm2 (6 minutes under the tanning lamp) was delivered to skin type II 
individuals (n=5) and 16 J/cm2 (8 minutes under the tanning lamp) to skin type III 





Blood pressure, heart rate, and body core temperature were measured at 15 minutes 
intervals. Blood samples for measurement of circulatory nitro-species were collected 
every 20 minutes. As one of the volunteer presented with difficult venous access, 
blood samples were only collected from 8 volunteers. Refer to page 33 for detail of 
the protocol. 
3.2.3 Statistic analysis 
Data were collected and recorded in Microsoft excel, later transfer to SPSS Statistic 
17.0 and GraphPad Prism 5 for statistic analysis. Data were analyzed using the 
following statistic tests: 
1. Paired Student’s t-test when comparing two groups of Gaussian distribution 
data with one measure. 
2. One-way repeated measures analysis of variance (ANOVA) with post hoc 
test (Bonferroni's multiple comparison test) when determining significance 
between different time points within a group of Gaussian distribution that 
have multiple measures. 
3. Two-way repeated measures ANOVA when comparing two or more groups 
Gaussian distribution with multiple measures. 
Data are expressed as mean ± standard error of the mean (SEM) unless otherwise 
stated. A p value less than 0.05 (p<0.05) is considered significant and in the 






3.3.1 RIECRF blood pressure study results 
     3.3.1.1 Blood pressure 
20 J/cm2 of UVA were delivered to all volunteers during sham and active irradiation. 
SBP dropped after sham irradiation from 121.67±3.24 mmHg to 118.33±2.98 mmHg 
which returned to baseline by 10 minutes post irradiation. During active irradiation, 
SBP increased from 120.67±4.03 mmHg to 122±3.03 mmHg immediately after 
irradiation and remained above the baseline throughout. None of the changes in SBP 
were significant (figure 3.1-A). 
DBP dropped after sham irradiation from 64.5±1.87 mmHg to 61.92±2.25 mmHg 
and rebounded above the baseline at 10 minutes post irradiation to 67.08±1.60 
mmHg. Immediately after active irradiation, DBP dropped from 66.42±2.13 mmHg 
to 61.83±1.65 mmHg, and this drop in DBP was found greatest at 20 minutes post 
irradiation at 61.67±1.57 mmHg. The reduction of DBP following active irradiation 
was found to be significant immediately post irradiation and at 20 minutes post 
irradiation. No significant differences were found following sham irradiation (figure 
3.1-B). Significant difference was not found between the sham versus active group. 




DBP. MAP decreased from 
83.56±1.84 mmHg to 80.72±1.59 mmHg immediately after sham irradiation and 
returned to baseline by 10 minutes post irradiation. During active irradiation, MAP 
decreased from 84.5±1.76 mmHg to 81.89±1.55 mmHg immediately post irradiation 
and gradually returns to baseline. MAP was lowest at 20 minutes post irradiation at 
81.33±1.37 mmHg. Data are graphed to show change from baseline in the active and 
sham irradiated groups in figure 3.1-C. However, none of the changes in MAP were 
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Figure 3.1 Blood pressure change after UVA irradiation (RIECRF study) 
A) SBP change after UVA irradiation, no significant change was seen between sham 
and active irradiation. Data are presented as mean ± SEM (n=12). 
B) DBP change after UVA irradiation, a significant reduction in DBP was seen 
immediately and at 20 minutes post active UVA irradiation (↑ indicate significant 
change when compare against the baseline). No significant difference was found 
between sham and active irradiation. Data are presented as mean ± SEM (n=12). 
C) MAP change after UVA irradiation. No significant difference was found between 
sham and active irradiation. Data are presented as mean ± SEM (n=12). 
 
* Graphs are charted as data obtained from the sham irradiation (took place during 
the first 80 minutes of the study) comparing against data obtained from the active 
irradiation (took place during the second 80 minutes of the same study); the same 
applies to heart rate, temperature and circulatory nitro species (refer to protocol 




     3.3.1.2 Heart rate, temperature and other cardiovascular parameters 
Heart rate, stroke volume and cardiac output were measured in this study. During 
active irradiation, there was an insignificant trend towards an increase in heart rate 
from 59.33±2.69 bpm before irradiation to 62.92±2.64 bpm immediately after 
irradiation. This increase in heart rate was not observed in sham irradiation. Two-
way ANOVA was done to compare the difference between sham and active, but no 
significance was seen (p=0.0716). The change in heart rate is shown in figure 3.2-A. 
Stroke volume was measured by bioimpedence. During active irradiation, there was a 
non significant trend to a small fall following UVA irradiation (146.59±11.95 mL 
before UV irradiation to 138.55±9.13 mL after UVA irradiation). There was no 
apparent pattern to the stroke volume in sham irradiation (figure 3.2-B). 
Cardiac output showed an increase from 8.46±0.51 L/min to 9.40±0.67 L/min during 
active irradiation and immediately returned to baseline post irradiation. During sham 
irradiation, cardiac output remained close to the baseline throughout (figure 3.2-C). 
None of these changes were significant. 
Body core temperature data were collected. Both sham and active UVA irradiation 
groups showed a non significant temperature rise immediately after irradiation that 
was less than 0.5 ºC and gradually returned to baseline post active irradiation, but 
somehow remains slightly elevated in sham irradiation. One-way repeated measures 
ANOVA showed the increase in temperature from baseline is not significant for both 
the sham and active irradiation. A two-way ANOVA showed no difference between 
the temperature rise between the sham irradiation and active irradiation suggesting a 
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Figure 3.2 Cardiovascular parameter and temperature changes in RIECRF study 
A) Change of heart rate from baseline after UVA irradiation, no significant change in 
heart rate was noted between sham and active irradiation. Data are presented as mean 
± SEM (n=12). 
B) Stroke volume change after UVA irradiation, no significant change was observed 
between sham and active irradiation. Data are presented as mean ± SEM (n=12). 
C) Cardiac output change after UVA irradiation, no significant change was observed 
between sham and active irradiation. Data are presented as mean ± SEM (n=12). 
D) Core temperature change from baseline after UVA irradiation, no difference is 
noted between the two groups. Data are presented as mean ± SEM (n=12). 
 
     3.3.1.3 Circulatory nitro-species analysis (RIECRF Study) 
Blood samples were obtained during the low nitrate diet visit for analysis of 
circulatory nitro-species (nitrite, nitrate, nitrosothiols and nitrosamine), and 25-OH 
vitamin D. An immediate rise in circulatory nitrite post active UVA irradiation was 
seen, from 0.50±0.04 µM pre-UVA to 0.72±0.04 µM immediately after irradiation. 
Nitrite remained elevated at 0.72±0.03 µM during 40 minutes post irradiation. This 
rise in circulatory nitrite is significant in all three time points when compared to the 
baseline. No change was observed in circulatory nitrite during sham irradiation other 
than a gradual decrease, however this drop is not significant when analyzed by a 
repeated measure ANOVA (figure 3.3-A). A two-way repeated measure ANOVA 
show a significant difference between the change of circulatory nitrite in sham and 
active irradiation (p=0.0176). 
Circulatory nitrate was found to non-significantly fluctuate around the baseline 
during sham irradiation, but fell significantly after active UVA irradiation when 
compared against baseline. Nitrate decrease from 11.79± 0.64 µM to 8.99±0.40 µM 
and remained below the baseline at 40 minutes post irradiation at 9.34±0.56 µM. 
Significant difference was noted at time point 20 between sham and active irradiation 




S-nitrosothiols and nitrosamines were measured. Both active and sham irradiation 
showed a similar pattern in the change in S-nitrosothiols. A non-significant trend of 
increasing circulatory S-nitrosothiols after sham and active irradiation can be seen, 
(figure 3.3-C). Just as with S-nitrosothiols, a similar pattern was produced in 
circulatory nitrosamines between active and sham irradiation, and no significant 
change was identified (figure 3.3-D). 
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Figure 3.3 Circulatory nitro-species analysis (RIECRF study) 
A) Circulatory nitrite post UVA irradiation in sham and active irradiation. 
Significance rise found at all time points only during active irradiation when 
compared against baseline as indicated by ↑. Significant difference was noted 
between the sham and active group at time point 20 and time point 40. Data are 
presented as mean ± SEM (n=12). 
B) Significant drop in circulatory nitrate was found during active irradiation at all 
time points when comparing against the baseline as indicated by ↑. Significant 
difference was noted between the sham and active group at time point 20. Data are 
presented as mean ± SEM (n=12). 
C) S-nitrosothiols change after UVA irradiation in both sham and active irradiation. 
No significant difference was found. Data are presented as mean ± SEM (n=12). 
D) Nitrosamine change after UVA irradiation in both sham and active irradiation. No 




     3.3.1.4 Other blood sample analysis 
Blood samples were drawn for 25-OH vitamin D analysis before and 24 hours after 
UVA irradiation to show that no sufficient UVB effect was involved in the study. 
Lehmann et al showed that UVB induced generation of calcitriol continuously 
increases up to 24 hour (Lehmann et al., 2001). Due to sample processing error, only 
part of the vitamin D samples were analyzed completely by the NHS laboratory, and 
nine complete set of data were obtained (the vitamin D analysis includes data 
obtained from both the high and low nitrate diet visit). 25-OH vitamin D increase 
from 39.67±8.22 nmol/L before UVA irradiation to 44.11±8.93 nmol/L 24 hours post 
UVA irradiation, but this was not significant at p=0.1010 (figure 3.4-B). 
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Figure 3.4 Vitamin D result for RIECRF study 
25-OH vitamin D measured before and 24 hours post active UVA irradiation. Data 






3.3.2 Lauriston blood pressure study results 
     3.3.2.1 Blood pressure 
Repeating the exact same procedure that was done in the RIECRF blood pressure 
study, both sham and active visit showed a slight reduction in SBP during irradiation. 
The drop in SBP during sham irradiation (from 122.47±2.20 mmHg to 118.83±2.97 
mmHg) visit was more pronounced than that of active irradiation (123.92±2.86 
mmHg to 121.31±2.96 mmHg), but the sudden reduction in SBP then returned to the 
baseline when the irradiation was done. Disregarding the sudden drop, the change in 
SBP was not significant in either active or sham irradiation group and no significance 
was found between the two groups (figure 3.5-A). 
DBP also showed a reduction during UVA irradiation in sham (67.17±1.01 mmHg to 
63.75±0.91 mmHg) and active groups (from 70.14±1.65 mmHg to 64.33±1.57 
mmHg), but the reduction was only significant for the active group when compared 
against its own baseline. The reduction in DBP returned to baseline immediately 
after sham irradiation but not after active irradiation, where the DBP remained below 
the baseline till the study finished. No significant difference was found in DBP 
change between sham and active irradiation (figure 3.5-B). 
MAP showed a reduction in both the sham and active irradiation just like SBP and 
DBP. However this time, a significant reduction is seen in active (88.07±1.79 mmHg 
to 83.32±1.69 mmHg) as well as in sham irradiation (85.60±1.10 mmHg to 
82.11±1.32 mmHg) during UVA irradiation. It is observed again that the drop of 
MAP in sham irradiation returned to baseline immediately post UVA but not in 
active irradiation. No significant difference was found in MAP change between sham 
and active irradiation. MAP graph is charted as change from baseline to show the 
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Figure 3.5 Blood pressure change after UVA irradiation (Lauriston BP study) 
A) SBP change after sham/active UVA irradiation, no significant change was 
observed. No significant difference was noted between sham and active irradiation. 
Data are presented as mean ± SEM (n=12). 
B) DBP change after sham/active UVA irradiation, the reduction in active irradiation 
during UVA exposure is significant as indicated by ↑. No significant difference was 
noted between sham and active irradiation. Data are presented as mean ± SEM 
(n=12). 
C) MAP change from baseline after sham/active UVA irradiation, reduction of MAP 
during UVA exposure is significant in both the sham and active group as indicated 
by ↑. No significant difference was noted between sham and active irradiation. Data 





     3.3.2.2 Heart rate and temperature 
Heart rate decreased gradually during the sham irradiation throughout the study and 
had fallen significantly 40 and 50 minutes post irradiation. In contrast during the 
active irradiation, there was an increase in heart rate immediately after UVA 
irradiation (from 62.83±2.30 bpm to 66.19±2.66 bpm) and then HR returned to 
baseline where it stayed (figure 3.6-A). 
Similar to the low nitrate diet visit, no change in core temperature was observed. 
Skin temperature was measured from two different sites and the average of the two 
was charted and analyzed. During sham irradiation, skin temperature increased 
1.53±0.05 ºC from baseline during irradiation and gradually returns to baseline after 
irradiation. Active irradiation showed a similar pattern, with skin temperature 
increasing 1.76±0.06 ºC from baseline and gradually returns to baseline. The increase 
in skin temperature was significant at all time points when compared to the baseline 
in both active and sham irradiation, but two-way ANOVA shows no significant 
difference between the two groups, suggesting a successful temperature control, 
p=0.7001 (figure 3.6-B). 
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Figure 3.6 Heart rate and temperature change in the Lauriston blood pressure study 
A) Change of heart rate after UVA irradiation, a significant drop of heart rate in 
sham irradiation was noted at time points 40 and 50 minutes when comparing against 
the baseline as indicated by ↑. No significant difference is seen between sham and 
active irradiation. Data are presented as mean ± SEM (n=12). 
B) Skin temperature change was charted as change from baseline, significant 
increase found in all time points at sham and active irradiation, but no difference is 





3.3.3 Combined data of the RIECRF & Lauriston blood pressure study 
     3.3.3.1 Difference between low versus high nitrate diet 
To determine whether there was a difference in physiological response to UVA 
irradiation between the high nitrate and low nitrate diet group, blood pressure and 
heart rate graphs were charted to compare the two groups. During active irradiation, 
SBP was volatile during the low nitrate diet visit but not in the high nitrate diet visit 
(figure 3.7-A). DBP and MAP during high nitrate diet visit seems to have a more 
pronounced reduction in blood pressure during UVA irradiation, but the rebound of 
blood pressure back toward baseline is also faster (figure 3.7-B&C). Heart rate in the 
low and high nitrate showed nearly an exact same pattern (figure 3.7-D). Graphs 
were charted as changes from baseline and two-way repeated measures ANOVA 
were used to compare for the differences between the two groups. No significant 
difference between high and low nitrate diet visit was noted in all four parameters 
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Figure 3.7 High versus low nitrate diet in cardiovascular parameter changes 
A) SBP change after active UVA in low and high nitrate diet visit, no significant 
difference was found between the two groups. Data are presented as mean ± SEM 
(n=12, p=0.3337). 
B) DBP change after active UVA in low and high nitrate diet visit, no significant 
difference was found between the two groups. Data are presented as mean ± SEM 
(n=12, p=0.7465). 
C) MAP change after active UVA in low and high nitrate diet visit, no significant 
difference was found between the two groups. Data are presented as mean ± SEM 
(n=12, p=0.7829). 
D) HR change after active UVA in low and high nitrate diet visit, no significant 





     3.3.3.2 Combined dataset 
Knowing that there are no differences in the cardio-physiological response toward 
UVA in the high and low nitrate diet group, the datasets of the two groups were 
combined to increase the sample size and re-evaluated to compare the difference 
between sham and active UVA’s effects on blood pressure. All graphs were plotted 
to show changes from baseline, thus comparing the differences between sham and 
active irradiation. 
After compiling all data, SBP still showed no significant change from baseline in 
both active and sham irradiation, although a visible reduction of 2.82±1.22 mmHg 
from baseline was seen during sham irradiation and gradually returns to the baseline. 
Two-way repeated measures ANOVA showed no significant difference between 
active and sham irradiation in altering SBP, p=0.3668 (figure 3.8-A).  
Sham irradiation also caused a non-significant reduction of DBP of 2.79±1.02 mmHg 
below baseline during the sham exposure (warming), and an immediate rebound 
back to the baseline after exposure. However active irradiation produced a significant 
reduction in DBP by 4.90±0.70 mmHg from baseline, and this was sustained through 
to 30 minutes post UVA irradiation (figure 3.8-B). A significant difference was 
noted between the effect of sham and active irradiation on DBP at time point 10, 
p=0.0071. 
MAP, calculated from SBP and DBP showed a reduction in both sham and active 
irradiation during UVA exposure, with sham irradiation showing a 2.80±0.98 mmHg 
and active irradiation showing a 3.50±0.73 mmHg drop from the baseline. This 
reduction was significant for both active and sham irradiation (figure 3.8-C). 
However, no difference was found between the effect on MAP between active and 
sham irradiation, p=0.0859. 
Gradual decrease of heart rate from baseline was noted in sham irradiation that 




significant increase was noted in active irradiation post UVA exposure with an 
increase of 3.57±1.08 bpm (figure 3.8-D). A significant difference between sham and 
active was noted at various time points after irradiation, p=0.0012. 
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Figure 3.8 Combined data of high and low nitrate diet 
A) Change in SBP after UVA irradiation, no significant difference was found 
between the two groups. Data are presented as mean ± SEM (n=24). 
B) Change in DBP after UVA irradiation, significant reduction from baseline was 
noted in active irradiation at time points marked by ↑. Significant difference was also 
noted between the two groups at time points 10 min. Data are presented as mean ± 
SEM (n=24). 
C) Change in MAP after UVA irradiation, significant reduction from baseline was 
noted in active irradiation during UVA exposure as indicated by ↓, this is not seen in 
sham irradiation. No significant difference was noted between the two groups. Data 
are presented as mean ± SEM (n=24). 
D) Heart rate change after UVA irradiation, significant increase of heart rate was 
noted in active irradiation (indicated by ↑) and significant difference between the 
sham and active irradiation was also noted at time points 0, 10, 30, 40 and 50 min. 




3.3.4 Indigo Sun blood pressure study results 
     3.3.4.1 Blood pressure 
As the results obtained from the RIECRF study only showed a reduction half as 
much as that observed in the Oplander study, I aimed to repeat the Oplander study 
using a fan installed commercial tanning lamp that allows the volunteers to be 
irradiated on both back and front. The Indigo Sun study was conducted in a local 
tanning salon, but due to the environmental setting (non-NHS research site), limited 
measurements were performed. 
Blood pressure was measured and charted before and 5 minutes after UV irradiation, 
followed up by a 15 minutes interval for another 70 minutes. SBP showed a slight 
(from 130.61±9.06 mmHg pre-UVA to 126.91±7.52 mmHg 5 minutes post 
irradiation) and non-significant reduction that lasted for 45 minutes during active 
irradiation which rebound above the baseline at the last two measurements. A similar 
trend was seen in the DBP (73.52±3.33 mmHg to 72.61±2.69 mmHg) and MAP 
(92.55±5.00 mmHg to 90.71±4.06). For sham irradiation, a non-significant spike in 
SBP and DBP was seen after UVA irradiation. This immediately returned to baseline 
in the next measurement (figure 3.9-A, B, C). Other than a significant rise of MAP in 
sham irradiation toward the end of the study the changes in SBP, DBP and MAP are 
considered non-significant when analyzed by one-way repeated measures ANOVA. 
Two-way ANOVA also showed no difference between the sham and active 
irradiation, p=0.1091. MAP graph is charted as change from baseline to show the 
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Figure 3.9 Blood pressure change after UVA irradiation (Indigo Sun study) 
A) SBP change after sham/active UVA irradiation, no significant change was 
observed. No difference was found between sham and active irradiation. Data are 
presented as mean ± SEM (n=9). 
B) DBP change after sham/active UVA irradiation, no significant change was 
observed. No difference was found between sham and active irradiation. Data are 
presented as mean ± SEM (n=9). 
C) MAP change from baseline after sham/active UVA irradiation, significant 
increase in MAP from baseline toward the end of the study in sham irradiation 
(indicated by ↑). No difference was found between sham and active irradiation. Data 





     3.3.4.2 Heart rate and temperature change in the Indigo Sun study 
The volunteers’ heart rate in both sham and active visit showed a non-significant 
reduction after experiencing UVA irradiation and remained thereafter constant 
(figure 3.10-A). 
Core temperature was again measured in this study. A gradual increase was seen 
throughout the study, but was the same during both sham and active visits, p=0.8898. 
This gradual increase reached a significant level at the last two time points (figure 
3.10-B). 
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Figure 3.10 Heart rate and temperature change in Indigo Sun study 
A) Change in heart rate after UVA irradiation, no significant change was noted. Data 
are presented as mean ± SEM (n=9). 
B) Core temperature change after UVA irradiation. Gradual increase of body 
temperature was seen and reached a significant level at the last two time points when 
comparing against baseline for both sham and active irradiation (indicated by ↑). No 
significant difference was noted between sham and active irradiation. Data are 





     3.3.4.3 Circulatory nitro-species change 
There was an immediate increase of circulatory nitrite post active UV irradiation 
(from 0.86±0.11 µM to 0.96±0.20 µM), which reached a peak at 40 minutes post UV 
irradiation (1.05±0.15 µM). A similar pattern was seen in sham irradiation, but the 
increase in circulatory nitrite only started 20 minutes post UVA irradiation, reaching 
a maximum at the end of the study. These changes in circulatory nitrite were not 
significant and two-way repeated measures ANOVA showed no difference between 
the sham and active group (figure 3.11-A). 
Baseline circulatory nitrate started at a higher level in the sham irradiation visit than 
the active irradiation visit, but both groups showed a very stable trend throughout the 
study and no significant change was found in-between time points or the groups 
(figure 3.11-B). 
S-nitrosothiols and nitrosamines were measured; the spiking of S-nitrosothiols and 
nitrosamines seen toward the end of the study could be due to possible contamination. 
No significant change was noted in sham and active irradiation for both RSNO and 
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Figure 3.11 Circulatory nitro-species analysis (Indigo sun study) 
A) Circulatory nitrite change after UV irradiation, no significant change was noted. 
Data are presented as mean ± SEM (n=8). 
B) Circulatory nitrate change after UV irradiation, no significant change was noted. 
Data are presented as mean ± SEM (n=8). 
C) Circulatory S-nitrosothiols change after UV irradiation, no significant change was 
noted. Data are presented as mean ± SEM (n=8). 
D) Circulatory nitrosamines change after UV irradiation, no significant change was 






3.4.1 Blood pressure change in different study groups 
A trend of blood pressure reduction was seen in the active irradiation of all three 
blood pressure studies, regardless of whether the volunteers had a high (Lauriston) or 
low (RIECRF) nitrate diet. Significant reduction in DBP from baseline during active 
irradiation was seen in all but the Indigo Sun study. These results are in keeping with 
those of Oplander (Oplander et al., 2009) who showed that UV irradiation produced 
a significantly greater fall in blood pressure than equivalent controlled warming. 
Rather than merely repeating the work of Oplander, I wished to measure whether 
high circulating (and thus skin) nitrate would enhance this UV induced hypotensive 
effect. Randomising subjects to both low/high nitrate diet arms, and sham or active 
irradiation arms would have entailed 4 visits. This presented two practical problems.  
Firstly, recruitment to a study involving 4 half day visits would have been very 
difficult, and secondly, with a minimum two week period between visits, the study 
would have taken at least 8 weeks to complete. The normal background seasonal 
variation in UV exposure to the volunteers would have varied greatly between the 
first and last visits over a 2 month or greater span which would have been a marked 
external confounding factor. The study design thus did not randomize subjects to 
sham or active irradiation, but gave these interventions serially. DBP fell more 
during and after active than sham irradiation. There are two possible explanations for 
this. It could be due to a delayed effect of the sham irradiation as this always 
preceded the active irradiation. Alternatively, and I believe more probably, the 
greater fall during and after active irradiation could be due to active irradiation itself. 
To confirm that the active radiation reduced blood pressure, I would need to carry 
out a separate study, omitting the high/low nitrate arm and randomizing the sequence 
in which subjects received active or sham irradiation. This would be a repeat of 
Oplander’s study and add nothing further to it. To confirm the cardio-active effects 
of UV radiation, I have subsequently carried out forearm plethysmography studies 
(described in chapter 4). In that study, subjects received active and sham irradiation 




irradiation induces vasodilatation. If sham irradiation were to cause a delayed fall in 
blood pressure, it would be doing this in the absence of vasodilatation, which implies 
a reduction in cardiac output. This seems highly unlikely given the rise in heart rate 
(figure 3.8-D) observed during the fall in blood pressure. 
A trend of reduction in blood pressure was seen in both sham and active irradiation 
during UVA exposure, suggesting a temperature associated vasodilatation 
independently of, but additional to that caused by direct UV irradiation. Despite this, 
and assuming no carryover effect from sham irradiation, a small but significant 
reduction in DBP from baseline was found during UVA irradiation (Lauriston BP 
study), immediately after active UVA exposure and at 20 minutes post irradiation 
(RIECRF study). The reduction of DBP was found to be significantly different from 
sham irradiation when the datasets were combined (3.8-B), and with a successful 
core and skin temperature control as shown in figure 3.2-D and 3.6-B, I suggest that 
the significant reduction in DBP is likely to be due to factors other than increased 
temperature if sham irradiation does not have any carryover effect. 
In comparing the high and low nitrate diet, no significant changes in cardiovascular 
response to active UVA exposure were found (figure 3.7) suggesting that dietary 
nitrate will not affect the blood pressure reduction effect induced by UVA irradiation 
of the skin. This absence of difference allowed us to combine datasets, and see that 
UVA exposure significantly reduces DBP during UVA exposure, and up to 30 
minutes post UVA irradiation. Keeping in mind that during active irradiation there 
was a significant increase in heart rate, and this might be the compensatory 
mechanism of our body’s homeostatic system toward the drop in blood pressure, 
masking a more profound reduction in blood pressure to be observed, this will be 
discuss in detail at section 3.4.2. The reduction in DBP I have found is relatively 
small (maximal 4.90±0.70 mmHg) when compared to the Oplander study who 
showed a DBP reduction ranging from 5~10 mmHg. However, a 5 mmHg reduction 
in DBP was found to decrease the risk of stroke by 34% and coronary heart disease 




DBP instead of SBP was found to have a significant drop in all study groups, and this 
could be due to the vasodilation effect produced from UVA stimulated nitric oxide 
release from the skin. SBP reflects the pressure of the heart during contraction and 
the rigidity of the blood vessels, whereas DBP is determined by the pressure between 
heart beats, reflecting the relaxation of the blood vessel. Nitric oxide activates 
soluble guanylate cyclase and forms cyclic GMP. This ultimately results in the 
relaxation of smooth muscle via dephosphorylation of the myosin light chain, and 
this might be why significant change in DBP instead of SBP was observed. 
Seasonal variation in blood pressure was found to be more profound in the older age 
groups, who were also found to have higher resting blood pressures (Brennan et al., 
1982). Other research in animals and humans has shown that aging as well as 
hypertension leads to impaired endothelium, and thus impaired endothelial nitric 
oxide synthesis. (Forte et al., 1997, Chou et al., 1998, Gokce, 2004, Moss et al., 2004) 
I hypothesized that an overall lower basal nitric oxide release in the older subjects 
will react more vigorously toward the nitric oxide released by UVA. In the Indigo 
Sun study, the volunteers had an older average age (51±4.02 years old) and higher 
resting blood pressure (130.61±9.06 / 73.52±3.33 mmHg) comparing to the RIECRF 
and Lauriston (22.29±0.32 years old, 122.29±2.44 / 68.28±1.37 mmHg) study group. 
I was expecting to see a greater reduction of blood pressure in the Indigo Sun study, 
but this was not seen. A trend of decrease in SBP and DBP after active UVA was 
noted but none of the change was considered significant. 
The initial aim of the Indigo Sun study was to reproduce the result from the Oplander 
study. The data I have obtained did not do this, but this could be due to different 
conditions in which I carried this study out. Ideally, studies involving blood pressure 
measurements should take place in a quiet and temperature controlled room to 
exclude tension and temperature associated blood pressure alteration (Woodhouse et 
al., 1993, Barnett et al., 2007). Although attempts were made, this was not possible 
to achieve in a tanning salon, as a below average room temperature was required to 
cool down the tanning lamps. During the Indigo Sun study the volunteers received a 




compliance with the tanning salon’s regulation, and this is likely to be an important 
confounder, supported by the non-significant rise in circulatory nitrite post 
irradiation. Lastly, toilet urgency was noted in some volunteers toward the end of the 
study, and this alone can be the cause an increase in blood pressure (figure 3.9-C). 
3.4.2 Heart rate, stroke volume, and cardiac output 
Human bodies have self regulatory system to maintain homeostasis. This especially 
affects the circulatory system, whose main purpose is to deliver oxygenated blood to 
all the tissues in our body. Circulatory system homeostasis is tightly controlled by 
altering cardiac output and systemic vascular resistance to reach a steady blood 
pressure, while cardiac output is closely associated with stroke volume and heart rate, 
alteration of any of the above listed will disturb our circulatory homeostasis. A 
schematic of the possible cardiac physiology response toward UVA induced blood 
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Assuming no carry over effects from sham irradiation on circulatory nitro-species, I 
have shown from the blood samples analysis a significant increase in circulatory 
nitrite, an oxidative end product of nitric oxide, suggesting a nitric oxide activity 
after UVA irradiation. Reduction of DBP as shown in the study was probably due to 
the vasodilation effect of nitric oxide, even though nitric oxide was found to dilate 
arteries, but studies have also shown nitric oxide having an effect in venous 
relaxation (Luscher et al., 1988, Vallance et al., 1989), thus might lead to decrease 
vascular resistance and venous blood pooling in the peripheral veins. The pooling of 
blood in peripheral vein decreases venous pressure, leading to a decreased end 
diastolic volume therefore reduced stroke volume. 
Baroreceptors located within the transverse aortic arch and the carotid sinus of the 
left and right internal carotid arteries regulate arterial pressure by negative feedback. 
With the baroreceptors decreased firing frequency due to the decreased blood 
pressure, heart rate increases as a compensatory mechanism. Other than this self-
regulatory system, a few studies have suggested that nitric oxide plays a role in the 
regulation of heart rate through the NO-cGMP pathway. Musialek’s study suggests 
low concentrations of nitric oxide donors (nanomolar to micromolar) gradually 
increase the heart rate by stimulation of hyperpolarization-activated inward current (If) 
via the NO-cGMP pathway, whereas high (millimolar) concentrations decreased it 
(Han et al., 1994, Musialek et al., 1997, Sears et al., 1999). My study has shown an 
increase in circulatory nitrite suggesting previous nitric oxide activity, thus the 
increase in heart rate after UVA irradiation could due to baroreceptor reflex from 
vasodilation and/or If stimulation, aiming to maintain the cardiac output in a 
homeostatic state as shown in figure 3.2-C. 
This finding of increase heart rate post UVA irradiation correlates with another two 
studies, (Chappe et al., 1981, Prens and Smeenk, 1983) in which various 
cardiovascular parameters were measured in man before and after UVA irradiation. 
A dose of 6.5~20 J/cm2 of UVA were administered in the Chappe’s study (11~48 
minutes of irradiation time). No significant change was found in blood pressure, but 




3.4.3 Circulatory nitro-species change after UVA 
After active UVA irradiation, there was a significant increase in circulatory nitrite 
that lasted at least 40 minutes after exposure. This was noted to occur simultaneously 
with the decrease in circulatory nitrate. 
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Figure 3.13 Nitrite versus nitrate change post UVA 
 
The significant drop in circulatory nitrate, suggest a possible conversion from nitrate 
to nitrite, which is then photo-decomposed to nitric oxide or from nitrate directly to 
nitric oxide, which is then oxidized back to nitrite. As I hypothesize that the 
conversion of nitrate to nitrite happens at the skin level, this could be enhanced by 
the presence of thiols in the skin. Dejam and colleagues have shown that irradiating 
plasma samples containing nitrates with thiol blocking agents decreases the 
formation of nitric oxide. This suggests that thiols play an important role in the 
reduction of nitrate to nitric oxide during UVA irradiation (Dejam et al., 2003). More 




3.4.4 Vitamin D 
Vitamin D was measured and no significant change was seen after active irradiation. 
This finding suggests that the lamp used does not produce enough UVB effect to 
cause photolysis of 7-dehydrocholesterol. Thus the reduction of DBP I have shown is 
likely to be independent of vitamin D synthesis. However, the standard of the 
vitamin D assay performed is untraceable, and whether this could have affected the 
result can no longer be confirmed as the original NHS laboratory team based in 






To summarize the findings, the following were shown in this chapter 
1. 20 J/cm2 of UVA irradiation slightly but significantly reduces DBP during active 
UVA irradiation comparing to sham UVA irradiaiton. 
2. UVA irradiation of the skin probably releases sufficient nitric oxide to produce a 
vasodilatory effect which reduces DBP, as evidenced by the increase in 
circulatory nitrite occurring simultaneously with the DBP reduction. 
3. This reduction of DBP is likely to be independent of temperature associated 
vasodilation and vitamin D involvement. 
4. UV radiation instead of nitrate is the limiting factor in the fall in blood pressure, 
as high and low nitrate groups showed no difference in the fall in blood pressure. 
Limitations in study design (as listed below), mean that the data in this chapter 
cannot irrefutably prove that UV lowers blood pressure compared to sham irradiation. 
1. Possible carryover or additional effect from sham irradiation affecting the blood 
pressure and circulatory nitro-species results cannot be excluded 
2. Even though no statistical difference was shown in blood pressure change 
between the WTCRF and the Lauriston group. Combining the dataset may have 
produced a misleading result as they were initially provided a different diet. 
To resolve these questions, I describe in the next chapter experts on the effects of UV 
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UVA irradiation of human skin increases circulatory nitrite, suggesting the presence 
of increased nitric oxide activity (Mowbray et al., 2009, Oplander et al., 2009). 
Mowbray et al described an increase nitrite concentration within the dialysate of the 
skin after UVA irradiation, further providing evidence that the source of nitric oxide 
release post UVA irradiation is the skin. However there is no evidence to suggest that 
this increase in circulatory nitrite is independent of heat associated NOS activity. 
NOS plays a role in thermoregulation by heat induced vasodilatation. Kellogg et al 
have found L-NAME (an eNOS inhibitor) infusion by micro-dialysis reduces SBF 
(Kellogg et al., 1999) and attenuates thermoregulatory reflex-mediated vasodilation 
during local warming of the skin (Kellogg et al., 1998). Their later study confirmed 
eNOS involvement in heat associated vasodilation during local warming (Kellogg et 
al., 2008a). Another study, also conducted by Kellogg and colleagues found 7-
nitroindazole (nNOS inhibitor) reduces cutaneous vascular conductance during 
whole body heat stress but not during local warming (Kellogg et al., 2008b, Kellogg 
et al., 2009) suggesting NOS plays different roles in thermoregulation. 
Drugs that inhibit platelet activity reduce cardiovascular diseases such as ischaemic 
heart disease and stroke (Gent et al., 1996, Rosenson and Tangney, 1998). Nitric 
oxide’s influence is not limited to vasodilation; it also plays a vital role in the 
inhibition of platelet aggregation (Mellion et al., 1981, Radomski et al., 1987) by 
blocking Rap1 (a Ras-like guanine-nucleotide–binding protein which controls the 
integrin αIIbβ3 activity and platelet aggregation) activation (Danielewski et al., 2005, 
Schultess et al., 2005). It will be of interest to investigate whether the amount of 
nitric oxide release by UVA irradiation of the skin is sufficient to affect the platelet 





I hypothesize that the increase of circulatory nitrite after UVA irradiation is due to 
the oxidation of nitric oxide released by photolysis of nitrite in the skin and 
circulation. This observed nitric oxide activity is independent of nitric oxide synthase, 
and will produce systemic vasodilatation including un-irradiated areas. I further 
hypothesize this is independent of the heat associated NOS effect, and the amount of 
nitric oxide released by 20 J/cm2 of UVA irradiation is sufficient to interfere with 
normal platelet activity. 
4.1.3 Aim of the Study 
In chapter 3 I showed that active UVA irradiation of the skin probably reduces blood 
pressure, but that this effect might possibly be due to a carryover effect from sham 
irradiation. The main aim of the study is to determine whether with strict temperature 
control, UVA will vasodilate the forearm vasculature in a NOS independent way 
which could account for a UV mediated fall in blood pressure. A secondary aim is to 
determine whether UVA irradiation of skin causes systemic arteriolar vasodilatation 
by studying the dermal microvasculature at a non-irradiated site. The final aim of the 
study is to inhibit nitric oxide synthase activity and determine whether, under strict 
temperature control, the nitric oxide effect produced from UVA photolysis of skin 
nitrogen oxide stores remains unchanged. Lastly, to determine whether the amount of 
nitric oxide released by 20 J/cm2 of UVA irradiation is sufficient to play a role in the 






4.2.1 Skin Blood Flow 
In the SBF study, four volunteers received the same dose of UVA irradiation that 
was given in the blood pressure study (chapter 2.1.3.1.1) over their body, legs and 
the left arm. SBF was then monitored by three laser Doppler SBF probes on the non-
irradiated right arm. Maximal and minimal SBF was determined by inflating a 
sphygmomanometer to 300 mmHg for 5 minutes and measures taken before and after 
deflation of the sphygmomanometer. 30 minutes of resting time were given before 
UVA irradiation and SBF was monitored for 20 minutes post irradiation. The 
protocol was followed as described in chapter 2.1.3.1 (page 38). 
4.2.2 Forearm Blood Flow 
The FBF study consisted of two phases. During the first phase twelve volunteers 
were irradiated on the right arm with 20 J/cm2 of UVA and the left arm was 
simultaneously irradiated with an infrared lamp for temperature control. Blood 
samples were drawn from both arms at the same time for circulatory nitro-species 
analysis. FBF was monitored via venous occlusion plethysmography. The aim for 
this part of the study was to confirm whether irradiation of one surface of an arm 
(body surface area of less than 4.5 %) is sufficient to produce an increase in FBF. 
During the second phase of the study, volunteers attended on two occasions. During 
one visit, a sham irradiation was given to the L-NMMA infused arm by covering up 
the lamp with silver foil blanket and during the active irradiation this barrier was 
removed. The sequence of visits was randomly allocated. As the computer program 
“Chart 5 for Windows” instantly records the skin temperature change, an electric fan 
was placed next to the forearm which was switched on and off to control the skin 
temperature change during active irradiation as close as possible to the baseline. 
Brachial artery cannulation was performed, allowing intra-arterial infusion of L-




8 µmol/min. Increase of FBF after inhibition of all the NOS will confirm that any 
vasodilation from UVA irradiation is NOS independent. The protocol was followed 
as described in chapter 2.1.3.2 (page 40) and 2.1.3.3 (page 43). 
4.2.3 Bleeding Time 
This study focused on measurement of bleeding time as the primary outcome for an 
indication of platelet activity. Twelve volunteers attended on two occasions, 
receiving whole body active irradiation on one visit and sham irradiation on the other. 
During active irradiation, two electric fans were used to control the whole body skin 
temperature. Bleeding time was measured by Ivy method before, immediately after 
and 20 minutes after irradiation. The protocol was followed as described in chapter 
2.1.4 (page 47). 
4.2.4 Statistic analysis 
Data were collected and recorded in Microsoft excel, later transferred to SPSS 
Statistic 17.0 and GraphPad Prism 5 for statistic analysis. Data were analyzed using 
the following statistic tests (methods described in page 59-60): 
1. One-way repeated measures analysis of variance (ANOVA) with post hoc 
test (Bonferroni's multiple comparison test) when looking for significance 
between different time points within a group of Gaussian distribution that 
have multiple measures. 
2. Friedman test with post hoc test (Dunn’s multiple comparison test) when 
looking for significance between different time points within a group of non-
Gaussian distribution that have multiple measures. 
3. Two-way repeated measures ANOVA when comparing two or more groups 






4.3.1 Skin blood flow study 
SBF change at the non-irradiated site was plotted. A trend towards increased SBF of 
less than 5 % was seen during irradiation (max SBF change is 4.36±1.88 % at 20 
minutes) which returned to baseline by 10 minutes post irradiation. One way 
repeated measure ANOVA was used to analyze the change in SBF. No significant 
change was seen (p=0.0721, figure 4.1-A). 
Skin temperature change during UVA (time points 0~22) irradiation at the non-
irradiated site was measured and plotted. A slight increase in skin temperature was 
seen, but this was less than 0.5 ºC. One-way repeated measures ANOVA was 
performed and showed no significant change of temperature from baseline (figure 
4.1-B). 
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Figure 4.1 Skin blood flow and temperature change 
A) Percentage change of SBF from baseline. Data are presented as mean ± SEM, no 
significant difference was observed (n=4). 
B) Temperature change from baseline at non-irradiated site during irradiation. Data 




4.3.2 Forearm blood flow study 
     4.3.2.1 Phase 1 – UVA and Infrared irradiation 
4.3.2.1.1 Forearm blood flow and temperature 
Significant increase in FBF was seen in both the UVA and infrared irradiated arm. In 
the UVA irradiated arm, FBF increased from 1.95±0.28 to 2.94±0.47 mL / 100 mL 
of tissue / min after irradiation and remained elevated until 60 minutes post 
irradiation. One-way repeated measures ANOVA showed forearm blood flow in 
UVA irradiated arm significantly increased at time points 0, 15, 45 and 60 minutes 
after irradiation when compared against the baseline. In the infrared irradiated arm, 
FBF increased from 1.87±0.33 to 2.94±0.56 mL / 100 mL of tissue / min, which also 
remained elevated until 60 minutes post irradiation. One-way repeated measures 
ANOVA also showed a significant increase in time points 0, 45 and 60 minutes after 
irradiation when compared to the baseline. Two-way ANOVA was used to monitor 
difference between UVA and infrared irradiation but no significant difference was 
found, p=0.9598 (figure 4.2-A). 
Temperature was measured using the skin temperature probe which was attached 
above the wrist cuff at the irradiation surface. Increase in skin temperature was 
plotted as temperature change from baseline and no significant difference was found 
between the UVA and infrared irradiated arm when analyzed by a two way repeated 
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Figure 4.2 Forearm blood flow and temperature change 
A) FBF change after irradiation. One-way ANOVA found significant increase of 
FBF from baseline in UVA irradiated arm found at 0, 15, 45 and 60 minutes after 
irradiation (as indicated by ↑); significant increase in infrared irradiated arm found at 
0, 45 and 60 minutes after irradiation. No difference was found between the UVA 
and infrared irradiated arm. Data are presented as mean ± SEM (n=12). 
B) Temperature change during UVA or infrared irradiation. No significant difference 
was found between the UVA and infrared irradiated arm. Data are presented as mean 
± SEM (n=12). 
 
4.3.2.1.2 Circulatory nitro-species analysis 
Blood samples were taken from the UVA and infrared irradiated arm simultaneously. 
Circulatory nitrite showed a gradual increase in both arms after irradiation. The UVA 
irradiated arm showed an increase in circulatory nitrite from 0.52±0.05 µM before to 
0.55±0.03 µM after UVA, and peaked at 40 minutes after irradiation at 0.61±0.04 
µM. In the infrared irradiated arm, nitrite increased from 0.52±0.04 µM before 
irradiation to 0.55±0.03 µM after irradiation and peaked at 60 minutes after 
irradiation at 0.66±0.14 µM. Nonetheless, the increase in circulatory nitrite in both 
arms was not significant when analyzed by one-way repeated measures ANOVA. 
Two-way repeated measures ANOVA showed no significant difference between the 
changes induced by UVA and infrared irradiation in circulatory nitrite, p=0.8211 
(figure 4.3-A). 
A trend towards a reduction in circulatory nitrate was found in both UVA and 
infrared irradiated arms. This was significant at 60 minutes post irradiation when 
analyzed by one-way repeated measures ANOVA (from 16.72±2.31 µM before 
irradiation to 15.12±1.92 µM 60 minutes post irradiation in infrared irradiated arm 
and from 17.64±2.39 µM before irradiation to 15.35±2.12 µM 60 minutes post 
irradiation in UVA irradiated arm). Two-way repeated measures ANOVA showed no 
significant difference between the changes UVA and infrared irradiation caused in 




A sudden drop in S-nitrosothiols was observed in the infrared irradiated arm, but this 
reduction was not significant when compared against the baseline using one-way 
repeated measures ANOVA. A trend towards a gradual reduction in S-nitrosothiols 
was found in the UVA irradiated arm, but this change was also not significant. Two-
way repeated measures ANOVA showed no significant difference between the 
changes UVA and infrared irradiation arm caused in circulatory S-nitrosothiols, 
p=0.3200 (figure 4.3-C). 
A slight increase in nitrosamine was found in both UVA and infrared irradiated arm 
after irradiation, but no significant change was detected by one-way repeated 
measures ANOVA. No significant difference was found between the two groups 
when two-way repeated measures ANOVA were used, p=0.1384 (figure 4.3-D). 
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Figure 4.3 Circulatory nitro-species analysis (FBF study – Phase 1) 
A) Circulatory nitrite difference between UVA and infrared irradiated arm. No 
significant change was found in both arms. Data are presented as mean ± SEM 
(n=12). 
B) Circulatory nitrate difference between UVA and infrared irradiated arm. 
Significant reduction of nitrate was seen at 60 minutes post irradiation in both UVA 
and infrared irradiated arm when compared against baseline. No significant 
difference was found between the infrared and UVA irradiated arm. Data are 
presented as mean ± SEM (n=12). 
C) Circulatory S-nitrosothiols difference between UVA and infrared irradiated arm. 
No significant difference was found in both groups. Data are presented as mean ± 
SEM (n=12). 
D) Circulatory nitrosamine difference between UVA and infrared irradiated. No 





     4.3.2.2 Phase 2 – L-NMMA infusion 
4.3.2.2.1 FBF & temperature change in sham versus active UVA 
A significant reduction of FBF was noted 20 minutes after L-NMMA infusion, and 
remained reduced until the 45 minute post irradiation measurement. Reduction of 
blood flow from L-NMMA infusion was seen at both sham and active irradiation 
visit in the L-NMMA infused / irradiated arm [(+)L-NMMA in short], whereas L-
NMMA infusion did not affect the blood flow in the contra-lateral arm / non-
irradiated arm [(-)L-NMMA in short]. Significant difference in FBF was noted 
between the infused and non-infused arm, p<0.0001 at all time points other than 
baseline in both sham and active irradiation when two-way repeated measures were 
used. Graphs were plotted using the FBF measured pre-L-NMMA infusion as 
baseline (figure 4.4-A&B). The significant reduction in FBF and the difference from 
non-infused arm suggest a successful inhibition of NOS as expected. 
Baseline of the FBF was reset using the measurement performed immediately before 
UVA irradiation and relative change instead of absolute change from baseline was 
presented for discussion (figure 4.4-C&D). In the (-) L-NMMA arm, during the 
active irradiation visit (this arm was neither irradiated by UVA nor infused with L-
NMMA) a trend of slight but not significant increase in FBF was shown, peaking at 
45 minutes after irradiation with an increase of 16.00±10.33 % (1.80±0.27 to 
2.01±0.30 mL / 100 mL of tissue / min) from baseline, whereas during the sham 
irradiation no increase trend was seen (2.18±0.18 to 2.08±0.28 mL / 100 mL of tissue 
/ min). No significant difference was seen in the FBF change at (-) L-NMMA arm 
between active and sham irradiation as analyzed by two-way repeated measures 
ANOVA, p=0.1963 (figure 4.4-C). 
In the (+) L-NMMA infused arm (which was also the irradiated arm), no significant 
change in FBF was seen during the sham irradiation. During active irradiation a trend 
showing an increase in FBF was seen, and this increase in FBF was significant at 30 
minutes post irradiation (time point 50, increase of 23.69±6.48 % from baseline 




baseline using one-way repeated measures ANOVA. There is also a significant 
difference found at time point 20 and 50 between the active and sham irradiation as 
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Figure 4.4 Forearm blood flow change (FBF study – Phase 2) 
A) FBF change in sham irradiation. Significant reduction in FBF seen after L-
NMMA infusion at all time points, difference from non-infused arm was noted by 
two-way repeated measures ANOVA. Data are presented as mean ± SEM (n=12). 
B) FBF change in active irradiation. Significant reduction in FBF seen after L-
NMMA infusion at all time points, difference from non-infused arm was noted by 
two-way repeated measures ANOVA. Data are presented as mean ± SEM (n=12). 
C) Relative change of FBF in (-) L-NMMA arm from baseline during sham and 
active irradiation. No significant change from baseline FBF was found and no 
difference was noted between the two groups. Data are presented as mean ± SEM 
(n=12). 
D) Relative change of FBF in (+) L-NMMA arm from baseline during sham and 
active irradiation. A significant increase in FBF from baseline was seen in active 
irradiation at 30 minutes post UVA exposure as analyzed by one-way repeated 
measures ANOVA (indicated by ↑). Significant difference also found between active 
against sham irradiation as analyzed by two-way repeated measures ANOVA at time 





Skin temperature was measured at irradiation site and controlled by electric fan 
during active irradiation in the (+) L-NMMA arm to keep the temperature rise close 
to baseline. One-way repeated measures ANOVA showed no significant difference 
in active irradiation from all the time points when compared against the baseline. 
Two-way repeated measure ANOVA was used to compare between sham and active 
irradiation in the (+) L-NMMA arm and no significant difference was found, 
p=0.9112 (figure 4.5), confirming that the change in skin temperature was 
successfully controlled. 
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Figure 4.5 Temperature change from baseline (FBF study – Phase 2) 
Temperature change in the (+) L-NMMA arm during sham and active irradiation. No 





4.3.2.2.3 Circulatory nitro-species analysis (part 1 - NOx) 
Blood samples were drawn from both (+) / (-) L-NMMA arms simultaneously during 
sham and active irradiation visits. Unfortunately during one of the sham irradiation 
visits, blood sample collection from the volunteer was unsuccessful, thus n=11 in all 
the sham irradiation blood samples. Blood sample data obtained from this particular 
volunteer during analysis of sham versus active were removed to achieve proper 
matching. Circulatory nitro-species analysis will be analyzed according to active 
versus sham irradiation and infused/irradiated versus non-infused/non-irradiated arm. 
Circulatory nitrite during sham and active irradiation in the (-) L-NMMA arm 
showed no obvious pattern and trends with no significant time points difference 
shown by one-way repeated measures ANOVA. Two-way repeated measures 
ANOVA were used to determine difference between sham from active irradiation but 
no significant difference was noted, p=0.5722 (figure 4.6-A). 
Circulatory nitrite during sham and active irradiation in the (+) L-NMMA arm 
showed a peaking of nitrite during active irradiation at 20 minutes post irradiation, 
however this rise was not significant as analyzed by one-way repeated measures 
ANOVA. Two-way repeated measures ANOVA was used to determine difference 
between sham from active irradiation and no significant difference was noted, 
p=0.9538 (figure 4.6-B). 
During sham irradiation, circulatory nitrite in the (+) and (-) L-NMMA arm showed 
no particular pattern with no significance detected with a one or two-way repeated 
measures ANOVA, p=0.7280 when looking for difference between the two arms 
(figure 4.6-C). During active irradiation, a trend of increase in circulatory nitrite at 
20 minutes post irradiation can be seen, but no significance was detected. Two-way 
repeated ANOVA showed p=0.7044 (figure 4.6-D). 
Circulatory nitrate in the (-) L-NMMA arm during both sham and active irradiation 




irradiation comparing against baseline as shown by one-way repeated measures 
ANOVA. However, no difference were seen between the two groups with two-way 
repeated ANOVA, p=0.3554 (figure 4.6-E).  
Just as in the un-infused arm, circulatory nitrate in (+) L-NMMA arm during both 
sham and active irradiation showed a gradual reduction. In sham irradiation, this 
reduction was found to be significant at 40 minutes post irradiation, and in active 
irradiation, significance was found in 20 and 40 minutes post irradiation when 
comparing against baseline as analyzed by one-way repeated measures ANOVA. No 
significant was seen in a two-way repeated measures ANOVA, p=0.3218 (figure 4.6-
F). 
Once again significant reduction in circulatory nitrate 40 minutes post sham 
irradiation was seen in both in (+) and (-) L-NMMA arm, but there was no difference 
between these two groups, p=0.5656 (figure 4.6-G). During active irradiation, 
circulatory nitrate showed a small peak in the L-NMMA infused arm after infusion 
of L-NMMA, but this increase was not significant. No difference was noted in the 
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Figure 4.6 Comparison of NOx by sham vs active and infused vs non-infused 
A) Circulatory nitrite change in (-) L-NMMA arm. No significant difference seen 
from change against baseline and no difference between sham and active was 
observed. Data are presented as mean ± SEM (n=11). 
B) Circulatory nitrite change in (+) L-NMMA arm. No significant difference seen 
from change against baseline and no difference between sham and active was 
observed. Data are presented as mean ± SEM (n=11). 
C) Circulatory nitrite change during sham irradiation. No difference observed 
between +/- L-NMMA infusion. Data are presented as mean ± SEM (n=12). 
D) Circulatory nitrite change during active irradiation. No difference observed 
between +/- L-NMMA infusion. Data are presented as mean ± SEM (n=12). 
E) Circulatory nitrate change in (-) L-NMMA arm. Significant reduction found at 40 
minutes after irradiation during both sham and active irradiation when compared 
against the baseline (indicated by ↑). No difference was noted between sham and 
active irradiation. Data are presented as mean ± SEM (n=11). 
F) Circulatory nitrate change in (+) L-NMMA arm. Significant reduction found at 
40 minutes after irradiation during both sham and active irradiation when compared 
against the baseline (indicated by ↑). No difference was noted between sham and 
active irradiation. Data are presented as mean ± SEM (n=11). 
G) Circulatory nitrate change during sham irradiation. No difference observed 
between +/- L-NMMA infusion. Data are presented as mean ± SEM (n=12). 
H) Circulatory nitrate change during active irradiation. No difference observed 





4.3.2.2.4 Circulatory nitro-species analysis (part 2 - RXNO) 
Circulatory S-nitrosothiols in both the (-) and (+) L-NMMA arm showed no 
significant change through the study. One-way repeated ANOVA was performed and 
no significant difference was found. Two-way repeated measures ANOVA in (-) and 
(+) L-NMMA arm showed p=0.9034 and p=0.8843 suggesting no difference between 
the sham and active group (figure 4.7-A&B). 
Comparison of circulatory S-nitrosothiols between the infused and non-infused arm 
was done by using a two-way repeated measures ANOVA. No difference was seen in 
sham (p=0.1063) and active (p=0.2109) irradiation (figure 4.7-C&D). 
Nitrosamine in the (-) L-NMMA arm showed a sudden increase after UVA 
irradiation, however no significant difference was found in-between time points and 
two-way repeated ANOVA showed no difference between active and sham 
irradiation, p=0.8216 (figure 4.7-E). 
In the L-NMMA infused arm, both active and sham irradiation showed slight 
reduction in nitrosamine after L-NMMA infusion, but this was not significant. Two-
way repeated measures ANOVA also showed no significance, p=0.8112 (figure 4.7-
F). 
Nitrosamine during sham irradiation showed a sudden drop after L-NMMA infusion 
in both (-) / (+) L-NMMA arm, but this was not significant. Two way repeated 
measures ANOVA showed no significant difference between the infused and non-
infused arm, p=0.5401 (figure 4.7-G). 
Just as with sham irradiation, active irradiation did not cause any significant change 
in circulatory nitrosamine. Two-way repeated measures ANOVA also showed no 
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Figure 4.7 Comparison of RXNO by sham vs active and infused vs non-infused 
A) Circulatory S-nitrosothiols change in (-) L-NMMA arm. No significant 
difference seen from change against baseline and no difference between sham and 
active was observed. Data are presented as mean ± SEM (n=11). 
B) Circulatory S-nitrosothiols change in (+) L-NMMA arm. No significant 
difference seen from change against baseline and no difference between sham and 
active was observed. Data are presented as mean ± SEM (n=11). 
C) Circulatory S-nitrosothiols change during sham irradiation. No difference 
observed between +/- L-NMMA infusion. Data are presented as mean ± SEM (n=12). 
D) Circulatory S-nitrosothiols change during active irradiation. No difference 
observed between +/- L-NMMA infusion. Data are presented as mean ± SEM (n=12). 
E) Circulatory nitrosamine change in (-) L-NMMA arm. No significant difference 
seen from change against baseline and no difference between sham and active was 
observed. Data are presented as mean ± SEM (n=11). 
F) Circulatory nitrosamine change in (+) L-NMMA arm. No significant difference 
seen from change against baseline and no difference between sham and active was 
observed. Data are presented as mean ± SEM (n=11). 
G) Circulatory nitrosamine change during sham irradiation. No difference observed 
between +/- L-NMMA infusion. Data are presented as mean ± SEM (n=12). 
H) Circulatory nitrosamine change during active irradiation. No difference observed 




4.3.3 Bleeding time study 
Bleeding time measurement was performed three times. Collected data were 
analyzed for Gaussian distribution by Shapiro-Wilk test and failed (p>0.05). An 
attempt to normalise the data by log transforming it was made but the data still 
showed non-Gaussian distribution, so Friedman test with Dunn’s multiple 
comparison were used instead of one-way repeated measures ANOVA. 
No increase in bleeding time was noted in the sham irradiation, whereas during 
active irradiation, a significant increase in bleeding time was noted at 20 minutes 
post irradiation (from 6.67±0.62 min to 8.50±1.23 min) when analyzed by Friedman 
test, although two-way repeated ANOVA showed no significant difference between 
sham and active irradiation, p=0.3929 (figure 4.8-A). 
Skin temperature was monitored from two sites and both the arm and thigh 
temperature showed no difference (p=0.9841 in arm and p=0.6963 in thigh) between 
active and sham irradiated visit of the study, showing a successful temperature 
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Figure 4.8 Bleeding time and temperature change 
A) Bleeding time change. Significant increase in bleeding time from baseline was 
seen at 20 minutes post active UVA irradiation as shown by Friedman test. No 
significant difference was noted between sham and active irradiation (n=12). 
B) Temperature change in the arm from baseline. No significant difference was 
shown between active and sham irradiation as analyzed by two-way repeated 
measures ANOVA (n=12). 
C) Temperature change in the thigh from baseline. No significant difference was 





4.4.1 Change in skin blood flow during UVA irradiation 
The main aim of the SBF study was to determine if UVA irradiation would cause an 
increase in SBF at a non-irradiated site, suggesting an overall systemic vasodilatation, 
which was reflected in the cutaneous circulation. 
A trend towards increased SBF was seen during UVA irradiation (figure 4.1-A), but 
this lasted for less than 10 minutes after the UVA lamp was switched off, suggesting 
that the increase of SBF observed is a thermoregulatory reaction toward whole body 
warming by UVA irradiation instead of a prolonged vasodilatation secondary to 
photolysis of skin stores of nitrogen oxides. 
Increase in SBF during body heating has been studied by different groups and this 
has shown that the increase of SBF is strongly associated with sympathetic fibres 
(Roddie et al., 1957, Roddie, 1963, Dietz et al., 1994). 
The reason an increase in SBF did not last longer after UVA irradiation could 
possibly be due to the thermoregulation effect dominating over the nitric oxide effect 
from photolysis of nitrite. It was shown in the previous skin temperature 
measurements that UVA irradiation of the skin increases temperature by 2~3 ºC 
during irradiation (figure 3.6 and figure 4.2), thus when the lamp was switched off, 
sudden cooling of the skin stimulates the vasoconstrictor fibres to conserve heat, 
therefore reducing SBF and masks the possible increase of SBF due to nitric oxide 




4.4.2 Forearm blood flow discussion 
     4.4.2.1 Forearm blood flow changes 
The FBF study was performed with and without the infusion of L-NMMA. In the 
first phase of the study, I wished to determine whether the irradiation of one arm will 
cause an increase in FBF. The result showed a significant increase in FBF in both 
UVA and infrared irradiated arm (figure 4.2-A). The initial increase in FBF could be 
due to a temperature effect (as I have created an exact same temperature rise with the 
infrared lamp, figure 4.2-B), but, the rise in FBF lasted for 60 minutes after the 
irradiation, suggesting there was more than just a temperature effect. Studies have 
suggested that whole body heat stress and local warming both causes a rise in FBF 
due to the stimulation of NOS, with neuronal nitric oxide synthase (nNOS) mediating 
the vasodilator response in heat stress and endothelial nitric oxide synthase (eNOS) 
mediating the vasodilatation in local warming. (Kellogg et al., 2008a, Kellogg et al., 
2008b, Kellogg et al., 2009) According to my hypothesis, the infrared irradiated arm 
should be showing an initial increase of FBF due to the heat, which returns to 
baseline after the irradiation. However, the data have shown that in the infrared 
irradiated arm, there is a significant rise in FBF post irradiation that became 
insignificant during the 15 and 30 minute time point and later found to increase 
significantly again at 45 and 60 minutes post irradiation. A crossover effect was 
initially hypothesised, in which the nitric oxide release in the UVA irradiated arm got 
carried over to the contra-lateral arm causing the increased FBF. The increase in 
circulatory nitrite was not found to be significant, but an increasing trend after 
irradiation was seen (figure 4.3-A), although the possibility that this is associated 
with the NOS effect from local warming or red/near infrared light’s ability to reduce 
nitrosyl hemes releasing nitric oxide (Lohr et al., 2009) cannot be excluded. 
The second phase of the FBF study included L-NMMA infusion. L-NMMA is a 
NOS inhibitor that inhibits all three types of NOS and can thus rule out any NOS 
mediated effects in vasodilatation. FBF measurement showed a significant reduction 
after L-NMMA infusion in all the time points confirming a successful inhibition of 




L-NMMA infusion lasted throughout the study, and the temperature was well 
matched during active irradiation to track that of the sham irradiation, with an 
average increase of less than 0.6 ºC (figure 4.5). Under these conditions, active UVA 
irradiation of the forearm still showed a significant increase in FBF 30 minutes post 
UVA irradiation. In addition to this, two-way repeated measures ANOVA also 
showed a significant difference between active and sham irradiation (figure 4.4-D). 
These findings confirm that the increase in FBF after UVA irradiation is independent 
of temperature and NOS, which is consistent with the initial hypothesis. 
In the L-NMMA infusion study, a cross over effect of increase FBF was observed 
during active but not sham irradiation. When FBF baseline was set from the pre-
UVA instead of pre-LNMMA measurement (figure 4.9-A&B), a greater rise of FBF 
was found in the L-NMMA treated arm which is likely to be due to the vasculature 
being more sensitive to nitric oxide, as it was not continuously exposed to 
constitutive nitric oxide release. In comparison, the un-irradiated arm during active 
irradiation showed a non-significant increase of FBF that had a similar trend to the 
irradiated arm, suggesting the possibility that nitric oxide released by photolysis of 
nitro-species in the irradiated arm was carried in the circulation (figure 4.10) and 
produced an effect at the contra lateral arm (figure 4.9-B). Even though FBF can be 
reflected by changes in SBF, it is not likely to be due to a temperature induced 
vasodilatation in this study, as I have: 
1. Successfully controlled the skin temperature change extremely close to the 
baseline during UVA irradiation. 
2. Demonstrated that the SBF increase at a non-irradiated site during the SBF 
study only lasts less than 10 minutes, but the trend of increase in FBF at the 
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Figure 4.9 Re-modification of figure 4.4-A&B, FBF change using pre-UVA as 
baseline 
 
     4.4.2.2 Circulatory nitro-species analysis 
During phase one of the FBF study, the circulatory nitrite change showed a non-
significant rising trend in both UVA and infrared irradiated arm. The small effect is 
probably due to the very limited body surface area that was irradiated (less than 4.5% 
of the total body surface area). The increase trend in nitrite found from the infrared 
irradiated arm could be due to the red/near infrared light’s ability to reduce nitrosyl 
hemes and release nitric oxide (Lohr et al., 2009) or a cross over effect from the 
UVA irradiated arm, where photolysis of nitric oxide species took place. The 
significant drop in nitrate is similar to that shown in the blood pressure study where 
the increased circulatory nitrite was accompanied by a reduction of circulatory nitrate 
(this will be further explained in chapter 5.4.4 for reduction of nitrate by thiols). 
The graph that was initially plotted for nitrite change in phase two FBF study was 
based on the change from pre L-NMMA infusion (figure 4.6). This data analysis 
might mask the real change of circulatory nitrite after UVA irradiation, and so has 
been re-plotted with nitrite levels immediately before irradiation as baseline. Doing 
this showed a greater increase in circulatory nitrite in the L-NMMA infused arm than 
the non-infused arm (figure 4.10) and a cross over effect during active irradiation can 
be seen. Although the increase was non-significant and only peaked at 20 minutes 




UVA irradiated arm increase nitrite by 0.08±0.04 µM at 20 minutes post UVA, 
whereas in L-NMMA study nitrite increased by 0.07±0.05 µM at 20 minutes post 
UVA. 
Kubo and colleagues gave 18 healthy volunteers increasing dose of L-NMMA 
infusion (1, 4, 8 and 16 µmol/min) and showed a significant reduction of total NOx 
(nitrite and nitrate) 5 minutes after 16 µmol/min L-NMMA infusion (Kubo et al., 
1994). Lauer and colleagues gave 8 volunteers an increasing dose of L-NMMA 
infusion (4, 8 and 12 µmol/min) and they showed significant nitrite but not nitrate 
reduction after 15 minutes of 8 and 12 µmol/min L-NMMA infusion (Lauer et al., 
2001). Whether their finding could be due to an effect from accumulated L-NMMA 
infusion was not stated, but their results clearly suggest intra-arterial L-NMMA 
infusion reduces circulatory nitrite and nitrate. Therefore the delay in the increase of 
circulatory nitrite during active irradiation is probably associated with the L-NMMA 
infusion (figure 4.10).  
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Figure 4.10 Circulatory nitrite change from baseline in FBF study – Phase 2 




During phase 2 of the FBF study, initial increase followed by gradual reduction of 
circulatory nitrate was found in both L-NMMA treated and untreated arm during 
active and sham irradiation (figure 4.6-E, F, G, H). Kubo et al suggests a reduced 
circulatory nitrate post L-NMMA infusion (Kubo et al., 1994) and whether the 
inhibition of constitutive NOS contributes to the reduction of circulatory nitrate in 
sham irradiation is unknown (nitrate in the circulation reflects the amount of dietary 
nitrate intake and the amount of nitric oxide oxidized by oxyhaemoglobin to nitrate). 
However, by setting pre-UVA circulatory nitrate instead of pre-L-NMMA as 
baseline showed a more rapid and profound reduction of circulatory nitrate in active 
irradiation (figure 4.11). Even though significant difference was not found between 
sham and active irradiation, circulatory nitrate decreases immediately after active 
UVA irradiation but not sham, suggesting that other than L-NMMA induced nitrate 
reduction, UVA might also contribute to the reduced nitrate. 
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Figure 4.11 Circulatory nitrate change from baseline in L-NMMA infused arm 
Nitrate change in the (+) L-NMMA arm during active and sham irradiation. 
Significant reduction in circulatory nitrate found during sham irradiation at 40 
minutes post irradiation (as indicated by ↓). Significant reduction in nitrate during 




4.4.3 Bleeding time 
Bleeding time was measured by Ivy’s method and a significant increase was noted in 
the active irradiation at 20 minutes post UVA irradiation (figure 4.8-A). The 
temperature was successfully controlled (figure 4.8-B&C) and the increase in 
bleeding time is thus likely to be due to the nitric oxide release from the skin after 
UVA irradiation. Bleeding time only serves as an indirect indication of platelet 
activity as other factor are involved in the process of clotting such as protein C, 
antithrombin, plasmin, prostacyclin, tissue factor pathway inhibitor and other clotting 
factors within the clotting cascade. This finding thus serves as a useful pilot study to 
suggest that nitric oxide released from UVA irradiation might be sufficient to inhibit 
platelet aggregation. Further work to more thoroughly investigate platelet activation 
after UVA irradiation is already planned and will be conducted by Dr. N.Lang 





From the studies outlined in this chapter, I can conclude the following: 
1. UVA irradiation of the skin is likely to produce a systemic effect, increasing 
blood flow even at non-irradiated sites, although the effect of temperature 
cannot be excluded as SBF is strongly correlated to temperature change. 
2. Local UVA irradiation of an isolated vascular bed causes vasodilatation and 
increased blood flow independently of temperature and nitric oxide synthase, 
suggesting an effect from UVA induced nitric oxide release from skin. 
3. UVA irradiation increases bleeding time independently of temperature, 
suggesting the amount of nitric oxide released is sufficient to produce an 
effect on inhibiting platelet aggregation. Sham irradiation produced a slight 
increase in bleeding time, so that the difference between sham and active was 



























Sunlight, particularly the UV spectrum is known to photo-decompose nitrite into 
nitric oxide. It has been shown by in vitro and in vivo studies that the decomposition 
of nitrite into nitric oxide occurs instantly (Treinin and Hayon, 1970, Zafiriou and 
Bonneau, 1987, Paunel et al., 2005, Mowbray et al., 2009). Stroke incidence appears 
to vary by season, but different studies have produced conflicting data as to when the 
peak incidence occurs: spring (McDowell et al., 1970, Chyatte et al., 1994), summer 
(Oberg et al., 2000), autumn (Chyatte et al., 1994, Langmayr et al., 1995) and winter 
(Shinkawa et al., 1990, Vinall et al., 1994). This inconsistent finding is multi-
factorial (data collection, method of analysis, population size, geographical data, 
follow up period) and it is hard to determine which, if any, study showed the correct 
finding. Nonetheless, many studies showed a north-south gradient in the increased 
risk for ischaemic heart disease and stroke in northern areas (Fleck, 1989, Rosengren 
et al., 1999, Cottel et al., 2000, Morris et al., 2001). Different risk factors have been 
considered, but within the UK after accounting for all known risk factors, 
cardiovascular risk is shown to correlate directly with latitude (Law and Morris, 
1998). 
From my previous studies I have demonstrated that 20 J/cm2 of UVA irradiation is 
likely to reduce DBP. I have also shown that this amount of UVA significantly 
increases FBF which is independent from temperature and nitric oxide synthase 
involvement. Although it is known that UVA is capable of nitrite photolysis to 
release nitric oxide, I wished to calculate the particular wavelengths within the UV 
spectrum that can release maximal amount of nitric oxide after correcting for solar 
irradiance. Identifying the total nitric oxide release from each particular wavelength 
and then correcting for solar irradiance will thus aid us in examining any variation in 
blood pressure and cardiovascular events with nitric oxide release and season. 
The reduction in blood pressure that was observed following UVA irradiation was 




nitrate. Both occurred immediately after UVA irradiation, suggesting causation. 
Dejam and colleagues suggest that thiols enhance non-enzymatic conversion of 
nitrate to nitric oxide and nitric oxide-adducts upon UV-exposure (Dejam et al., 
2003). The nitrate reduction that was shown following UVA irradiation of the skin 
might be enhanced by the presence of thiols in either the circulation or the rich store 





I hypothesise that photolysis of nitrite by UVA is concentration and energy 
dependent, and also wavelength specific. I further hypothesise that thiols are 
involved in the reduction of nitrate during UVA irradiation, accounting for the 
decreased circulatory nitrate and increased circulatory nitrite that was been observed. 
5.1.3 Aim 
The main aim of the study is to show a difference in nitric oxide production by 
various wavelengths within the UVA and UVB spectrum. The total amount of nitric 
oxide release from each particular wavelength will then be re-calculated according to 
solar irradiance to determine the association of nitric oxide release at different 
latitudes and seasons. 
The other aim of the study is to identify whether the presence of thiols enhances 





5.2.1 Aqueous nitrite irradiation 
Different concentrations of aqueous nitrite solution were irradiated with a broadband 
UVA cabinet installed with 12 Philips TLK 40W/10R bulbs (350~400 nm, max at 360 
nm) for different lengths of time (10 to 640 seconds) to determine a dose response for 
UVA energy and nitrite concentration. In a second experiment, a nitrite solution at a 
fixed concentration of 0.01 M was irradiated with a monochromator at wavelengths 
ranging from 270 nm to 400 nm at 10 nm interval with 1 J/cm2 of energy being 
delivered at each wavelength. The duration of irradiation varied as the irradiance was 
different at each wavelength (table 5.1). The rate of nitric oxide release from each 
wavelength was also determined. 
Wavelength 
(nm) 
Spatial Mean Irradiance 
(mW/cm2) 
Time to deliver 1 J/cm2 
(sec) 
270 1.8 556 
280 3.29 304 
290 5.37 186 
300 7.95 126 
310 10.6 94 
320 13.8 73 
330 17.2 58 
340 20.7 48 
350 24.1 42 
360 27.1 37 
370 29.6 34 
380 31.9 31 
390 32.7 31 
400 33 30 
Table 5.1 Irradiance and duration required to deliver 1 J/cm2 
Measurement performed by Karne McBride from the medical physic department. 




5.2.2 Correction for solar irradiance 
Solar irradiance (Sasha et al.) at the earth’s surface is governed by the ozone column 
and varies by latitude and season (NASA, 2009). Using the product of irradiance and 
the monochromator data derived above, I was able to calculate the theoretical 
maximum amount of nitric oxide that would be cleaved from nitrite. I performed 
these calculations for different latitudes across the globe on June, 21, 2011 (the day 
that has the most daylight in the Northern hemisphere, and least in the Southern 
hemisphere) and Dec, 21, 2011 (the day that has the most daylight in the Southern 
hemisphere, and least in the Northern hemisphere). 
5.2.3 Thiols (cysteine) study 
Three main sources of thiols (glutathione, cysteine and homocysteine) are present in 
both human skin and circulation. Glutathione, the most abundant low molecular 
weight thiol in the skin (Persson et al., 2002) is known to be synthesized from 
cysteine and serve as a reservoir for cysteine (Huang et al., 1988, Lu, 2009). Cysteine 
was thus chosen instead of glutathione to be used in this study. A cysteine solution 
was prepared and placed in the stripping vessel connected to a gas phase 
chemiluminescence meter followed by injection of potassium nitrate with/without 
UVA irradiation and with/without sulphanilamide. Details of this study were 
described earlier in chapter 2.2.4 (page 54). 
5.2.4 Statistical analysis 
Data were collected and recorded in Microsoft excel and Chart 5 for Windows, later 
transferred to SPSS Statistic 17.0 and GraphPad Prism 5 for statistic analysis. Data 
were analyzed using Student’s t-test, Regression analysis, two-way repeated 
ANOVA with post hoc test (Bonferroni's multiple comparison test) where 






5.3.1 Dose response for nitric oxide formation by irradiating aqueous nitrite 
Different concentrations of aqueous nitrite solution were irradiated with a broad 
spectrum UVA lamp for approximately three minutes until the maximal production 
of nitric oxide during irradiation reached a plateau, suggesting that the rate of nitric 
oxide formation by UVA photolysis reaches equilibrium. The highest point (peak) of 
the plateau for the nitric oxide release was plotted and regression analysis was used 
to analyze the data. The results showed the maximal nitric oxide production available 
increases linearly with the nitrite concentration, r2=0.9473, p=0.0011 (figure 5.1-A). 
Two different concentrations of aqueous nitrite solution were then irradiated at 340 
nm for different times (and thus energy). 340 nm was used as this was the 
wavelength that showed the highest rate of nitrite photolysis (figure 5.2-B). The total 
release was then calculated from area under the curve. The total nitric oxide release 
by UVA irradiation also increases linearly with irradiation time (figure 5.1-B), 
r2=0.9972 and 0.9876 in the 0.01 M and 0.001 M nitrite solution irradiation, both 
regressions showed a p value of less than 0.0001 (p<0.0001). The results suggest that 
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Figure 5.1 Dose responses by time and concentration in nitrite photolysis by UVA 
A) Peak nitric oxide release by UVA irradiation. Regression analysis showed the 
release of nitric oxide is dependent on the concentration of NaNO2 (p=0.0011) (95% 
CI is 0.7696 to 0.9972). 
B) Dose response of total nitric oxide release following 340nm irradiation for 
different time and thus total energy. Regression analysis showed the release of nitric 
oxide is dependent on time of irradiation in both nitrite solutions irradiated, 95% CI 
is 0.9973 to 0.9999 in the 0.01 M trial (p<0.0001) and 0.9567 to 0.9991 in the 0.001 




5.3.2 Monochromator results 
The action spectrum for nitrite to release nitric oxide was determined. After 
irradiation of the different solutions with 1 J/cm2 of energy, the area under the curve 
(representing the total amount of nitric oxide released when 1 J/ cm2 of energy was 
delivered at each particular wavelength) was plotted, showing that the highest nitric 
oxide release fell within the UVB spectrum, peaking at 280 nm (figure 5.2-A). 
As the irradiation time required to deliver 1 J varies for each wavelength, the peak of 
release from each wavelength could not be determined, thus aqueous nitrite solution 
was once again irradiated by different wavelengths for a fixed duration of one minute. 
The slope (calculated from the baseline and the peak of the curve using the 
difference of y divided by the difference of x between the two points) of nitric oxide 
release during irradiation by different wavelengths were then plotted, with the peak 
falling between 340~350 nm (figure 5.2-B). 
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Figure 5.2 NO detected from nitrite solution after irradiation by different 
wavelengths 
A) Release of nitric oxide calculated from area under curve after irradiation by 
wavelengths ranging from 270~400 nm using a fixed energy of 1 J/cm2. 
B) Slope for nitric oxide release by each wavelength ranging from 270~400 nm, the 




5.3.3 Correction by solar irradiance and column ozone 
Nitric oxide release data from sodium nitrite at each wavelength was multiplied by 
solar irradiance data obtained from the National Center for Atmospheric Research to 
show the calculated difference in nitric oxide release at various latitudes and at 
different times of the year. The variation in nitric oxide release by latitude is shown 
in Northern and Southern hemisphere and correlates with the area under each curve 
(figure 5.3-A, B, C, D). The possible nitric oxide release from nitrite clearly 
increases toward the equator, peaking at 20ºN and 20ºS during summer time and at 
the equator during winter period. The pattern of nitric oxide release for 60ºS seen at 
figure 5.3-C was different from others, this is due to the absence of column ozone 
during June, 21, 2011, thus allowing more UVB to enter the Earth surface resulting 
in more nitric oxide produced within the UVB spectrum. 
Two-way repeated measures ANOVA were used to determine the difference in 
calculated nitric oxide release at different latitudes during summer and winter. These 
figures differed significantly in Northern and Southern hemispheres, at latitude of 40º, 
50º and 60º between June and December (figure 5.3-E and F). 
The total nitric oxide release from various latitudes were calculated by area under 
curve and plotted accordingly and analyzed by regression. In Northern hemisphere 
(figure 5.3-G), there is a significant correlation in both June (p=0.0006, r2=0.7900) 
and December (p<0.0001, r2=0.9227). The same finding was noted for Southern 
hemisphere (figure 5.3-H) with the correlation of nitric oxide release and latitude in 
June (p<0.0001, r2=0.9291) and December (p=0.0006, r2=0.7865). This result 
suggests a lesser nitric oxide production via nitrite photolysis in geographical areas 
further away from the equator. 
An overview of nitric oxide production during June and December across the latitude 













































































































































































Figure 5.3 Nitric oxide release corrected by solar irradiance 
A) Nitric oxide release from nitrite in Northern hemisphere at different latitude 
during June. 
B) Nitric oxide release from nitrite in Northern hemisphere at different latitude 
during December. 
C) Nitric oxide release from nitrite in Southern hemisphere at different latitude 
during June. 
D) Nitric oxide release from nitrite in Southern hemisphere at different latitude 
during December. 
E) Nitric oxide production in Northern hemisphere during June and December, 
significant difference at 40, 50 and 60 ºN as shown by two-way repeated measures 
ANOVA. 
F) Nitric oxide production in Southern hemisphere during June and December, 





G) Correlation of total nitric oxide release in Northern hemisphere by latitude, 
significant correlation found in both June and December by regression. 
H) Correlation of total nitric oxide release in Southern hemisphere by latitude, 
significant correlation found in both June and December by regression. 
Total NO Release (Jun vs  Dec)































5.3.4 Cysteine study 
A broad spectrum UVA lamp was used to irradiate cysteine solution or aqueous 
potassium nitrate (KNO3) solution alone. This showed no significant release of nitric 
oxide suggesting that UVA irradiation of KNO3 or cysteine alone cannot form any 
nitric oxide (figure 5.5-A, B). 
A 0.05 M solution of L-cysteine hydrochloride 1-hydrate in PBS was placed within 
the stripping vessel and KNO3 was added into the cysteine solution (figure 5.5-C). 
This alone released nitric oxide from the nitrate solution, suggesting that cysteine can 
convert nitrate to nitric oxide, either through the process of nitrate → nitrite → nitric 
oxide or from nitrate directly to nitric oxide. 
To determine the process of nitrate reduction by cysteine, the above procedure was 
repeated, but with UVA irradiation after the addition of aqueous nitrate into cysteine 
solution. Once UVA was switched on, a rapid release of nitric oxide was seen (figure 
5.5-D), suggesting that UVA accelerates the process of nitrate reduction by cysteine, 
and probably the process of nitrate reduction by cysteine involves nitrite. 
To determine whether the reduction of nitrate by cysteine occurred via an 
intermediate reduction to nitrite, sulphanilamide was added into the stripping vessel 
along with cysteine solution and irradiated by UVA. Sulfanilamide avidly binds to 
nitrite. In these conditions, no nitric oxide release occurred following injection of 
KNO3 into the stripping vessel (figure 5.5-E). 
To confirm that formation of nitrite is a part of the reduction process, KNO3 was 
once again added into the cysteine solution, and when reduction is initiated, 
sulphanilamide was added into the stripping vessel and the UVA lamp switched on. 
With the addition of sulphanilamide, the rapid release of nitric oxide seen in figure 
5.5-D was abolished and the release of nitric oxide as seen in figure 5.5-C was also 






















Figure 5.5 Reduction of nitrate by cysteine which is enhanced by UVA irradiation 
A) ① addition of cysteine solution into stripping vessel 
② broadband UVA on 
B)  ① addition of aqueous nitrate solution into stripping vessel 
② broadband UVA on 
C)  ① cysteine bubbling in the stripping vessel 
② injection of aqueous nitrate solution into stripping vessel 
D)  ①cysteine bubbling in the stripping vessel 
② injection of aqueous nitrate solution into stripping vessel 
③ broadband UVA on 
E) ① cysteine bubbling in the stripping vessel with sulphanilamide added 
② broadband UVA on 
③ broadband UVA off 
④ aqueous nitrate solution added 
⑤ broadband UVA on 
F) ① cysteine bubbling in the stripping vessel 
② injection of aqueous nitrate solution into stripping vessel 






5.4.1 Dose response in photolysis of aqueous NaNO2 by UVA 
The dose response clearly showed a positive correlation between the concentration of 
nitrite and duration of exposure to UVA against the amount of nitric oxide release 
(figure 5.1), suggesting the possibility that a longer exposure under the sun will result 
in a higher circulatory nitric oxide species. I was thus surprised not to have seen a 
bigger reduction in blood pressure in my high nitrate diet volunteers. However, the 
relative increase of nitrite in the Oplander’s study (which was not controlled for diet) 
(Oplander et al., 2009) was similar to mine at twenty minutes post irradiation, the 
time point where the biggest drop in DBP was found within the volunteers (Table 
5.2). 
Relative ↑ of NO2- 
Time post UVA 
My study  (Oplander et al., 2009) 
0 min 47.53±30.68% N/A 
15 min N/A 43±22% 
20 min 43.21±28.51% N/A 
40 min 47.39±26.61% N/A 
45 min N/A 59±32% 
75 min N/A 40±26% 
Table 5.2 Comparing relative increase of circulatory nitrite with Oplander et al 
Relative increase in circulatory nitrite from my study and the Oplander study both 
showed a 43% increase at twenty minutes post irradiation. Data are presented as 
mean ± standard deviation. 
 
This suggests that the release of nitric oxide by irradiation of human skin is 
independent from diet but instead energy related, as in my study and the Oplander 
study, we both gave 20 J/cm2 of UVA, with the only difference being that they 
irradiated the whole body of older volunteers who presented with higher baseline 
blood pressure and I irradiated one side of the body with young volunteers who 




5.4.2 Photolysis of nitrite being wavelength specific 
Nitric oxide release by nitrite photolysis was noted to be present from wavelength 
270 nm all the way up to more than 400 nm, involving UVC, UVB, and UVA 
spectrum (figure 5.2). It is already known that both UVA and UVB are capable of 
nitrite and nitrate photolysis to release nitric oxide (Jankowski et al., 1999, Honrath 
et al., 2000), and I confirmed this finding. When a fixed amount of energy was used 
to irradiate aqueous nitrite solution, wavelength 280 nm released most nitric oxide 
from nitrite. Even though UVB was shown to produce more nitric oxide by nitrite 
photolysis in vitro when fixed energy was delivered, UVB irradiance reaching 
human skin is very low compared to UVA. I would expect UVA wavelengths to be a 
more important spectrum in nitric oxide production when human are exposed to 
sunlight. The rate (as represented by slope in figure 5.2-B) of nitrite photolysis was 
found to be most rapid at around 340~350 nm, suggesting UVA (320~400 nm) 
would be more potent in the procedure of nitrite photolysis. 
5.4.3 Total Nitric oxide release from NO2- during summer and winter across 
the globe 
When the data obtained from monochromator irradiation of aqueous nitrite is 
corrected by solar irradiance and plotted at different latitudes (figure 5.3-A~D), the 
majority of nitric oxide released clearly falls within the UVA (315~400 nm) 
spectrum (with the area under the curve accounting more than 80% of the total nitric 
oxide produced). This suggests that even with the application of an extremely 
effective sunscreen, the photolysis of nitrite to nitric oxide would probably not be 
affected (as sunscreens predominantly block UVB radiation). 
A seasonal difference in nitric oxide formation from nitrite photolysis can be seen in 
both Northern and Southern hemisphere (figure 5.3-E~F), with more nitric oxide 
released during summer compared to winter. Nitric oxide release from nitrite 
photolysis was also found to have a positive correlation with latitude, with less nitric 




agreement with many studies that suggested higher cardiovascular risks / events and 
blood pressures during winter as well as at places further away from equator (Rose, 
1961, Brennan et al., 1982, Fleck, 1989, Law and Morris, 1998, Cottel et al., 2000, 
Morris et al., 2001). 
Significant seasonal differences in nitric oxide formation from nitrite photolysis were 
found at 40~60°N and 40~60°S. Thus it will be interesting to know whether seasonal 
variation in blood pressure and cardiovascular events are more prominent in these 
geographical areas when comparing to other geographical areas such as 30°N to 30°S. 
5.4.4 Reduction of nitrate by cysteine 
It has been suggested that the presence of thiols will enhance the formation of nitric 
oxide in nitrate photolysis (Dejam et al., 2003). I thus tried irradiating aqueous 
cysteine or nitrate solution with a broad spectrum UVA lamp. When aqueous 
cysteine or nitrate solution alone were irradiated by UVA (figure 5.5-A~B), there 
was minimal release of nitric oxide, and this was probably due to photolysis of the 
small amount of nitrite present in PBS. When KNO3 was added into cysteine solution, 
there was a gradual release of nitric oxide over the duration of about ten minutes 
(figure 5.5-C) even without UVA irradiation.  Nitrate reducton to nitrite has been 
suggested by Dejam and colleagues but detailed mechanisms were not described. I 
think the likely mechanism involves the formation of disulfide bond (equation 1) by 
the coupling of two thiol groups (Witt, 2008). Probably the loss of electrons through 
oxidation of thiols involve electron transfer of nitrate, releasing oxygen to react with 
the free hydrogen, and through this process, nitrate can be reduced to nitrite 
(equation 2 & 3 – low intensity pathway). 
1.  RSH + RSH
oxidation
�⎯⎯⎯⎯⎯� RSSR + 2H+ + 2e− 
2.  2NO3− + 2RSH → 2NO2− + RSSR + H2O2 
3.  2NO2− + RSH → NO. + RSNO + O2 + H+ 
 




solution (figure 5.5-D), there was a sudden boost of nitric oxide release, suggesting 
cysteine induced nitric oxide release from nitrate (equation 4 – high intensity 
pathway). 
4.  2NO3− + 2RSH → 2NO2−
↓ℎ𝑣𝑣
+ RSSR + H2O2 
 2NO. + O2 
 
To confirm the mechanism behind this, sulphanilamide was added into the stripping 
vessel before and after the addition of KNO3 solution. When sulphanilamide was 
added before KNO3 solution, addition of KNO3 did not cause any nitric oxide 
formation (figure 5.5-E), and addition of sulphanilamide after KNO3 inhibits nitric 
oxide formation (figure 5.5-F). This suggests that in the presence of thiols (cysteine), 
nitrate will be first converted to nitrite then to nitric oxide, and if UVA is present, 
accelerates the process of nitric oxide formation by photo-decomposing nitrite. The 
alternative reduction pathway of nitrate to NO shown in equation 5 thus seems 
unlikely, as sulphanilamide binds avidly to nitrite and not nitrosothiols (Wang et al., 
2006). If the mechanism shown in equation 5 were to take place, there would still be 
presence of nitric oxide release even after the addition of sulphanilamide due to 
photodecomposition of nitrosothiols.). 
5.  2NO3− + RSH → NO2− + RSNO + OH− + O2 
The major nitrogen oxide stores in skin is nitrate (Mowbray et al., 2009), and as our 
skin is rich in thiols (Persson et al., 2002), this mechanism could explain why UVA 
irradiation of our skin will release sufficient nitric oxide to vasodilate arterioles and 
decrease blood pressure. I further hypothesize that under normal circumstances, the 
skin store of nitro-species and the circulatory nitro-species will reach equilibrium as 
following the conversion of nitrate to nitrite, oxidation back to nitrate will slowly 
occur. In the presence of UVA, the skin store of nitrate will be reduced by thiols, and 





As UVA penetrates into the dermal vasculature, I hypothesise that it is possible 
nitrate reduction also takes place in the circulation since thiols were found to be 
present in the blood. The key factor leading to the disruption of equilibrium during 
UVA irradiation was the absence of haemoglobin in the skin. Without haemoglobin 
in the skin, nitric oxide produced by nitrate and nitrite during UVA irradiation cannot 
be oxidized back to nitrate immediately leading to a consequent decrease in skin 
stored nitrate. This then causes an interruption of the equilibrium, leading to a shift 
of circulatory nitrate from the circulation to skin, producing an end result of an 
increase circulatory nitrite and a reduction in circulatory nitrate post UVA irradiation 
(figure 5.6). 
The amount of nitrate reduced in the circulation does not correlates with the increase 
in circulatory nitrite (figure 3.13), with more nitrate reduced than nitrite formed. 
However, measurement of circulatory nitro-species does not reflect the dynamic of 
total nitric oxides stores in humans. The missing nitrate from the circulation could be 
due to a portion of nitric oxide produced from nitrate reduction at skin level exiting 
into the atmosphere, or could be due to increase excretion by the kidney but more 












From the study results I have obtained, I can conclude that nitrite photolysis is 
wavelength specific and is concentration dependent. The majority of nitric oxide 
formed from nitrite photolysis via solar irradiation falls within the UVA spectrum, 
which directly correlates with latitude and shows significant seasonal variation. 
These findings supports with the initial hypothesis in which I suggest that the 
seasonal and latitude variation in blood pressure as well as cardiovascular events 
could be associated with sunlight induced nitrite photolysis. 
I can also conclude that cysteine plays a major role in nitrate reduction under normal 
circumstance by reducing it to nitrite then nitric oxide, and that the presence of UVA 


















EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE 
IN 





The correlation of season and latitude with blood pressure has been noted since the 
1960s and observed in other more recent studies (Rose, 1961, Brennan et al., 1982, 
Rostand, 1997). Around the world at different geographical areas, a north-south 
gradient in the development of cardiovascular events has also been described in 
various studies (McDowell et al., 1970, Fleck, 1989, Douglas et al., 1991, Chyatte et 
al., 1994, Vinall et al., 1994, Langmayr et al., 1995, Law and Morris, 1998, 
Rosengren et al., 1999, Cottel et al., 2000). Others have suggested that the correlation 
of season and latitude in blood pressure and cardiovascular events is associated with 
the availability of sunlight (Rostand, 1997, Feelisch et al., 2010), but, no direct 
evidence has ever been shown that lacking sunlight increases the risk for 
cardiovascular disease or having greater life time sun exposure reduces blood 
pressure and is protective against cardiovascular disease. 
As early as 1928, an association between UV light and skin cancer was observed 
(Findlay, 1928), and in 1936 Roffo demonstrated in animal studies that UV alone 
was capable of carcinogenesis (Roffo, 1936). The following year, Peller and 
Stephenson reported that naval seamen who had long term exposure to sun and other 
environmental factors had an eight times higher incidence of skin and lip cancer than 
the civil population (Peller and Stephenson, 1937). 
From the 1970s it became clear that ultraviolet rays, in particular UVB lead to DNA 
mutations and the development of skin cancer (Setlow, 1974, deGruijl et al., 1993). 
Skin cancers are classified into different types based on the histological origin. 
Melanoma of the skin was found to have a closer association with sun burn, moles 
and skin colour (Beral et al., 1983, Lew et al., 1983). Basal cell carcinoma of the skin 
was noted to have an association with intermittent sun exposure and sun burn, 
particularly during teenage years (Kricker et al., 1995) rather than being associated 
with cumulative sun exposure (Gallagher et al., 1995). Only squamous cell 
carcinoma (SCC) of the skin was associated with total life time sun exposure 




With evidence suggesting that the formation of SCC indicates excess long term 
cumulative sunlight exposure, the decision to use SCC as a marker for excess 
lifetime sunlight exposure was made. 
6.1.1 Hypothesis 
I hypothesized that the individuals who had long term chronic exposure to the sun as 
shown by the development of squamous cell carcinoma of the skin, would have a 
higher basal circulatory nitric oxide due to photolysis of nitric oxide stores by the sun. 
Therefore, they will have reduced cardiovascular morbidity such as hypertension 
(HTN), myocardial infarction (MI), ischaemic heart disease (IHD) and stroke. 
6.1.2 Aim 
Data extracted from PCCIU database allowed two studies to be performed. The first 
aim was to determine whether the odds of developing SCC is increased/decreased if 
patients develops cardiovascular diseases (hypertension, MI, IHD and stroke) prior to 
the date of SCC being recorded. The other aim is to determine whether the 
development of SCC will be protective for future development of various 




6.2 Material and Methods 
6.2.1 PCCIU data extraction 
A total of 4348 SCC cases (2286 female and 2062 male) were extracted using the 
criteria mentioned in chapter 2.3 for case selection within the PCCIU database. Each 
case was matched with three controls by their age, gender and the general practice 
attended. 
6.2.2 Data cleaning 
The initial hypothesis was that individuals who had accumulated enough sun 
exposure would be protected from the future development of cardiovascular diseases. 
Thus if the SCC patients were diagnosed with any CVDs, the date at which the SCC 
was diagnosed was used as a cut-off point to classify the database into two groups. 
Data were analysed before and after cleaning using this time point to utilise the 
database for either a case-control or retrospective cohort study as follows:  
1. Cardiovascular diseases presenting before the diagnosis of SCC. The data 
here were used for a case-control study, investigating various CVDs as 
potential risk factors in the development of SCC. 
2. Cardiovascular diseases presenting after the diagnosis of SCC. Here the data 
were handled as a retrospective cohort study, where SCC was defined as an 
exposure, and I determined whether the exposure to SCC increased or 
decrease the risk of developing various CVDs after the diagnosis of SCC. 
The matched controls for the SCC patients, if presenting with CVD were also 
classified into two groups using the date their matched SCC patient was diagnosed 
with SCC as the cut-off point. The recreated pair of databases were then analysed 
again for odds ratio and relative risk. The data re-grouping was performed by Dr. 




6.2.3 Statistical analysis 
Data were initially stored in SPSS and later transferred into comma-separated values 
(CSV) files for analysis by the software R. Conditional logistic regression along with 
Wald’s test were used to analyse the data for matched case-control study and relative 
risk used for the matched retrospective cohort study. Data in the case-control study 
were presented as odds ratio ± 95% confidence interval. A p-value less than 0.05 is 
considered statistically significant. In the retrospective cohort study, data are 
presented as relative risk ± 95% confidence interval. When the 95% confidence 
intervals did not overlap 1 this was considered significant (p value is not suitable for 





6.3.1 Statistical analysis of data before cleaning 
Before the data were cleaned and organized, basic statistics showed that within the 
SCC patients 69.09% presented with hypertension, 9.96% presented with MI, 20.3% 
presented with IHD and 12.88% presented with stroke. Whereas in the matched 
controls, 56.78% presented with hypertension, 7.89% presented with MI, 15.6% 
presented with IHD and 10.73% presented with stroke (table 6.1). Cause and effect 
cannot be determined from this crude data. 




Hypertension 3004, 69.09% 7406, 56.78% 
Myocardial infarction 433, 9.96% 1029, 7.89% 
Ischaemic heart disease 884, 20.33% 2044, 15.67% 
Stroke 560, 12.88% 1400, 10.73% 
Table 6.1 Basic statistics of the initial data 





6.3.2 Statistical analysis for cases that develop CVD before diagnosis of 
SCC 
Table 6.2 shows the statistics for the total cases, percentage and odds ratio of the 
SCC patients and their matched controls who were diagnosed with CVDs before the 
date that their SCC was diagnosed. Data shown here suggests a higher association of 
CVDs with the future development of SCC (table 6.2-A). In the analysis of odds 
ratio, all types of cardiovascular diseases that were measured showed a significant 
odds ratio, being 1.67 (1.55, 1.81) in hypertension, 1.28 (1.11, 1.47) in myocardial 
infarction, 1.37 (1.24, 1.52) in ischaemic heart disease and 1.19 (1.04, 1.37), 
suggesting the presence of hypertension, MI, IHD and stroke increases the odds of 
developing SCC (table 6.2-B). 




Hypertension 2040, 46.92% 4797, 36.78% 
Myocardial infarction 302, 6.95% 724, 5.55% 
Ischaemic heart disease 650, 14.95% 1505, 11.54% 
Stroke 319, 7.34% 816, 6.26% 
 
B) SCC vs controls 
Odds ratio (95% CI) 
Wald’s test (p) 
Hypertension 1.67 (1.55,1.81) < 0.001 
Myocardial infarction 1.28 (1.11,1.47) <0.001 
Ischaemic heart disease 1.37 (1.24,1.52) < 0.001 
Stroke 1.19 (1.04,1.37) 0.011 
Table 6.2 Basic statistics – matched case-control study 
A) Percentage of the SCC patients and their controls that were diagnosed with CVD. 




6.3.3 Statistic analysis for cases that develop CVD after diagnosis of SCC 
After the dataset was regrouped, those that developed CVDs after the diagnosis of 
SCC were compared. There is a higher incidence of hypertension, MI, IHD and 
stroke in those who had developed SCC than in their matched controls (table 5.3-A). 
The relative risk for SCC patients to develop hypertension, myocardial infarction, 
ischaemic heart disease and stroke are 1.11 (1.04, 1.18), 1.29 (1.05, 1.58), 1.30 (1.12, 
1.51) and 1.26 (1.09, 1.46), with the confidence interval not overlapping 1, suggests 
a significant increase risks for the SCC patients to develop various CVDs. 




Hypertension 964, 22.17% 2609, 20.00% 
Myocardial infarction 131, 3.01% 305, 2.34% 
Ischaemic heart disease 234, 5.38% 539, 4.13% 
Stroke 241, 5.54% 584, 4.48% 
 
B) SCC vs controls 
Relative Risk (95% CI) 
Hypertension 1.11 (1.04,1.18) 
Myocardial infarction 1.29 (1.05,1.58) 
Ischaemic heart disease 1.30 (1.12,1.51) 
Stroke 1.26 (1.09,1.46) 
Table 6.3 Basic statistics – retrospective cohort study 
A) Incidence of SCC patients and their controls in developing various CVDs. 






6.4.1 Study design discussion 
In most scenarios, both case-control and retrospective cohort studies rely on a 
database where exposure to risk as well as development of diseases have already 
occurred and been recorded. In case-control studies a group of people presenting 
with a “disease” of interest are matched with a group of controls that do not have this 
disease. Retrospective observations then identify possible risk factors. Retrospective 
matched cohort studies differs from case-control study in that a group of people that 
were exposed to a “risk or exposure” of interest are matched with controls who were 
not exposed to the identified risk factor. Outcome observations then identify whether 
exposure to the selected risk increases or decreases development of certain diseases 
in the future. The way that the PCCIU database fitted into the two models is shown 
in a schematic below (figure 6.1). 
 
Figure 6.1 PCCIU database as a case-control or retrospective cohort study 
Data for matched case-control study are presented in table 6.2 and retrospective 




A frequent concern with case-control studies is that they rely on retrospectively 
collected exposure or biological data which may have been inadequately recorded. 
Validation of databases can reduce the impact of this measurement error (Chatterjee 
and Wacholder, 2002). Squamous cell skin cancer diagnoses were drawn from 
general practice records participating in the PCCIU database using the search terms 
(refer to appendix, page 221). I excluded patients with conditions other than sunlight 
which would predispose to SCC (immunosuppressive conditions and chronic 
vascular ulcers). Misdiagnosis of cutaneous SCCs with for example SCCs from non-
cutaneous sites metastasising to the skin might account for some of the SCC cases 
that I used. An individual hand search of all the records used (4348 SCC cases) 
would be needed to reduce the chances of this occurring. Nonetheless, the large 
number of SCC cases recorded, the careful case matching, and marked differences 
observed suggests that measurement errors would have had to be large to account for 





6.4.2 Association of hypertension and CVDs with SCC 
In the case control series I analysed, the odds ratio for developing an SCC was 
significantly increased in subjects with hypertension, MI, IHD and stroke (table 6.2-
B), suggesting that the presence of these cardiovascular diseases increase the risks of 
developing squamous cell carcinoma. 
It has previously been shown that the presence of high blood pressure alone is a risk 
factor for increasing mortality in all sorts of cancers (Dyer et al., 1975, Gillis et al., 
1975, Khaw and Barrett-Connor, 1984). Specifically hypertension strongly increases 
the risk of mortality in colon cancer (Dyer et al., 1975), kidney cancer (Raynor et al., 
1981, Grove et al., 1991), epidermoid cancer of the head and neck (Raynor et al., 
1981), lung cancer (Khaw and Barrett-Connor, 1984), breast cancer (Khaw and 
Barrett-Connor, 1984), endometrial cancer (Maatela et al., 1994) and prostate cancer 
(Fitzpatrick et al., 2001). 
It has been suggested that the use of anti-hypertensive drugs is the cause of increased 
cancer mortality. Reserpine and β-blockers were not found to be linked (Hole et al., 
1993, Muldoon and Kuller, 1993, Hamet, 1996) but hydrochlorothiazide is highly 
associated with the increased risk of renal cancer morbidity and mortality (Finkle et 
al., 1993, Weinmann et al., 1994). 
Photosensitivity is a side effect of thiazide diuretics, and this is worse when 
combined with a second photosensitising agent (Harber et al., 1959, Ophir et al., 
1984, Robinson et al., 1985). Jensen and colleagues investigated these diuretics and 
found an increase incidence rate ratio for using hydrochlorothiazide, amiloride and 
indapamide in the future development of melanotic and non-melanotic skin cancer 
(Jensen et al., 2008). While this does not explain the association for increased 
mortality of all cancers in hypertensive patients, it could account for the increased 
incidence of SCC in the hypertensive cohort. 




IHD and stroke (Kannel et al., 1986, Flack et al., 1995, Lewington et al., 2002). 
Therefore, with hypertension showing an odds of 1.67 (1.55, 1.81), the possibility 
that the significant increase in odds for MI 1.28 (1.11, 1.47), IHD 1.37 (1.24, 1.52) 
and stroke 1.19 (.04, 1.37) were due to presence of hypertension cannot be excluded. 
The role of nitric oxide in tumour growth is complex. Some clinical studies have 
found over expression of iNOS in carcinomas such as colorectal cancer, lung cancer, 
Barret’s oesophagus and associated adeno-carcinomas (Fujimoto et al., 1997, Ambs 
et al., 1998, Wilson et al., 1998). The relationship of nitric oxide and tumour 
progression has been revised (Fukumura et al., 2006) with the majority of animal 
studies showing iNOS to be involved in inducing angiogenesis of tumours. Nitric 
oxide produced by the host or tumour encourages blood flow to the pathologic site, 
resulting in tumour growth, carcinogenesis and tumour metastasis (Gauthier et al., 
2004, Kashiwagi et al., 2005). Other studies suggest NOS inhibitor and NOS 
knockout mice have increased metastasis and size of tumour (Qiu et al., 2003), but 
the role of nitric oxide in tumour growth and initiation is yet to be confirmed as nitric 
oxide might play a double role that can both enhance and suppress growth and 
metastasis depending on the tumour’s characteristics (Shi et al., 2000). 
A reduced basal nitric oxide production was found in individuals with essential 
hypertension (Forte et al., 1997) and a decreased expression of the eNOS gene in 
hypertensive rodents (Huang et al., 1995, Chou et al., 1998). Some studies however 
appear to show an increase in iNOS activity during the development of hypertension 
(Chou et al., 1998, Cheng et al., 2004). Should this increase in iNOS expression 
associated with hypertension be confirmed, this could account for the association 
with SCC formation. One of the known aetiological steps in SCC formation is the 
mutation of p53 gene. Such mutations are associated with over-expression of iNOS 
(Forrester et al., 1996) as the resultant higher nitric oxide production provides a 
selective growth advantage for tumour cells with mutant p53 (Ambs et al., 1998). 
However, the experimental data showing an over-expression of iNOS in hypertensive 
humans and animals reported the site of increased iNOS activity at the aorta and 




keratinocyte. Thus the contribution of iNOS in SCC development is probably very 
limited. 
An additional factor that might slightly contribute to the increased odds in SCC by 
hypertension is the first-line treatment of hypertension, which is widely known to 
involve life-style modifications such as a low salt diet, limited alcohol intake, weight 
loss and increase physical exercise (Appel et al., 2003). Increasing physical exercise 
is associated with increasing outdoor activity, thus exposing the patients to extra 
sunlight. However, development of SCC is known to be associated with total life 
time sun exposure, and whether the modification of life-style will be of a large 
enough degree to increase the odds of SCC is extremely slim. 
In addition to the possible involvement of thiazide diuretics in raising the odds ratio 
of developing SCC, there are other risk factors for developing this cancer. These 
include: UV exposure, infection by human papillomavirus, exposure to chemical 
carcinogen, immunosuppression, leukaemia, lymphoma, ulcers, radiation dermatitis 
and many others as outlined by Alam and Ratner (Alam and Ratner, 2001). Smoking 
is a known risk factor for many vascular diseases (Doll et al., 1994) and was 
suggested by some to be associated with SCC of the skin (Aubry and Macgibbon, 
1985). SCC may share further risk factors with those for the development of 
hypertension, MI, IHD and stroke. With my large sample size, I had hoped that these 
risk factors would balanced out, but it was not possible to match for, or exclude them 
during the case-control selection, as the PCCIU database does not contain this level 
of detail. Thus with the odds ratio of less than 2, these various cardiovascular 
diseases might suggest a true association with SCC development, but may also be 




6.4.3 SCC increases the risk of CVDs? 
Compared to controls, the SCC patients had a higher incidence in developing 
different types of CVDs shown in table 6.3. The relative risk for hypertension is 1.11 
(1.04, 1.18), for MI is 1.29 (1.05, 1.58), for IHD is 1.30 (1.12, 1.51) and for stroke 
being 1.26 (1.09, 1.46). These changes were significant, with the 95% confidence 
interval range exceeding 1 in all cases. 
Even though a relative risk greater than one suggests an increased risk, for 
epidemiologic researches a relative risk less than two can be difficult to interpret as 
coincidence, statistical bias or effects of confounding factors that are sometimes not 
evident (Daling et al., 1994) may be responsible. Cautious interpretation of these data 
is thus required. 
During the process of categorizing the database into two groups as mentioned earlier, 
it was noted that a proportion of the hypertension diagnosed in the SCC patients was 
made approximately a week to a month after the diagnosis of SCC. It was suggested 
by the British Hypertension Society in 1993, 1999, 2004 and even now that at least 
two blood pressure measurements in separate occasions need to be made in order to 
confirm the diagnosis of hypertension. The two measurements need to be at least one 
week apart depending on the blood pressure of the first measurement (Sever et al., 
1993, Ramsay et al., 1999, Williams et al., 2004). Therefore it is very likely that a 
portion of the SCC patients already present with hypertension, but was only recorded 
by the clinic when they presented with SCC and was confirmed a few weeks later. 
Other than hypertension, risks for other CVDs such as MI, IHD and stroke were also 
noted to be higher in SCC patients. However, with the relative risk less than two, the 
possibility that these CVDs are associated with the pre-developed but undiagnosed 
hypertension before the diagnosis of SCC cannot be excluded. Other than data 
selection bias, life style modification due to the diagnosis of SCC might also play a 




Even though the recommended guidelines for treatment of SCC by the British 
Association of Dermatologists do not include avoidance of sunlight exposure 
(Motley et al., 2002), dermatologists have nonetheless been widely discouraging 
direct sun exposure, especially in high risk groups. Rhee and colleague have 
investigated the behavioural change in patients treated with non-melanoma skin 
cancer, in which they have demonstrated patients changing their sun-protective 
behaviours after treatment (Rhee et al., 2008). Whether this behavioural change after 
the diagnosis of SCC alters the risk for developing CVDs is unknown, but in my data 
set, subjects who had developed SCC were more likely to develop CVD after the 
diagnosis of SCC was made than matched controls. This could be due to behavioural 
change, with reduced sunlight exposure and thus reduced UV derived nitric oxide 
released into the circulation.  
One major disadvantage for a retrospective cohort study is bias in the way data were 
initially recorded. Most retrospective cohort studies are conducted by extracting data 
from an existing database not specifically tailored for the study. There is thus a risk 
that during the selection of cases and controls, unavoidable confounders will also be 
included and I cannot definitively conclude that SCC increases the risks for 
development of hypertension and other CVDs. 
A solution for this bias is to perform database validation or to conduct a prospective 
cohort study, where a clear time point for the diagnosis of SCC is identified and 
extracted from the population. After excluding pre-existing CVDs such as 
hypertension, MI, IHD and stroke, the selected cases are then matched with their 
controls where an observation period (e.g five years) is set. The incidence of CVDs 
by the end of that period will be able to provide a clearer result, whether SCC 





From the data shown, I have failed to support my initial hypothesis with a 
retrospective cohort study. In fact, against my expectations, SCC appeared to 
increase the risk of developing various types of CVDs. However, factors such as an 
unvalidated database, confounding from undiagnosed pre-existing hypertension, 
possible common risk factors and selection bias cannot be excluded. 
From the case-control study, it was found that the presence of hypertension, MI, IHD 
and stroke significantly increases the odds of developing SCC of the skin. This 
association between hypertension and other CVDs with SCC may be due to the use 
of drugs with photosensitising side effects such as hydrochlorothiazide and amiloride 
which are used to treat hypertension. Increased expression of iNOS during the 
development of hypertension could also contribute to the p53 mutations which can 
drive SCC formation. However, with the odds of less than 2 and the previously listed 

























Globally, cardiovascular disease is the leading cause of death, and a lot of the 
cardiovascular associated morbidity including hypertension is found to correlate with 
latitude and season. Hitherto, research studies has accounted for these findings with 
temperature change and vitamin D synthesis from solar irradiation. The discovery 
that UVA irradiation of human skin releases nitric oxide in 2005 by Paunel and 
colleagues (Paunel et al., 2005) has suggested a new mechanism in which UVA can 
affects cardiovascular health. Blood pressure responses from nitrite photolysis in the 
skin and circulation by UVA have further supported this (Oplander et al., 2009, 
Feelisch et al., 2010). 
The main aims of my research studies were to investigate whether the nitric oxide 
activity produced from nitrite photolysis after UVA irradiation of the skin and 
circulation is detectable, and also to confirm the origin of this nitric oxide released 
into the circulation. Additionally, I also aimed to investigate whether UVA induced 
nitrite photolysis is associated with the latitude and seasonal variation of blood 
pressure and cardiovascular mortality. In this thesis, these aims were achieved by a 
series of in vivo and in vitro studies. 
I have conducted in vivo studies that demonstrated the systemic, local and cellular 
effects of UVA irradiation on human skin by monitoring different parameters 
including blood pressure, heart rate, cardiac output, SBF, FBF and bleeding time. I 
have also conducted in vitro studies to identify the solar wavelengths that allow 
maximal nitrite photolysis and the role of thiols in nitrate reduction in the presence of 
UVA. Lastly, I have conducted two epidemiology studies, using a retrospective 
cohort study investigating whether squamous cell carcinoma increases or decrease 
the risk of cardiovascular diseases and a case-control study to determine whether the 
presence of different cardiovascular diseases increases or decreases the odds in the 
development of squamous cell carcinoma of the skin. A schematic summarizing all 









7.2 Systemic → local → cellular effect produced from UVA irradiation of skin 
7.2.1 Overview of finding and concluding discussion 
My study on the effects of UV on blood pressure incorporated a high and low nitrate 
arm and was designed to build on the study of Oplander et al showing that UVA 
irradiation lowers blood pressure. Randomisation of subjects to an active/sham 
irradiation and low/high nitrate diet would have involved 4 visits. This would have 
created recruitment difficulties and also led to a seasonal delay of 8 weeks or more 
between first and final visits. The level of background irradiance between these visits 
would have confounded the results. For these two reasons, and as Oplander had 
already demonstrated a clear effect of UV in lowering blood pressure, we opted to 
use a study design in which sham irradiation preceded active, but to randomize 
subjects to low or normal/high nitrate diets. DBP fell and heart rate rose during 
active, but not sham irradiation. This might have been due to a carryover effect from 
the sham irradiation, but I consider this unlikely as my forearm plethysmography 
data showed vasodilation during and after the active, but not sham irradiation 
treatment. Firm confirmation that UV lowers blood pressure would have necessitated 
a direct repeat of Oplander’s study which I did not carry out. I will compare my data 
with the Oplander study under the assumption that the results observed were due to 
UVA. 
Assuming no carryover effect from sham irradiation, data collected from the 
RIECRF and Lauriston blood pressure study showed a slight but significant 
reduction of DBP from baseline at different time points after 20 J/cm2 of UVA 
irradiation despite the small sample size. However this reduction is not significantly 
different from sham irradiation. After combining the data from these two studies, 
increasing sample size and power, a significant reduction of DBP from sham 
irradiation was observed at 10 minutes post irradiation. The reduction in DBP was 
accompanied by a significant rise in heart rate and change in circulatory nitro-species, 
suggesting a compensatory homeostatic mechanism to maintain blood pressure as 




Compared to my findings, the Oplander study showed a more prominent reduction in 
both systolic and diastolic blood pressure, which is likely to be due to differences in 
methodology, baseline blood pressure and age group (Oplander et al., 2009). The 
1982 MRC hypertension trial showed a variation in blood pressure according to 
season (Brennan et al., 1982), and also showed a more prominent reduction in blood 
pressure within the older age groups who had a higher baseline blood pressure. With 
evidence suggesting that basal production of nitric oxide is lower in hypertensive 
patients and decreases with aging (Forte et al., 1997, Lyons et al., 1997), it is 
therefore possible that Oplander and colleagues were able to show a more prominent 
blood pressure reduction in volunteers with higher resting blood pressure. 
The major difference in blood pressure change between active and sham irradiation 
was the time taken for blood pressure to return to baseline. During sham irradiation, 
both systolic and diastolic blood pressure returned to baseline by 10 minutes post UV, 
whereas the blood pressure in active irradiation gradually returns to the baseline over 
the duration of 60 minutes. As shown in the Lauriston BP study, skin temperature 
during active UVA irradiation even when controlled to produce a similar rise to that 
of sham irradiation, showed a significant rise from baseline (figure 3.6-B, page 83). 
Thus the trend of blood pressure reduction during sham irradiation which returned to 
the baseline within 10 minutes after the lamp was switched off (figure 3.8-A, B, C, 
page 87-88) suggests temperature induced vasodilatation. Another observation 
suggesting the heat generated by the UVA lamp can affect blood pressure was shown 
in the SBF study. In that study, a non-significant increasing trend in SBF at the non-
irradiated site was observed during irradiation. The increase in SBF diminished after 
the lamp was switched off, suggesting temperature induced vasodilation. In contrast, 
active irradiation with a significant reduction in blood pressure and a slower return of 
blood pressure to baseline suggests factors other than temperature, such as nitric 
oxide photolysed from nitrogen oxide stores. 
My combined results suggest that the nitric oxide like activity, such as reduction of 
blood pressure after UVA irradiation of the skin could be due to the significant rise 




nitric oxide activity is not associated with thermoregulatory vasodilation or nitric 
oxide synthase stimulation by local warming of the skin. 
During the FBF study, NOS in the forearm was inhibited by intra-arterial infusion of 
L-NMMA. The effective temperature control during active irradiation, which 
matched the sham treated arms still produced a significant rise in FBF following 
UVA irradiation of the forearm (figure 4.4, page 118-120). This suggests 
temperature and NOS independent vasodilatation after UVA irradiation. The increase 
in circulatory nitrite was not shown to be significant, but there are three possible 
causes for this finding. 
1. Limited total body surface area that was irradiated (less than 4.5%). 
2. The dilution effect of blood continuously flowing through the forearm 
carrying the NO/NO2- away from the irradiated site. 
3. L-NMMA induced reduction in circulatory nitrite. 
In the absence of carryover effect from sham irradiation, circulatory nitro-species 
from the RIECRF study showed a significant increase in circulatory nitrite and 
significant reduction in circulatory nitrate post UVA irradiation. I had suggested that 
the increased nitrite is due to oxidation of nitric oxide by oxyhaemoglobin. During a 
normal physiological response, both nitric oxide and nitrite should have been 
oxidized to nitrate by reacting with oxyhemoglobin (with the oxidation half-life of 
nitrite ≈ 45 minutes (Ignarro et al., 1993)), thus finding a reduced circulatory nitrate 
was an unexpected finding. I then hypothesized a possible reduction of nitrate by 
thiols at the end of chapter 3 and this hypothesis was confirmed to be possible by the 
in vitro study shown in chapter 5. 
In chapter 5 I have shown the accelerated nitric oxide formations from potassium 
nitrate reduction in the presence of cysteine and UVA. The reduction of nitrate to 




sulphanilamide was shown to inhibit this nitric oxide production effect (figure 5.5, 
page 153-155). From the data obtained, I have suggested a possible pathway (figure 
5.6, page 161), where the major difference between skin and circulatory balancing of 
nitric oxide, nitrite and nitrate is the absence of haemoglobin in the skin. There could 
also be an increased excretion of nitrate via kidney due to the increased blood flow. 
Without the presence of haemoglobin in the skin during UVA irradiation, I propose 
there will be a decreased amount of nitrate and increased nitric oxide / nitrite at the 
skin level. In order to maintain equilibrium of nitric oxides species between dermal 
store and the circulation, there will be: 
1. A gradient shift of nitrate from the circulation into the skin. 
2. Diffusion of nitric oxide / nitrite from skin to the circulation to give the 
picture of reduced nitrate and increased nitrite within the circulation. 
One finding that did not fit into this hypothesis was the reduced circulatory nitrate in 
the L-NMMA FBF study, where significant reduction of nitrate was found in both 
sham and active irradiation. However, if the three sets of results gathered from 
different studies are put into comparison by relative change from baseline (table 7.1), 
the reduction of circulatory nitrate is likely to be due to the L-NMMA infusion. As 
L-NMMA inhibits all nitric oxide synthases, L-NMMA infusion reduces basal nitric 
oxide formation, leading to a reduced amount of nitric oxide being oxidized to nitrate 
by oxyhemoglobin. As shown in table 7.1, during the blood pressure study where 
whole body UVA irradiation was given, a significant reduction of nitrate was seen 
immediately after irradiation, and by 40 minutes post UVA circulatory nitrate fell by 
approximately 20 % from the baseline. Whereas in the UVA/Infrared FBF study, 
with only one arm irradiated by UVA, a small and progressive, rather than immediate 
reduction of nitrate can be seen in both the irradiated and the contra-lateral arm 
(probably due to the crossover effect). By 40 minutes post UVA, there is a non-
significant reduction of approximately 0.25 % in the UVA irradiated arm and 5 % in 
the contra-lateral arm. Significance reduction of about 18 % was found at 60 minutes 
post irradiation, but this amount was less than that of whole body irradiation. Lastly, 




reduction of circulatory nitrate was found in both sham and active visit when 
compare to the UVA/Infrared study. Significant reduction in circulatory nitrate was 
found starting from 40 instead of 60 minutes post irradiation. Data from this table 
also showed the active irradiated arm which was also the L-NMMA infused arm 
having the biggest reduction in circulatory nitrate, suggesting a nitrate reduction 













































































































































































































































































































































































































At the cellular level, I have shown a significant prolongation of bleeding time from 
baseline but not from sham irradiation after active UVA irradiation. The sample size 
in this study was too small to give adequate power to conclusively show that the 
nitric oxide released by UVA irradiation of the skin affects platelet function. 
However, this finding is not significantly different from sham irradiation and other 
confounders such as methodology, blinding procedure and clotting factors may be 
involved. 
7.2.2 Limitations 
The major limitation of the blood pressure study (as mentioned in chapter 3) was the 
design in which active followed sham irradiation. As sham/active UV irradiation had 
already been studied by Oplander we chose not to repeat this, but to investigate the 
mechanism further determine whether supplementary nitrate augmented the effects 
of UVA. While in isolation, our BP data do not prove that UV lowers blood pressure, 
they are intended to be supplementary to our mechanistic data on forearm blood flow 
and to Oplanders studies. 
All the volunteers recruited in my studies were healthy individuals, and results 
shown by the Oplander study suggest that those with higher baseline blood pressure 
such as hypertensive patients benefits more from UVA irradiation. Further studies 
with hypertensive patients are necessary to determine how beneficial UVA 
irradiation will be in a clinical setting. 
As mentioned earlier in chapter 4, bleeding time is not a direct measurement of 
platelet activity, and thus an increased bleeding time does not always mean inhibition 
of platelet aggregation. Studies with more direct measurement of platelet activity 
need to be performed to confirm the effect of UVA irradiation on platelet function. 
Additionally, even though the prolonged bleeding time was found to increase 
significantly from baseline, it is not significantly different from the sham irradiation. 
My data from the bleeding time measurements was not normally distributed, which 




design (the operator was not blinded). 
Lastly, 20 J/cm2 of UVA is usually not accessible by Edinburgh population (if one 
was exposed without cover to the sun from 11:30~12:30 during a clear sky day in 
July at 50° N (e.g. Exeter, Prague, Brussels, Frankfurt), one would receive 
approximately 17 J/cm2 of UVA (Diffey and Elwood, 1994)), and whether the effects 
produced from these volunteers are due to sudden exposure to large amount of UVA 
is unclear. More studies are required to identify the minimal dose required to produce 
such effect. 
7.2.3 Future work 
Randomization of the sham and active visit for the blood pressure study will be 
helpful in clarifying whether the significant reduction seen in DBP is due to chance, 
carry over effect from sham irradiation or active UVA irradiation. Increasing the 
sample size of future study is also needed to prove conclusive data on the bleeding 
time study. 
Other than recruitment of hypertensive patients to determine how they can benefit 
from UVA irradiation, non-invasive studies such as coronary flow reserve (CFR) by 
trans-thoracic Doppler echocardiography and platelet monocyte aggregation (PMA) 
can be performed. CFR allows the determination of maximal coronary arterial flow 
above the normal resting state volume, and the assessment of CFR provides 
information reflecting the health and vasodilatory capacity of coronary 
microvasculature. This measurement will be able to show whether UVA irradiation 
is beneficial for patients suffering from ischaemic heart disease. PMA being a 
sensitive marker for platelet activation will be a suitable method for determination of 
platelet response after UVA irradiation of the skin. These studies will further 
investigate the effect of UVA in cardiovascular physiology and further justify the use 




7.3 Global health implication by UVA induced nitrite photolysis – by theory 
7.3.1 Overview of finding and concluding discussion 
Wavelength specific data for nitrite photolysis was determined in this study. Using a 
fixed energy, the maximum nitric oxide release from nitrite photolysis falls within 
the UVB spectrum (figure 5.2-A, page 147), but when corrected for solar irradiance, 
the maximum nitric oxide release falls within the UVA spectrum peaking at 330 nm 
(figure 5.3-A, B, C, D, page 149). 
Latitudes and seasons were found to strongly correlate with total nitric oxide release, 
showing the most nitric oxide release at 20ºN and 20ºS instead of the equator. This is 
due to the earth tilting at an angle of approximately 23.4º (figure 7.2) during June 
and December, thus showing the peak release of nitric oxide at 20ºN and 20ºS. If 
measurements were performed during March and September equinoxes when the sun 
was directly above celestial equator, maximal release of nitric oxide will be found at 
equator. 
 




Disregarding the seasons, modelling the total nitric oxide released by solar irradiance 
showed a significant correlation with latitude (figure 5.3-G&H, page 150). Studies 
have shown cardiovascular mortality (in the Northern Hemisphere) having a North-
South gradient in different geographical areas and further studies is required to 
determine whether this correlates with the nitric oxide released from solar irradiance 
at different latitudes. The greatest seasonal variation in nitric oxide release occurs at 
latitudes 40~60ºN and ºS (figure 5.3-E&F, page 150). 
7.3.2 Limitations 
The amount of nitric oxide release from nitrite photolysis was derived from an in 
vitro study, and this does not necessarily reflect the amount of nitric oxide that will 
be released in humans, even though studies measuring nitric oxide release following 
UVA irradiation of human skin and homogenates correlates with my modeling 
(Paunel et al., 2005, Suschek et al., 2010). Direct measurement of circulatory nitric 
oxide species as well as cardiac parameters will nonetheless be required to confirm 
the effect of sunlight on cardiovascular health at different latitudes.  
7.3.3 Future work 
Research findings of correlation between CVD incidence and seasons is not 
consistent in all geographical areas, and whether such seasonality will be more 
prominent in geographical areas between 40~60ºN and ºS will be worth investigating. 
The direct measurement of basal circulatory nitric oxide release in populations at 
different geographical area will demonstrate a more direct association with the 
latitude variation in photolysis of nitric oxide stores. Such studies should be helpful 
in clarifying the association of sun exposure (particularly the role of nitric oxide 




7.4 CVD as a risk for SCC of the skin or SCC of the skin as a risk for CVD? 
7.4.1 Overview of finding and concluding discussion 
From the matched cohort study that originally aimed to investigate whether 
development of squamous cell carcinoma is a protective factor against development 
of CVD, I have found that in fact development of squamous cell carcinoma increases 
the risk of hypertension (table 6.3-B, page 170). However, with the borderline 
confidence interval and low relative risk, bias due to chance, study design and 
behavioural change cannot be excluded. Further confirmation studies such as a 
prospective cohort study discussed in chapter 6.4.3 would be needed to confirm this 
finding. 
From the case control study, I have identified that presence of hypertension, MI, IHD 
and stroke significantly increases the risk of developing SCC in the future, with 
hypertension showing the highest odds of 1.58 (table 6.2-B, page 169). The 
association of hypertension with increased cancer morbidity and mortality was 
shown early in the 1970s. With limited knowledge, the causation of various cancers 
by hypertension is yet to be clarified. Even though in the scenario of SCC, drugs 
used for hypertension treatment such as photosensitizing diuretics are most likely to 
cause this increased risk of skin cancer development, other common risk factors 
between SCC and CVD such as smoking were not equally matched in the study. 
With the odds of less than 2 this result may not reflect the true correlation. 
7.4.2 Limitations 
As mentioned in chapter 6, database validation is very important in epidemiology 
studies, especially for minimizing errors. With the PCCIU database not validated for 
SCC and CVD studies, the result may reflect biased data, and validation of this 
database is suggested before further studies be conducted using this database. 
Both the case control and retrospective cohort study are retrospective observation 




identify definite causes and effects. In the profiles data from the PCCIU database, 
information about the hypertensive treatments given to the patients was not provided, 
and thus I can only suggest that hypertensive treatment (diuretics associated with 
photosensitivity) may be the reason for the increased risk of SCC formation. 
7.4.3 Future work 
My findings suggest that diuretics with photosensitising side effects such as 
hydrochlorothiazide (one of the first line pharmaceutical treatments for hypertension) 
could be associated with the increased risk of SCC development. The association of 
hydrochlorothiazide with SCC has already been shown by Jensen and colleagues 
(Jensen et al., 2008). However, my study was not matched for hypertension 
treatments and database was not validated for SCC and CVD studies, thus re-analysis 
of the result after database validation would improve the quality of these data. Proper 
matching for known common risk factors such as smoking and excluding 
confounders such as the photosensitizing effect of anti-hypertensive medications 
should also be performed. Excluding cases that received hydrochlorothiazide or other 
drugs known to increase photosensitivity would be helpful in determining the true 
association between SCC and various CVDs. 
Additionally, to exclude the possibility that over-expression of iNOS in hypertensive 
patients contribute to the increased risk of SCC formation, investigation of iNOS 
activity in SCC patients, particularly at the pathology site will be helpful in clarifying 
the role of nitric oxide in the development of SCC. 
Lastly, a prospective cohort study would be able to determine whether SCC is a 
protective factor for development of various CVDs, although the process of ruling 




7.5 Summary Conclusion 
UVA irradiation of the skin in healthy volunteers may alter cardiovascular 
physiology as shown in the forearm blood flow study, in which the finding is 
independent from temperature and nitric oxide synthase involvement. Change of 
blood pressure, heart rate, and circulatory nitro-species are not proven in isolation 
from our studies, but in conjunction with our authors (Oplander) and with our 
forearm blood flow studies, this seems highly likely. Nitric oxide is released via thiol 
mediated reduction of nitrate, which is accelerated by the presence of UVA. This is 
likely to contribute to the cardiovascular responses observed. 
Maximal nitric oxide release from nitrite photolysis by solar irradiation falls within 
the UVA spectrum and this total nitric oxide release significantly correlates with 
season and latitude, with more nitric oxide produced during summer and at 
geographical area closer to equator. 
The finding of increased odds for the future development of squamous cell 
carcinoma of the skin in individuals with hypertension, myocardial infarction and 
ischaemic heart disease can only be confirmed after validation of the PCCIU 
database. Patients diagnosed with squamous cell carcinoma of the skin were also 
found to be associated with increased risks in presenting with cardiovascular diseases. 
However this association needs further investigation. 
Wald and Law have claimed that reducing four cardiovascular risk factors (low 
density lipoprotein cholesterol, blood pressure, serum homocysteine and platelet 
function) regardless of pre-treatment levels can reduces heart attack and stroke by 
80% (Wald and Law, 2003). Lewington et al and Lawes et al claimed decreasing of 
blood pressure in any form to be protective against stroke and cardiovascular 
mortality (Lewington et al., 2002, Lawes et al., 2004). The findings from my study 
suggest UVA irradiation of the skin might be associated with beneficial 
cardiovascular effects. Hopefully in the near future, having some sunshine everyday 
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C. Measurement of Food Nitrite and Nitrate 
 Average serving (g) Nitrite (μmol) Nitrate (μmol) 
Cereal 80 2.406 1.864 
Bread 100 0.574 0.000 
Butter 50 0.613 0.000 
Jam 50 0.170 0.000 
Pasta 300 0.993 0.000 
Sauce 75 1.409 0.000 
Cheese 50 0.893 0.000 
Apple 200 1.483 0.000 
Orange 200 0.793 0.000 
Banana 150 0.000 26.866 
 Average serving (L) Nitrite (μmol) Nitrate (μmol) 
Milk 0.1 7.154 2.576 
Still H2O 2.0 0.000 7.187 





D. Search terms used for selecting SCC patients in PCCIU database 
Terms (patient may have 1 or more than 1 conditions) Number of patients 
Malignant neoplasm overlapping lesion of skin 1 
Malignant neoplasm of skin of heel 1 
Squamous cell carcinoma, spindle cell type 1 
Malignant neoplasm of skin of toe 1 
Squamous cell carcinoma, large cell, non-keratinising type 2 
Squamous cell carcinoma, small cell, non-keratinising type 2 
Malignant neoplasm of skin of great toe 2 
Malignant neoplasm of skin of hip 2 
Malignant neoplasm of perianal skin 2 
Malignant neoplasm of skin of buttock 3 
Malignant neoplasm of skin of trunk, excluding scrotum, 
NOS 
3 
Malignant neoplasm of skin of thumb 4 
Malignant neoplasm of skin of axillary fold 5 
Malignant neoplasm of skin of external auditory meatus 5 
Squamous cell carcinoma in situ with questionable stromal 
invasion 
5 
Malignant neoplasm of skin of upper limb or shoulder 
NOS 
5 
Malignant neoplasm of skin of finger 6 
Malignant neoplasm of skin of knee 6 
Malignant neoplasm of skin of perineum 7 
Malignant neoplasm of skin of foot 9 
Malignant neoplasm of upper eyelid 9 
Malignant neoplasm of skin of groin 9 
Malignant neoplasm of scalp or skin of neck NOS 11 
Malignant neoplasm of skin of lower limb or hip NOS 13 
Malignant neoplasm of skin of ankle 13 




Squamous cell carcinoma of skin 14 
Malignant neoplasm of scalp and skin of neck 16 
Malignant neoplasm of skin of upper limb and shoulder 16 
Malignant neoplasm of skin of abdominal wall 23 
Malignant neoplasm of skin of thigh 26 
Malignant neoplasm of skin of upper arm 30 
Squamous cell carcinoma, microinvasive 31 
Malignant neoplasm of skin of lower limb and hip 36 
Malignant neoplasm of canthus 43 
Malignant neoplasm of pinna NEC 43 
Squamous cell carcinoma, keratinising type NOS 46 
Malignant neoplasm of lower eyelid 48 
Malignant neoplasm of skin of chin 48 
Malignant neoplasm of skin of fore-arm 51 
Malignant neoplasm of skin of eyebrow 52 
Malignant neoplasm of skin of auricle (ear) 64 
Malignant neoplasm of skin of hand 73 
Malignant neoplasm of skin of chest, excluding breast 76 
Malignant neoplasm of skin of shoulder 76 
Squamous cell carcinoma, metastatic NOS 77 
Malignant neoplasm of skin of other and unspecified part 
of face NOS 
90 
Malignant neoplasm of skin of ear and external auricular 
canal 
99 
Basosquamous carcinoma 99 
Malignant neoplasm of other specified skin sites 109 
Malignant neoplasm of scalp 110 
Malignant neoplasm of skin of ear and external auricular 
canal NOS 
115 
Malignant neoplasm of skin of back 119 




Malignant neoplasm of skin of lip 132 
Malignant neoplasm of skin of other and unspecified parts 
of face 
137 
Malignant neoplasm of skin of neck 152 
Malignant neoplasm of skin of lower leg 184 
Malignant neoplasm of eyelid including canthus 314 
Malignant neoplasm of skin of temple 346 
Malignant neoplasm of skin of cheek, external 460 
Malignant neoplasm of skin of forehead 474 
Malignant neoplasm of skin of nose (external) 632 
Squamous cell carcinoma in situ NOS 925 
Bowen's disease 1252 
Malignant neoplasm of skin NOS 1626 
Squamous cell carcinoma NOS 4559 
 
